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Background: Heavy menstrual bleeding (HMB) is a common problem, yet evidence to inform decisions
about initial medical treatment is limited.
Objectives: To assess the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing
intrauterine system (LNG-IUS) (Mirena®, Bayer) compared with usual medical treatment, with exploration of
women’s perspectives on treatment.
Design: A pragmatic, multicentre randomised trial with an economic evaluation and a longitudinal
qualitative study.
Setting: Women who presented in primary care.
Participants: A total of 571 women with HMB. A purposeful sample of 27 women who were randomised
or ineligible owing to treatment preference participated in semistructured face-to-face interviews around
2 and 12 months after commencing treatment.
Interventions: LNG-IUS or usual medical treatment (tranexamic acid, mefenamic acid, combined
oestrogen–progestogen or progesterone alone). Women could subsequently swap or cease their
allocated treatment.
Outcome measures: The primary outcome was the patient-reported score on the Menorrhagia
Multi-Attribute Scale (MMAS) assessed over a 2-year period and then again at 5 years. Secondary outcomes
included general quality of life (QoL), sexual activity, surgical intervention and safety. Data were analysed
using iterative constant comparison. A state transition model-based cost–utility analysis was undertaken
alongside the randomised trial. Quality-adjusted life-years (QALYs) were derived from the European Quality
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of Life-5 Dimensions (EQ-5D) and the Short Form questionnaire-6 Dimensions (SF-6D). The intention-to-treat
analyses were reported as cost per QALY gained. Uncertainty was explored by conducting both deterministic
and probabilistic sensitivity analyses.
Results: The MMAS total scores improved significantly in both groups at all time points, but were
significantly greater for the LNG-IUS than for usual treatment [mean difference over 2 years was
13.4 points, 95% confidence interval (CI) 9.9 to 16.9 points; p< 0.001]. However, this difference between
groups was reduced and no longer significant by 5 years (mean difference in scores 3.9 points, 95% CI
–0.6 to 8.3 points; p= 0.09). By 5 years, only 47% of women had a LNG-IUS in place and 15% were still
taking usual medical treatment. Five-year surgery rates were low, at 20%, and were similar, irrespective
of initial treatments. There were no significant differences in serious adverse events between groups.
Using the EQ-5D, at 2 years, the relative cost-effectiveness of the LNG-IUS compared with usual medical
treatment was £1600 per QALY, which by 5 years was reduced to £114 per QALY. Using the SF-6D,
usual medical treatment dominates the LNG-IUS. The qualitative findings show that women’s experiences
and expectations of medical treatments for HMB vary considerably and change over time. Women had
high expectations of a prompt effect from medical treatments.
Conclusions: The LNG-IUS, compared with usual medical therapies, resulted in greater improvement over
2 years in women’s assessments of the effect of HMB on their daily routine, including work, social and family
life, and psychological and physical well-being. At 5 years, the differences were no longer significant. A
similar low proportion of women required surgical intervention in both groups. The LNG-IUS is cost-effective
in both the short and medium term, using the method generally recommended by the National Institute for
Health and Care Excellence. Using the alternative measures to value QoL will have a considerable impact on
cost-effectiveness decisions. It will be important to explore the clinical and health-care trajectories of the
ECLIPSE (clinical effectiveness and cost-effectiveness of levonorgestrel-releasing intrauterine system in
primary care against standard treatment for menorrhagia) trial participants to 10 years, by which time half
of the cohort will have reached menopause.
Trial registration: Current Controlled Trials ISRCTN86566246.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 19, No. 88. See the NIHR Journals Library website
for further project information
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Plain English summary
Heavy menstrual bleeding (HMB; or heavy periods) is a common problem in women presenting to theirgeneral practitioners. Initial treatment should usually be medical, using non-hormonal pills, the
contraceptive pill or the levonorgestrel contraceptive coil. However, it is unclear whether or not the coil is
more effective than pills and if it is more acceptable to women, particularly in the medium term.
We randomly assigned 571 women with HMB to treatment with the coil or pills. We asked them to assess
the impact that their periods had on their daily life, at intervals over a 5-year period. We also explored their
experiences and expectations through interviews.
All participants found that their symptoms and quality of life significantly improved, regardless of which
treatment they started with, although those who had the coil fitted showed more improvement within
2 years. Not all women continued with the treatment: by 5 years, just over half had the coil removed
because of unpredictable bleeding, and 85% of those taking pills had changed treatments, mainly to the
coil, or stopped treatment. One in five women in each group went on to have surgery, for example a
hysterectomy. We could not conclude that the coil was definitely a cost-effective treatment because the
results differed depending on the calculation used.
Our trial shows that medical treatments should be considered first in women seeking treatment in primary
care. Both the coil and pills are effective treatments over a 5-year period, with the coil more effective over
the first 2 years only.
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Scientific summary
Background
Heavy menstrual bleeding (HMB), also called menorrhagia, is a common problem that can significantly
affect women’s lives, burdening individuals and health-care systems. Initial management should
usually be medical, using tranexamic acid or mefenamic acid, combined oral contraceptives or the
levonorgestrel-releasing intrauterine system (LNG-IUS) (Mirena®, Bayer). Short-term reduction in menstrual
blood loss may not translate into an improvement in a woman’s overall menstrual experience or quality of
life (QoL) or her need to seek further treatment, particularly as LNG-IUS discontinuation rates can be high.
Objectives
Primary objective
To assess the clinical effectiveness of the LNG-IUS compared with usual medical treatment for women
seeking treatment for HMB in primary care in the short term (2 years following randomisation).
Secondary objective
l To assess the clinical effectiveness of initial treatment with the LNG-IUS compared with usual medical
treatment for women seeking treatment for HMB in primary care in the medium term (5 years
following randomisation).
l To determine the cost-effectiveness of the LNG-IUS compared with usual medical treatment in the
short and medium term.
l To explore the perspectives of trial participants or women with HMB who declined to be randomised in
a longitudinal qualitative study.
l To measure the reliability and validity properties of the Menorrhagia Multi-Attribute Scale (MMAS).
Methods
Study randomised trial
Women between 25 and 50 years who presented to their general practitioner (GP) with HMB over at least
three consecutive cycles were eligible to participate. Women were excluded if they intended to become
pregnant over the next 5 years, were taking hormone replacement therapy or tamoxifen (SoltamoxTM,
Rosemount Pharmaceuticals), had intermenstrual or post-coital bleeding or findings suggestive of fibroids
or other disorders, or had contraindications to, or a preference for, either the LNG-IUS or usual medical
treatments. All patients provided written informed consent.
Patients were allocated to a treatment group in a 1 : 1 ratio via a central randomisation service, with
minimisation used to achieve balance between the groups with respect to age (< 35 years or ≥ 35 years),
body mass index (≤ 25 kg/m2 or > 25 kg/m2), duration of symptoms (< 1 year or ≥ 1 year), need for
contraception and presence or absence of menstrual pain.
Participants were randomly assigned to either the LNG-IUS or usual medical treatment. Usual treatment
options included mefenamic acid, tranexamic acid, norethisterone, a combined oestrogen–progestogen or
progesterone-only oral contraceptive pill (any formulation), or medroxyprogesterone acetate (Depo-ProveraTM,
Pfizer Ltd) injection and were chosen by the physician and patient on the basis of contraceptive needs or the
desire to avoid hormonal treatment.
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The primary outcome measure was the condition-specific MMAS, which is designed to measure the effect
of HMB on six domains of daily life (practical difficulties, social life, psychological health, physical health,
work and daily routine, and family life and relationships).
Secondary outcome measures included general health-related QoL [using the Short Form questionnaire-36
items (SF-36) and the European Quality of Life-5 Dimensions (EQ-5D)] and sexual activity. Outcomes were
obtained before randomisation and at 6 months, 1, 2 and 5 years after randomisation. Data were collected
regarding all serious adverse events, hospitalisations and reasons for discontinuation of the study drug.
The study was designed for 90% power (at p< 0.05) to detect small to moderate (0.3 standard deviations)
differences in the mean MMAS score between groups at any one time point. This required an enrolment
of 470 patients; we increased the sample size to 570 to allow for up to 20% loss to follow-up.
Analysis was by intention to treat with continuous measures compared using multilevel repeated-measures
models, including parameters allowing for participant, treatment, time and baseline score. A range of
sensitivity analyses was performed on the primary outcome to test the robustness of the results.
Longitudinal qualitative study
A purposeful sample of women randomised into the ECLIPSE (clinical effectiveness and cost-effectiveness
of levonorgestrel-releasing intrauterine system in primary care against standard treatment) trial for
menorrhagia, or who declined participation owing to strong preferences for a particular treatment, was
selected. Fifty-one semistructured face-to-face interviews were conducted in the respondents’ homes by a
female researcher.
Initial interviews were conducted within 1–3 months of commencing medical treatments and between
12 and 14 months later. Interviews followed broad topic areas including menstrual history and experience,
social factors influencing experience, relationships and family life, and emotional well-being as well as
treatment preference and experience of treatments. Interviews were transcribed verbatim. Data were
analysed using iterative constant comparison to identify emerging themes until saturation and
respondent validation.
Economic evaluation
A state transition model-based cost–utility analysis was undertaken alongside the randomised trial. The
model structure was informed by clinical input and the pathways followed by women in the trial, and all
parameters used were based on trial data.
The evaluation was based on an outcome of cost per quality-adjusted life-year (QALY), derived from the
EQ-5D and SF-36 values [using a Short Form questionnaire-6 Dimensions (SF-6D) conversion algorithm],
obtained up to 5 years. Costs were collected from a UK NHS perspective in a primary care setting, with
data on health-care resource use collected from women. Two analyses based on 2- and 5-year time
horizons were conducted.
The intention-to-treat analyses were reported, in terms of incremental cost-effectiveness ratios (ICERs),
as cost per QALY gained. The base-case analysis and three deterministic sensitivity analyses were carried
out using the EQ-5D and then repeated using the SF-36 as an additional sensitivity analysis. Uncertainty in
the model was explored by conducting both deterministic and probabilistic sensitivity analysis (PSA); the
latter used to construct cost-effectiveness acceptability curves.
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Results
Clinical effectiveness
Between February 2005 and July 2009, a total of 571 women with HMB from 63 UK centres were
randomly assigned to either the LNG-IUS (285 women) or usual medical treatment (286 women). In the
usual medical treatment group, 75% were initially treated with mefenamic acid or tranexamic acid or a
combination of these two drugs. Study questionnaire booklets were returned by 84% and 74% of the
participants at 2 and 5 years, respectively.
Women in the LNG-IUS group were almost twice as likely as those in the usual treatment group to still
be receiving their assigned treatment at 2 years (64% vs. 38%; p< 0.001), while by 5 years only 47% had
a LNG-IUS in place and 15% were still taking usual medical treatment. The most common reasons cited
for discontinuation of the LNG-IUS were lack of effectiveness and irregular or prolonged bleeding. Of the
228 women who discontinued usual medical treatment by 5 years, 43% switched to the LNG-IUS. The
most common reason for discontinuation of usual medical therapy was lack of effectiveness.
At 6 months, total scores on the MMAS had improved significantly, compared with baseline scores, and
these improvements were maintained through to 2 years. Improvements in these scores were significantly
greater among women assigned to the LNG-IUS than among those assigned to usual treatment over the
course of 2 years [mean difference in scores 13.4 points, 95% confidence interval (CI) 9.9 to 16.9 points;
p< 0.001]. However, this difference between groups was reduced and no longer significant by 5 years
(mean difference in scores 3.9 points, 95% CI –0.6 to 8.3 points; p= 0.09).
In a sensitivity analysis that excluded women who crossed over from the assigned treatment to the other
study treatments, improvement with the LNG-IUS compared with usual medical treatment increased (mean
difference in scores over 2 years was 17.8 points, 95% CI 14.1 to 21.5 points; p< 0.001). Other sensitivity
analyses yielded results that were not materially different from the results of the primary analysis.
Domains from the SF-36 were generally significantly improved from baseline in both groups at all time
points up to 2 years, although the scores were better for women in the LNG-IUS group than for those in
the usual treatment group in seven of the eight domains in the analysis over all time points; mental health
was the only domain for which there were no significant between-group differences. By 5 years, the only
significant difference between groups was seen in the general health perception domain of the SF-36
and favoured the LNG-IUS. No significant differences were seen between treatments with respect to the
EQ-5D instrument. The treatments did not differ significantly with respect to the scores for the pleasure,
discomfort and frequency domains of the Sexual Activity Questionnaire in either the short or medium term.
There were no significant differences in serious adverse events between groups.
Five-year surgery-free survival rates were comparable, irrespective of initial treatments, estimated to be 80%
(95% CI 74% to 84%) in the LNG-IUS group versus 77% (95% CI 71% to 82%) in the usual medical
treatment group (hazard ratio 0.90, 95% CI 0.62 to 1.31; p= 0.6). In total, there were 24 ablations in the
LNG-IUS group versus 31 in the usual treatment group, as well as 30 hysterectomies in both groups.
Economic evaluation
Using the EQ-5D, at 2 years, the relative cost-effectiveness of the LNG-IUS compared with usual medical
treatment was £1600 per QALY, which by 5 years was reduced to £114 per QALY in the base-case
analyses. This increase in cost-effectiveness is caused by both an increase in the mean difference in QALYs
generated (of 0.023) between 2 and 5 years and a reduction in the mean difference in the costs of
treatment over the same period, from a difference of £100 at 2 years to a difference of £17 at 5 years.
All deterministic sensitivity analyses supported the base-case results. PSAs showed that from £2000 per
QALY at 2 years, and £500 at 5 years, the LNG-IUS has a greater probability of being the more
cost-effective intervention.
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However, using the SF-36 to produce utility values, usual medical treatment was assessed as being less
costly, by £100, and generated 0.002 more QALYs than the LNG-IUS at both 2 and 5 years, showing that
usual medical treatment dominates treatment using the LNG-IUS.
Longitudinal qualitative study
The findings show that women’s experiences and expectations of medical treatments for HMB vary
considerably and change over time. Practitioners, in addition to considering a range of practical issues
when discussing treatments with women, should consider that rate of menstrual blood flow, pain and
well-being, alongside wider functioning socially or at work, may be as or more important to women
as volume of menstrual blood loss experienced. Women had high expectations of a prompt effect from
medical treatments. Unpredictable irregular bleeding with the LNG-IUS was more problematic than the
volume of blood loss for women in this study, owing to its impact on their established behavioural coping
mechanisms for HMB. Women viewed standard treatment options, such as oral tranexamic acid, as a
short-term measure, and one that was more within their personal control.
Conclusions
The results of the ECLIPSE trial show that the LNG-IUS, compared with usual medical therapies, leads to
greater improvement over 2 years in women’s assessments of the effect of HMB on their daily routine,
including work, social and family life, and psychological and physical well-being. These findings were no
longer significantly different at 5 years.
The higher rate of discontinuation in the usual treatment group than in the LNG-IUS group could reflect
greater symptom relief with the LNG-IUS, but another possible explanation is that discontinuation of
usual medical treatment does not require consultation. Nonetheless, by 5 years, 53% of women in the
LNG-IUS group had had the system removed, generally owing to lack of effectiveness or to irregular or
prolonged bleeding.
In the primary care setting, treating HMB using the LNG-IUS costs more, but is also more effective, using
the EQ-5D as the outcome, than usual medical treatment in both the short and medium term. As the
National Institute for Health and Care Excellence (NICE) guidelines recommend interventions if the ICER
is below £20,000 per QALY, the LNG-IUS would be considered cost-effective. The difference in the
cost-effectiveness results derived by using the alternative measures to value QoL will have a considerable
impact on cost-effectiveness decisions. The different measures did not just change the strength of
cost-effectiveness of the same treatment, but the most cost-effective treatment itself changed.
Implications for health care
The results provide unique and valuable practical information for women and primary care practitioners
when considering choice of, and what to expect from, medical treatments for HMB. Our clinical results
support the NICE guidelines that recommend that medical treatment options should be considered
when women initially present with HMB in primary care and that the LNG-IUS should be considered
first. Women with HMB, a relatively normal-sized uterus on examination and no other risk factors
(e.g. intermenstrual bleeding, post-coital bleeding, irregularity of the menstrual cycle which has been
assessed by an endometrial biopsy) can be successfully treated and expect a significant reduction in the
range of negative impacts of HMB on QoL. Although the LNG-IUS is more effective than other usual
medical options within the first 2 years of treatment, both the LNG-IUS and usual medical treatments are
shown to be helpful initial choices 5 years later. The low overall rates of surgery underline the importance
and feasibility of initial medical management of women with HMB in primary care, and the avoidance
of referral to secondary care.
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The use of the LNG-IUS is cost-effective in both the short and medium term, using the method generally
recommended by NICE. However, when the SF-6D is used to generate QALYs, the main base-case results are
reversed and usual medical treatment is shown to be more cost-effective at both 2- and 5-year time points.
Therefore, the recommendation to decision-makers differs depending on the outcome measure used.
Qualitative data indicate that clinicians in primary care should also focus on the wider life context for those
presenting with HMB rather than solely on the amount of blood loss experienced by women. They support
the trial evidence that if women persevere with their LNG-IUS, they will probably experience significant
improvement in menstrual symptoms and related QoL. Our data suggest other treatment options, while
less effective, may suit individual circumstances by remaining helpful and more within their control.
Recommendations for further research
It will be important to continue assessment of the ECLIPSE trial participants to 10 years, as we expect that
over half of our cohort will have reached menopause at that stage. This can examine the clinical and
health-service trajectories that women initially treated for HMB in primary care may follow in the longer
term. Relevant data are lacking in these contexts. Such further research may helpfully identify the nature of
continuing use of treatments, particularly the LNG-IUS, and any differential impact on frequency of surgical
interventions in the longer term.
The difference in the results of the economic outcomes arising from the different instruments used to
derive utilities may be explained by the limited recall periods used in these measures and their focus only
on health-related QoL. These conflicting findings suggest that these measures may be capturing different
aspects of QoL, which clearly has an impact on the results. Further consideration of alternative measures to
assess cost-effectiveness, such as willingness to pay, which provides a broader assessment of well-being, is
also needed.
Trial registration
This trial is registered as ISRCTN86566246.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Heavy menstrual bleeding
Definition and diagnosis
Heavy menstrual bleeding (HMB), also called menorrhagia, is a common problem that can significantly
impact on women’s lives and burden individuals and health-care systems. The National Institute for Health
and Care Excellence (NICE) states that ‘for clinical purposes, HMB should be defined as excessive menstrual
blood loss which interferes with the woman’s physical, emotional, social and material quality of life (QoL),
and which can occur alone or in combination with other symptoms’.1 In many previous studies, attempts
were made to define HMB using an objective measure of blood loss, by weighing sanitary products or using
the alkaline haematin method, with a loss of more than 80ml of blood per cycle being considered excessive.
Menstruation changes over a woman’s reproductive lifespan, with cycle length decreasing and the duration
and heaviness of the period increasing with age. Heaviness is thus subjective, defined relative to what a
woman considers normal and is influenced by sociocultural and psychological well-being factors. QoL and
actual menstrual blood are not closely linked,2,3 so any interventions should aim to reduce the burden of the
symptoms for the woman.
Heavy menstrual bleeding is generally considered to be heavy cyclical menstrual blood loss over a minimum
of three consecutive cycles without any intermenstrual or post-coital bleeding. Where no organic pathology
is present, the term dysfunctional uterine bleeding is used, whereas abnormal uterine bleeding includes
that caused by uterine pathology, for example fibroids or genetic factors (e.g. von Willebrand disease).4–6
The majority of women with HMB have no pathology that can be attributed as the cause of their symptoms,
while approximately 30% will have uterine fibroids and 10% uterine polyps, with malignant causes being
rare in the pre-menopausal population.7
With a subjective definition, diagnosis of HMB is made through careful history taking, with any suggestion of
pathology such as intermenstrual or post-coital bleeding prompting further investigation, including physical
examination, ultrasound and biopsy if endometrial hyperplasia or cancer is suspected. Objective measures
are inconvenient and impractical, and indirect measures of menstrual blood loss, such as pictorial diaries, are
not consistently accurate and these too fail to reflect women’s experience of what is burdensome for them.8
A full blood count is recommended by the NICE guidelines,1 but serum ferritin and oestradiol measurement
are not considered worthwhile. Further testing for coagulation or thyroid disorders are dependent on
symptoms and personal history.
Epidemiology
In various cohorts studies, reported prevalence has ranged from 4% to 51%, although it is acknowledged
that differences in definition, measurement (objective vs. subjective), clinical and cultural setting will
undoubtedly influence reporting.1 A UK survey of women aged 18–54 years indicated an annual
community incidence HMB of 25% and prevalence of 52%, with a slight increase with increasing age.9
Heavy menstrual bleeding accounts for 19% of gynaecologist office consultations in the USA10 and 20%
in the UK,11 and each year around 6% of women in the USA consult their general practitioner (GP).12
Another survey found that while 22% of menstruating women over 35 years considered their periods heavy
and interfering with their lives, only 7% had consulted their GP in the preceding 6 months.13 Despite the
many factors influencing women’s decisions not to seek help,14 the number and cost of consultations and
treatments impose substantial demands on the NHS. In 2004–5, there were 7179 hysterectomies and 9701
endometrial ablations performed; compared with 1989–90 this represents a 69% decrease and an 11-fold
increase in the number of procedures for HMB, respectively.15 Rates of surgical procedures for HMB are
17.8 per 10,000 women aged 25–44 years in the USA,16 and 14.3 per 10,000 women in the UK.17
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Management of heavy menstrual bleeding
There are many treatments used for HMB, including medical therapies and surgical procedures. At the
commencement of the ECLIPSE (clinical effectiveness and cost-effectiveness of levonorgestrel-releasing
intrauterine system in primary care against standard treatment for menorrhagia) trial, the Royal College
of Obstetricians and Gynaecologists (RCOG) guidelines18 stated that the initial management should be
usually medical, using the combined oral contraceptive (COC), tranexamic acid or mefenamic acid or the
levonorgestrel-releasing intrauterine system (LNG-IUS) (Mirena®, Bayer) for women not specifically requiring
contraception, but prepared to accept hormonal treatments. For those women requiring contraception,
the options are COCs and the LNG-IUS.
In early 2007, NICE produced clinical guidelines for the management of HMB.1 In these guidelines,
pharmaceutical treatments were recommended as the first line of therapy, regardless of whether the
women presents in primary or secondary care. Endometrial ablation may be considered as initial therapy,
although only after full discussion of the risks and benefits of this and other treatments. Hysterectomy
should not be offered as first-line treatment. The RCOG guidelines18 at the time considered the evidence
for the effectiveness of other drug therapies as limited, and advised that high-dose norethisterone and
long-acting injectable progestogens be used only if all other medical treatments are unsuitable or
unacceptable. NICE, however, included these hormonal options in the guidelines to be considered after
the LNG-IUS, tranexamic acid, mefenamic acid and COCs.
Tranexamic acid
Tranexamic acid is a plasminogen activator inhibitor that exerts an antifibrinolytic effect on the
endometrium, reducing menstrual blood loss by 50%.19 It is taken in high doses, of up to 1 g four times
per day, during the first 5 days of the menstrual cycle. Initial concerns regarding a potential increase in
adverse thrombogenic events has been refuted by long-term studies showing no excess risk.20
Mefenamic acid
Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID), which can reduce the formation
of prostaglandins, implicated in the abnormal clotting in the endometrium by inhibiting the enzyme
cyclo-oxygenase. It is also taken on days 1–5 days of the menstrual cycle, at a dose of 500mg three times
per day, but it is contraindicated in women with bleeding disorders. In terms of reducing menstrual blood
loss, mefenamic acid substantially reduces objectively measured loss, but not to the same extent as
tranexamic acid.21
Combined oral contraceptive pill
Combined oral contraceptives of any formulation reduce the thickness of the endometrium and inhibit
ovulation, with a resultant reduction in menstrual blood loss of 43%.22 There is no evidence of any relative
difference with other medical treatments. COCs are not suitable for everyone. They are contraindicated for
those with a personal history or risk factors for thromboembolism, a body mass index (BMI) of ≥ 35kg/m2
or migraine with aura, and are advised to be used with caution in women over 35 years who smoke or
who are overweight or obese.23
Norethisterone
Norethisterone is a synthetic progesterone which can reduce menstrual blood loss in ovulatory women if
10–15mg is taken daily from day 5 to day 26 of the cycle, but is ineffective if taken only during the late
luteal phase, from day 19 to day 26 of the menstrual cycle. Compared with tranexamic acid or the
LNG-IUS, norethisterone is not as effective at reducing objectively measured menstrual blood loss.21,24
Levonorgestrel-releasing intrauterine system
The LNG-IUS is a highly effective long-acting reversal contraceptive. Since 2009 in the USA, and earlier in
Europe, the LNG-IUS has been available for HMB.23 The LNG-IUS is a T-shaped plastic frame containing
52mg of levonorgestrel, which is released at a rate of approximately 20 µg per day and is licensed for
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5 years’ use, after which it should be removed and replaced if desired. Fertility is quickly restored after
removal. The LNG-IUS is contraindicated in women with a congenital uterine anomaly or who have fibroids
that distort the uterine cavity, in women with a uterine or pelvic infection, and in those with a history
of gynaecological cancers. The adverse events of interest fall into two categories: those related to an
intrauterine device, such as dysmenorrhoea, irregular bleeding, ectopic pregnancy and expulsion of the
device; and those related to progestogens, such as bloating, weight gain and breast tenderness. The main
disadvantage of the LNG-IUS is the disruption to the menstrual cycle, particularly in the first 6 months,
with the number of bleeding and spotting days increasing to a median of 18 days and the cycle becoming
irregular in approximately 20% of women, before reducing in duration and severity.25 The proportion of
women who are amenorrhoeic a year following insertion has been reported at around 12%.26,27
Effectiveness of the levonorgestrel-releasing intrauterine
system for heavy menstrual bleeding
Clinical effectiveness of the levonorgestrel-releasing intrauterine system
compared with medical treatments
Prior to the initiation of the ECLIPSE trial, the most comprehensive summary of the data for the LNG-IUS
came from a systematic review which identified 10 studies of the LNG-IUS for women with heavy
menstrual blood loss (≥ 80ml per cycle).28 Of these, only five studies were randomised controlled trials
(RCTs),20,24,29–31 and only four reported menstrual blood loss reduction in those with the LNG-IUS in place
for 3–12 months, in whom the reduction in blood loss ranged from 79% to 96%.
In 2007, the NICE guidance1 considered all pharmaceutical treatments for HMB. In comparing the LNG-IUS
with non-surgical options, NICE referred to the Cochrane review,27 which cited three small randomised trials
comparing the LNG-IUS with norethisterone,24,32 mefenamic acid32,33 or danazol32 (Danol®, Sanofi-aventis),
although the trial reported by Cameron et al.32 used a now discontinued formulation of the LNG-IUS. From
this review, the odds ratio for amenorrhoea (> 3 months) was 8.67 [95% confidence interval (CI) 1.52 to
49.35] in favour of the LNG-IUS. The odds ratio for the proportion of women unwilling to continue with
treatment was 0.27 (95% CI 0.10 to 0.67) and for the proportion of women satisfied with treatment the
odds ratio was 2.13 (95% CI 0.62 to 7.33), both in favour of the LNG-IUS.
For COCs, only one small RCT of four treatments existed at the time of the NICE guidelines,34 suggesting
that COCs reduce menstrual blood loss to a greater extent than the NSAID naproxen, but less than
mefenamic acid or the gonadotropin-releasing hormone antagonist danazol. However, the COC used was
a first-generation formulation and no data exist for the lower oestrogen doses now available.
There was sufficient evidence in three systematic reviews for NICE to conclude that a tranexamic acid
causes a clinically significant reduction in menstrual blood loss for women with HMB, ranging from 29%
to 58% in studies lasting up to 1 year, although long-term data are missing.11,21,27,35 NSAIDs (mefenamic
acid or naproxen) were also found to produce clinically important reductions in menstrual blood loss,
ranging from 20% to 49%, but were inferior to danazol and tranexamic acid, although NSAIDs have
fewer adverse effects than danazol.36,37
The NICE guidelines development group stated that, in its interpretation of the evidence for pharmaceutical
treatments for HMB, a high value was placed on reduction of menstrual blood loss and minimising
adverse effects. The guidelines development group based its assessment first on the clinical effectiveness
of treatments and, second, on the cost-effectiveness of treatments. The results of the systematic review
showed that the LNG-IUS, mefenamic acid, tranexamic acid and COCs could be considered equivalent in
terms of clinical effectiveness. However, the guidelines went on to state that, if both hormonal and
non-hormonal treatments are acceptable, then the order in which treatment should be considered should
be the LNG-IUS, then tranexamic acid, a NSAID or COC, then norethisterone on days 5–26 of the cycle.
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An updated review identified seven further randomised trials,38–44 involving only 718 women in total, which
compared the LNG-IUS with non-hormonal and hormonal treatments. In an industry-sponsored review,45
reduction in menstrual blood loss was achieved in only 230 women, from five studies,33,38,43,44,46 in which
the LNG-IUS was administered. Reported median blood loss had decreased by 85% by 3 months, and had
further decreased, by a total of 94%, by 12 months, remaining constant thereafter to 5 years.
The emphasis of all the previous trials has been on the reduction in menstrual blood loss. Very few
trials collected data on QoL or impact of the symptoms. A small study of the LNG-IUS compared with
norethisterone found no difference in the proportion of women in whom menstrual blood loss interfered
with their QoL after treatment.24
The trial by Lahteenmaki et al.31 did report on QoL, measured using visual analogue scales (VASs) rather than
any validated scale. The study selected women awaiting a hysterectomy and offered them the option of
randomisation between continuing their existing treatment and the LNG-IUS. The lack of blinding and the
control group remaining on an unsatisfactory treatment is likely to have influenced the women’s attitude to
treatment and subjective assessment of QoL, therefore, is inherently biased against existing therapy.31
Clinical effectiveness of the levonorgestrel-releasing intrauterine system
compared with surgery
Prior to the start of the ECLIPSE trial, there were six RCTs comparing the effectiveness of the LNG-IUS
with surgery, two using first-generation ablation methods,29,30 three comparing the LNG-IUS with
second-generation thermal balloon ablation47–49 and one comparing the LNG-IUS with hysterectomy.50
No difference in the rates of amenorrhoea or satisfaction rates were seen compared with endometrial
ablation, although menstrual blood loss was reduced to a greater extent with ablation.29,48
In a subsequent Cochrane review of medical versus surgical treatments for HMB,51 an additional six trials,
four49,52–54 comparing the LNG-IUS with thermal balloon ablation, one55 comparing the LNG-IUS with
hysterectomy and two38,56 comparing the LNG-IUS with first-generation ablation, were included. There was
no statistically significant difference in satisfaction rates up to 2 years or in most domains of the Short
Form questionnaire-36 items (SF-36) measure of QoL. As before, endometrial ablation was significantly
more effective than the LNG-IUS in controlling bleeding at 1 year (relative risk 1.19, 95% CI 1.07 to 1.32;
p= 0.001). Hysterectomy stopped all bleeding and provided greater satisfaction, but caused serious
complications for some women. This review considered the long-term data to be weak.
This review was extended by obtaining individual patient data in order to be able to standardise outcome
data, such as satisfaction or, the corollary, dissatisfaction.57 Rates of dissatisfaction with the LNG-IUS
and non-hysteroscopic endometrial destruction were similar (18% vs. 23%; odds ratio 0.8, 95% CI 0.4 to
1.5; p= 0.4). Lack of data from individual patients prohibited any further investigation of subgroups or
first-generation ablative methods. There was weak evidence to suggest hysterectomy is preferable to the
LNG-IUS (dissatisfaction 5% vs. 17%; odds ratio 2.2, 95% CI 0.9 to 5.3; p= 0.07).
As might be anticipated, women having surgical treatment were significantly less likely to require further
surgery within 1 year than women who had a LNG-IUS (relative risk 0.13, 95% CI 0.05 to 0.33;
p= 0.00002). None of the hysterectomy group required additional surgery, while about 3% of women
who had endometrial ablation required extra surgery during the first year, compared with about 15% of
women who were allocated the LNG-IUS. One study38 reported that 14% (4/29) of the surgical group
underwent repeat ablation within 3 years (with two having subsequent hysterectomy), while 30% (9/30)
of women allocated to the LNG-IUS group discontinued its use and ‘were offered’ endometrial resection.
In a Finnish trial58 of 117 women with a LNG-IUS, 60 women no longer had it in situ 5 years after
randomisation; 50 of these women had had a hysterectomy (42% of those randomised to the LNG-IUS)
and one had had endometrial ablation.
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The NICE guidelines1 highlighted the high level of subsequent surgery associated with the LNG-IUS and
recommend that endometrial ablation may be offered as an initial treatment for HMB after full discussion
with the woman of the risks and benefits and of other treatment options, while hysterectomy should not
be used as a first-line treatment solely for HMB.
Cost-effectiveness of the levonorgestrel-releasing intrauterine system
compared with other treatments
The first trial to incorporate a cost-effectiveness analysis was the Finnish trial cited above.50,58 There was no
statistically significant difference in QoL scores between the two treatment groups at 5 years, as measured
by the European Quality of Life-5 Dimensions (EQ-5D) instrument. Mean direct costs remained significantly
lower in the LNG-IUS arm (US$1892) than in the hysterectomy arm (US$2787), despite 42% of women
in the LNG-IUS arm going on to have a hysterectomy. This trial, however, compared the LNG-IUS with
hysterectomy in women referred to hospital. No economic analysis relevant to the use of the LNG-IUS in
a UK primary care setting is available, nor had the relative cost-effectiveness of the LNG-IUS relative to
medical treatment been assessed at the start of the ECLIPSE trial.
The health economic assessment performed in the process of developing the NICE guidelines populated
a decision model with data predominantly from the Finnish study, and made significant assumptions
regarding the effectiveness and discontinuation rates of COCs, tranexamic acid and mefenamic acid. The
results showed that the LNG-IUS is the more effective treatment option when long-term use of a treatment
is required, as the LNG-IUS generated more quality-adjusted life-years (QALYs), at a lower cost, than
any other pharmaceutical treatment strategy. The base-case result was £840 per QALY gained.1 The
uncertainty in this result was not explored at all and so the result could be highly misleading.
Rationale for the ECLIPSE trial
An early systematic review highlighted the lack of evidence on the relative benefits of the LNG-IUS
compared with medical treatment and recommended large pragmatic trials.28 This was reiterated by the
NICE guidelines.1 The LNG-IUS is an effective, relatively safe, treatment for HMB, at least in the short term,
although it is less effective than endometrial ablation. However, women with HMB often have additional
concerns, which may be altered by treatment. These include the presence or absence of pain, risk of
sexually transmitted disease and reproductive function. Short-term reduction in menstrual blood loss may
not translate into an improvement in a woman’s overall QoL or her need to seek further treatment,
particularly as the LNG-IUS discontinuation rates are high.
Moreover, the consequences of HMB and its treatment extend for many years, and so a treatment that
appears to be effective at 1 year may merely delay, not prevent, a definitive solution such as surgical
intervention. None of the early trials measured the effect of HMB on women’s lives or followed women for
longer than 1 year. In relation to the LNG-IUS, there may be ‘phase shifting’ of the patient’s journey. For
example, once the device is removed, some patients’ symptoms may recur, resulting in later surgery. If a
woman discontinues any medical treatment, it could be because the HMB has resolved, or it could be
that the treatment does not produce sustained benefit. This means that it is essential to determine and
compare the long-term consequences of different treatments over a prolonged period of time appropriate
to the long natural history of HMB.
It is also unclear whether or not women presenting in primary care with HMB are best treated with a
LNG-IUS. The LNG-IUS is slightly more difficult to insert than standard contraceptive coils and specific
training for GPs is required.1 A LNG-IUS is occasionally associated with troublesome menstrual irregularities,
especially in the first few months, and is often removed for this reason. Given the potential complications,
better evidence to establish the effectiveness of the LNG-IUS as a first-line therapy is needed before it
becomes widely used in primary care.
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It is apparent that a RCT of the LNG-IUS should take into account a range of patient needs and
preferences. These include:
l women’s preferences for contraception: some desire the maintenance of fertility, some require
contraception contemporaneously with relief from HMB, while some others may want to be sterilised
l long-term assessment of the treatment ‘pathway’, with different initial policies
l self-reported outcome measures that identify the impact of treatment on overall QoL and further
treatment decisions
l the initial management of HMB in primary care
l the clinical effectiveness and cost-effectiveness, and acceptability of treatment policies.
The choice of comparator needs to reflect current practice. The treatment objective in HMB is to alleviate
heavy menstrual flow and, consequently, to improve QoL. Iron-deficiency anaemia must also be prevented.
Both the superseded RCOG18 and NICE guidelines supported the use of COCs, tranexamic acid, mefenamic
acid, injectable medroxyprogesterone acetate (Depo-ProveraTM, Pfizer Ltd) and norethisterone, with the
choice dependent on the woman’s preferences for hormonal or non-hormonal treatments and contraceptive
needs. The comparison group was defined as usual medical treatment, with the choice specific drug being a
joint decision between the GP and patient.
Objectives
Primary objective
To assess the clinical effectiveness of the LNG-IUS compared with standard medical treatment for women
seeking treatment for HMB in primary care in the short term (2 years following randomisation).
Secondary objective
l To assess the clinical effectiveness of initial treatment with the LNG-IUS compared with standard
medical treatment for women seeking treatment for HMB in primary care in the medium term
(5 years following randomisation).
l To determine the cost-effectiveness of the LNG-IUS compared with standard medical treatment in the
short and medium term.
l To explore the perspectives of trial participants or women with HMB who declined to be randomised in
a longitudinal qualitative study.
l To measure the reliability and validity properties of the Menorrhagia Multi-Attribute Scale (MMAS).
INTRODUCTION
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Chapter 2 Outcome measures for the evaluation
of treatment of heavy menstrual bleeding
Introduction
Heavy menstrual bleeding is a common gynaecological condition in the UK that has a significant impact on
many women’s well-being. The principal driver for treatment of HMB is women’s experience of its impact
on their lives. Women are mainly treated on the basis of symptoms, and therefore assessment of the
condition and of the effectiveness of treatment has a large subjective component. There is poor correlation
between quasi-objective measures of HMB, for example self-reports of blood loss, so a woman’s subjective
assessment of the perceived impact on her QoL is increasingly used to assess treatment success. As the
aim of treatment is to improve women’s well-being and QoL, it is necessary to have valid and reliable
instruments to measure this.
A systematic review of research published before the ECLIPSE trial,59 which assessed the quality of QoL
instruments from 19 studies of HMB, was used to select the most appropriate instruments to use for the
trial. Studies for the review were identified through MEDLINE, EMBASE, Science Citation Index, Social
Science Citation Index, Cumulative Index to Nursing and Allied Health Literature and PsycLIT, and the
references of primary and review articles. Search terms included menorrhagia, questionnaires, psychometry,
psychometrics, psychological(al) tests and QoL. Studies were selected if they measured QoL in women
with HMB as either an outcome measure or as part of the development of the QoL instrument itself. They
were assessed using a checklist of items for clinical face validity (i.e. issues relevant to patients’ expectations
and concerns) and items for measurement properties (including reliability, responsiveness, criterion or
construct validity and acceptability).60
In terms of quality, although 90% of studies complied with more than half of the criteria for measurement
properties, only 37% of studies complied with more than half the criteria for face validity. Only two
studies61,62 used a condition-specific QoL instrument for HMB, which considered the most appropriate
measure to assess the effect of treatment; these were instrument development studies rather than studies
using the instrument as an outcome measure. The generic SF-36 was the most commonly used (63% of
studies). This generic instrument has been validated in HMB60 and seems to be reliable and responsive;60,63
however, it is designed to assess QoL on a continuum from full health to death over the previous 4 weeks.
Therefore, the SF-36 is not entirely appropriate for women with HMB because the symptoms of HMB are
cyclical and the condition is distressing, but not life-threatening. This makes using the SF-36 on its own
an inappropriate instrument for a patient-based outcome measure in HMB.
This review concluded that there is a need for methodologically sound condition-specific QoL instruments in
HMB with clinical face validity to assess treatment outcomes. One condition-specific instrument identified
as having high face validity is the MMAS, developed by Shaw et al.61 This was developed in collaboration
with women with HMB using a multi-attribute utility method.64 It was decided that this scale should be the
principal outcome measure for the ECLIPSE trial. However, although the MMAS was designed to have good
face and content validity, other psychometric properties of this instrument, such as reliability, convergent
and discriminant validity, and floor and ceiling effects, could not be evaluated in the original study. One
study reported a small advantage for the MMAS over the SF-36 in predicting management outcome for
HMB,65 but otherwise the measurement properties of the questionnaire when used in a treatment or
observational study had not been reported before. These properties of the MMAS were assessed at the
beginning of the ECLIPSE trial.
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The disadvantage of the MMAS is that, as a condition-specific measure, it is anchored by full health and
the worst possible state for the condition, rather than full health and death, as in generic measures.
This is important in the economic evaluation of treatments, which is recommended by NICE.66 Since
economic evaluation is used by decision-making bodies such as NICE to help with decisions about resource
allocation, it is important in the context of treatment trials. NICE endorses the use of generic instruments
in economic evaluation of treatments in order to calculate the QALY.66 The QALY reflects changes in both
the quantity of life and the QoL, where quality is measured on a scale from 0 (death) to 1 (full health).
In order to undertake an economic evaluation in the ECLIPSE trial, it was therefore necessary to include
generic measures in addition to the condition-specific MMAS. In the systematic review cited above,59
the SF-36 health survey questionnaire was the most commonly used generic instrument. However, NICE
recommend the use of the EQ-5D,66 which can more straightforwardly be converted to QALYs. Clark et al.59
suggest that, in order to ensure that a trial has an appropriate set of outcome measures, a condition-specific
instrument could be used in combination with a generic instrument. It was therefore decided to combine
the MMAS with a generic instrument. There was better evidence for the use of the SF-36 in HMB, but given
the recommendation from NICE to use the EQ-5D and its relative brevity it was decided to use both generic
instruments in the ECLIPSE trial. In addition to the QoL instruments, it was decided to include a measure of
sexual well-being. Clinical experience has shown that sexual activity is an important dimension of women’s
lives which may be specifically affected by HMB. The outcome measures used are described below.61
Outcome measures used in the ECLIPSE trial
Menorrhagia Multi-Attribute Scale
The MMAS questionnaire captures the subjective consequences of HMB on six domains: practical
difficulties, social life, psychological well-being, physical health, work routine and family life. Each of the
six domains has four statements which represent four levels of response. Respondents indicate the
statement which best matches their feelings for each domain. The statement scores derive from a
weighting of the domains and a weighting of the statements in level of severity by women in the origin
study. Scores range from 0 (worst possible state in all domains) to 100 (best possible state in all domains).
Medical outcomes study: Short Form questionnaire-36 items
The SF-36 version 2 is a 36-item short-form survey that measures general health-related QoL. The SF-36 is
a practical and reliable way to obtain important health outcomes data in a variety of settings, measuring
eight domains of health: physical functioning, role limitations owing to physical health, bodily pain, general
health perceptions, vitality, social functioning, role limitations owing to emotional problems and mental
health. Respondents are asked to recall how they have felt over the previous 4 weeks. It is commonly used
in studies of HMB.65
European Quality of Life-5 Dimensions
The EQ-5D is a standardised instrument for use as a measure of health outcome and is widely used in
economic evaluations of medical interventions. Applicable to a wide range of health conditions and
treatments, it provides a simple descriptive profile and also a single-index value for health status measured
on a VAS.
The Sexual Activity Questionnaire
The Sexual Activity Questionnaire (SAQ) was developed as a self-report questionnaire, for use in
gynaecological clinical trials, which would be quick to complete and acceptable to the majority of women.67
Three dimensions of perceptions of sexual activity are measured: pleasure, discomfort and habit.
OUTCOME MEASURES FOR THE EVALUATION OF TREATMENT OF HEAVY MENSTRUAL BLEEDING
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Measurement of reliability and validity properties of the
menorrhagia multi-attribute quality-of-life scale
Method
Participants
Data from the first 431 women enrolled in the ECLIPSE trial were analysed for this study.
Procedure
Participants completed the MMAS, SF-36 version 2, EQ-5D and the SAQ as part of the baseline measures
for the trial before randomisation, but before treatment. Fifty women were also invited to participate in a
test–retest study of the MMAS and completed the questionnaires again within 2 weeks of the baseline
measurement, but before treatment commenced.
Psychometric analysis
The measurement properties of the MMAS were assessed using traditional psychometric procedures.
Estimates of reliability and validity were made using intra- and inter-test correlations, with additional
comparison of means for the subscales of the questionnaire. Floor and ceiling effects were also assessed
using frequency data on high and low scores.
Results
The mean age of the participants was 41.25 years [standard deviation (SD) 5.3 years]. The ethnic mix of
the sample was representative of the patient population for the area and the trial as a whole, with 93%
of women categorising themselves as from the two main ethnic groups, white British (83%) and South
Asian (10%).
Reliability
Of the 50 women asked to take the questionnaire again within 2 weeks, 49 returned completed
questionnaires. The test–retest correlation for the total MMAS score was acceptable (r= 0.836), suggesting
that it is stable over time. Cronbach’s alpha was calculated as a measure of internal consistency of the
six items of the MMAS. The Cronbach’s alpha value was 0.82 and lies within the range 0.7 and 0.9,
suggesting that the items are all measuring aspects of the same construct.68 Evidence of the homogeneity
of the MMAS was also provided by the item total correlations (the correlation between each item and the
total score minus that item) which range between 0.44 and 0.68. Only one such correlation fell below 0.6,
that for ‘practical difficulties’ caused by HMB.
Validity
The MMAS has already been shown to have good face validity, so this analysis concentrated on construct
validity, that is the extent to which the instrument measures what it is intended to measure. An important
method of demonstrating construct validity is by showing that an instrument correlates with other
instruments measuring similar constructs, for example generic QoL scales (convergent validity), and does
not correlate with measures of different constructs, for example age and BMI (discriminant validity).
Convergent validity
To show convergent validity, correlations between test scores should be moderate to high, that is 0.4 or
higher. Table 1 shows the correlations between the MMAS total score, the subscales of the SF-36 and the
EQ-5D. These show moderate correlations for most components of the SF-36, but weaker correlations for
physical functioning, general health perception and for the EQ-5D standardised score.
The individual domain scores of the MMAS were compared with the SF-36 subscales. With the exception
of the practical difficulties domain on the MMAS, which did not significantly correlate with any SF-36
subscale, the highest correlations were between each of the MMAS domains and the SF-36 social
functioning scale. The correlation between the psychological health scales of the two instruments is 0.39,
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and that between the MMAS relationships scale and the SF-36 emotional role limitations is 0.47. However,
these correlations of subscales should be interpreted with caution as there are only 4 points on the MMAS
subscales. In order to investigate these relationships further, respondents were divided into four groups
for each MMAS domain and their scores on the SF-36 were compared using analysis of variance. The
results for most subscales and domains were highly significant for each comparison, with high scores on
the MMAS corresponding to high scores on the SF-36. Again, the exception was for comparisons in the
practical difficulties domain. Here, three comparisons were not significant: mental health (F3,422= 1.66;
p= 0.175), pain (F3,424= 0.62; p= 0.60) and general health (F3,415= 2.21; p= 0.09).
There was a small non-significant difference in the total MMAS scores of women reporting that they were
not engaging in sexual activity on the SAQ and those who were (38.86 and 41.49, respectively). It may be
that the MMAS relationship domain reflects a particular problem with sexual relationships. To test this,
comparisons were made between the scores on the pleasure, discomfort and habit scales of the SAQ
for women scoring at the four different levels of the relationship domain. This revealed a statistically
significant effect of level on the discomfort scale (F3,321= 4.05; p= 0.008), but non-significant effects of
pleasure (F3,321= 1.71; p= 0.165) and habit (F3,326= 2.54; p= 0.057).
Discriminant validity
The MMAS total score would not be expected to correlate with age or BMI. As expected, these correlations
are very low for age (r= 0.086) and for BMI (r= –0.057). As well as providing evidence for the validity of the
MMAS, it suggests that it can be used with all age groups.
Acceptability
All items in the MMAS were completed by all participants, indicating that the instrument was acceptable
to them.
Floor and ceiling effects
In psychometric instruments, floor and ceiling effects have implications for the precision of the instrument
and its responsiveness to change, as they reduce the likelihood that the instrument will measure further
improvement or deterioration. In this sample, five (1.2%) women’s scores were the lowest possible and
three (0.7%) were the highest possible. The overall distribution of scores was slightly positively skewed
(skew= 0.41, standard error= 0.12), which is what might be expected in a sample of women just about to
embark on treatment for HMB. These statistics indicate that there are no floor or ceiling effects.
TABLE 1 Correlations between the MMAS total score, the EQ-5D summary and the SF-36 subscales
Questionnaire and domains
MMAS total score
r n
SF-36 subscales
Physical functioning 0.33 420
Physical role limitations 0.45 422
Emotional role limitations 0.49 421
Social functioning 0.54 427
Mental health 0.40 426
Energy/vitality 0.42 426
Pain 0.38 428
General health 0.32 419
EQ-5D summary score 0.32 428
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Discussion
This study investigated further the psychometric properties of the MMAS. It has shown that, in addition
to having high face validity, the MMAS has good convergent and discriminant validity, and test–retest
reliability. It also has high internal consistency, with a Cronbach’s alpha score of 0.82, which is further
evidence of reliability and indicates that all the items are measuring different aspects of the same construct.
The overall MMAS score showed moderate correlation with most of the subscales of the SF-36. Lower
correlations were found for physical functioning and general health perception. Rather than being a
negative feature, these low correlations may reflect the inappropriateness of the SF-36 as the sole measure
of QoL in women with HMB. The physical functioning subscale is heavily weighted to mobility and self-care,
not likely to be affected by HMB. The general health subscale and the EQ-5D, which was also relatively
poorly correlated with the MMAS, may not be precise enough to measure differences in this patient group,
especially when women are asked to consider their general condition rather than that pertaining to their
menstrual cycle.
Conversely, scores on the practical difficulties subscale of the MMAS were not related to other QoL
measures. This domain of the MMAS is very specific to HMB, relating to sanitary protection and flooding
and may pick up specific important issues not measured by generic scales.
All women completed the whole of MMAS, which suggests that it is acceptable to women and seen to be
relevant. It could be argued that this sample was more highly motivated than women with HMB more
generally because they had already agreed to take part in the ECLIPSE trial. However, there were missing
data in other questionnaires administered at the same time. These results suggest that the MMAS has
good measurement properties and is, therefore, an appropriate condition-specific instrument to measure
the outcome of treatment for HMB.
General discussion
In this chapter we have discussed some of the challenges in assessing the outcome of treatment trials for
HMB. We have demonstrated that the MMAS is a reliable and valid instrument to measure the impact
of HMB, and its treatment, on women. However, although the MMAS appears to be the most suitable
measure, owing to its condition-specific nature it cannot produce QALYs and is therefore not appropriate
for economic evaluation.
A more recent systematic review of the QoL instruments used in HMB by Sanghera et al.69 found no
consensus on the most appropriate economic measure to use when valuing outcomes in HMB, with both
the SF-36 and EQ-5D lacking face validity. Evidence suggests that women do not consider HMB to
be solely a health-related condition, so purely generic health-related QoL measures are unsuitable. This is
supported by the analysis, which showed that the practical difficulties question in the MMAS did not
correlate with any of the components of the health-related generic instruments.
A different approach that Sanghera et al.69 explored in their review is willingness to pay (WTP). WTP
considers a broader range of QoL than that related to health. Many studies have successfully elicited WTP
values in other disease areas,70 so perhaps WTP could prove to be the most suitable economic measure in
HMB in future trials. However, even at the time of this later review there was insufficient evidence for its
use, with only one study reviewed assessing the reliability of WTP.69
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Conclusions
At the beginning of the ECLIPSE trial the evidence suggested that while the primary outcome of the trial,
that is, the impact of treatment on women with HMB, should be measured by a condition-specific
instrument, economic evaluation of the trial required generic instruments. In addition, clinical experience
suggested that sexual well-being was an aspect of women’s lives particularly affect by HMB, so it was
decided to investigate this in more detail using the SAQ. Consequently, four self-report instruments were
chosen to measure the outcomes of the ECLIPSE trial, MMAS as the primary outcome measure with the
SF-36 version 2, the EQ-5D (both the profile and VAS scores) and the SAQ as secondary outcome measures.
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Chapter 3 Methods and results of the randomised
controlled trial up to 2 years’ follow-up
Objectives
The study rationale is presented in Chapter 1. The objectives of the RCT presented in this chapter were to
assess the clinical effectiveness of the LNG-IUS compared with standard medical treatment for women
seeking treatment for HMB in primary care, with up to 2 years’ follow-up.
Methods
Population
Women between 25 and 50 years of age who presented to their GP with HMB involving at least three
consecutive menstrual cycles were eligible to participate. Women were excluded if they intended to
become pregnant over the next 5 years, were taking hormone replacement therapy or tamoxifen
(SoltamoxTM, Rosemount Pharmaceuticals), had intermenstrual bleeding (between expected periods) or
post-coital bleeding or findings suggestive of fibroids (abdominally palpable uterus equivalent in size to
that at 10–12 weeks’ gestation) or other disorders, or had contraindications to or a preference for either
the LNG-IUS or usual medical treatments. Women with heavy, irregular bleeding were ineligible unless the
results of endometrial biopsy were reported to be normal; no further investigations were mandated by
the protocol. All patients provided written informed consent.
Randomisation
Patients were assigned to a study group by telephone or a web-based central randomisation service at the
University of Birmingham Clinical Trials Unit. A computerised, minimised randomisation procedure was used
to achieve balance between the groups with respect to age (< 35 years or ≥ 35 years), BMI (≤ 25 kg/m2 or
> 25 kg/m2), duration of symptoms (< 1 year or ≥ 1 year), need for contraception (yes or no) and heavy
HMB alone or HMB accompanied by menstrual pain. GP practice was not included as a minimisation
variable to avoid any chance of the allocation becoming too predictable.
Study interventions and compliance
Eligible women who provided written informed consent were randomly assigned to either the LNG-IUS
or usual medical treatment. Usual treatment options included mefenamic acid, tranexamic acid,
norethisterone, a combined oestrogen–progestogen or progesterone-only oral contraceptive pill (any
formulation), or medroxyprogesterone acetate injection and were chosen by the physician and patient on
the basis of contraceptive needs or the desire to avoid hormonal treatment.1,18 The particular medical
treatment to be used was specified before randomisation. Subsequently, treatments could be changed
(from one medical treatment to another, from the LNG-IUS to medical treatment, or from medical
treatment to the LNG-IUS) or could be discontinued because of a perceived lack of benefit, side effects, a
change in the need for contraception, referral for endometrial ablation or hysterectomy, or other reasons,
according to usual practice.1,18 Treatment changes reported by patients were confirmed with the GP.
Outcome measures and follow-up
The primary outcome measure was the condition-specific MMAS,61,71 which is designed to measure the
effect of HMB on six domains of daily life (practical difficulties, social life, psychological health, physical
health, work and daily routine, and family life and relationships). Summary scores, which range from
0 (severely affected) to 100 (not affected), were assessed at 6 months, 1 year and 2 years after
randomisation. Details on how summary scores are calculated can be found elsewhere.61 The MMAS has a
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high degree of reliability and internal consistency,71 has good content and construct validity,61,71 is
responsive65,72 and is acceptable to respondents.61,65,71,72 Secondary outcome measures included general
health-related QoL and sexual activity. To assess QoL, we used three instruments: the SF-36 version 2
[with scores ranging from 0 (severely affected) to 100 (not affected)], the EQ-5D [with scores ranging from
−0.59 (health state worse than death) to 100 (perfect health state)] and the EQ-5D VAS [with scores
ranging from 0 (worst health state imaginable) to 100 (most perfect health state imaginable)]. The validated
SAQ measures pleasure [with scores ranging from 0 (lowest level) to 18 (highest level)], discomfort [with
scores ranging from 0 (greatest) to 6 (none)] and frequency (assessed relative to perceived usual activity as
an ordinal response).73 Scores were obtained before randomisation and by mail at 6 months, 1 year and
2 years after randomisation. Data were collected from participating clinicians regarding all serious adverse
events, defined as adverse events that resulted in death, disability or hospitalisation. Patients were also
asked to report any hospitalisations and adverse events leading to discontinuation of the study drug.
Study oversight
The study sponsor was the University of Birmingham. Study oversight was provided by an independent
steering committee and an independent data and safety monitoring committee, whose three reviews of
interim data provided no reason to modify the trial protocol on the basis of pragmatic stopping criteria,74
other than to support revision of the recruitment target, which is described in Statistical considerations.
The study was conducted in accordance with the protocol, which is available at www.nets.nihr.ac.uk/
projects/hta/020602. Approval of the study was obtained from the South-West England Multicentre
Research Ethics Committee, and clinical trial authorisation was received from the Medicines and Healthcare
products Regulatory Authority. All medications and devices were prescribed by providers through the NHS.
The manufacturers of the LNG-IUS and other therapeutic agents used in the study were not involved in
any aspect of the trial.
Statistical analysis
The study was originally designed to have 95% power at p< 0.01 to detect small to moderate (0.3 SD)
differences in mean MMAS score between groups at any one time point.75 Following interim review of
recruitment rates, in consultation with the independent data monitoring committee, the power and
type 1 error parameters were revised to more conventional levels of 90% and p= 0.05, to allow timely
completion of the study. This required an enrolment of 470 patients; we increased the sample size to 570
to allow for up to 20% loss to follow-up.
Analyses was by intention to treat with continuous measures compared using multilevel repeated-measures
models,76 including parameters allowing for participant, treatment, time and baseline score. Responses
including all three time points were considered in the primary analysis. Differences between slopes were
assessed by including treatment-by-time interaction parameters in the models. If these were not significant
(p> 0.05), then they were dropped from models and constant treatment differences over time were
assumed. In a similar fashion, treatment-by-subgroup interaction parameters were included in the above
model to test for the importance of the prespecified subgroup parameters (same as the minimisation
variables, see Randomisation). Treatment effect estimates within subgroups are presented where
interaction parameters were statistically important. Differences between groups at each assessment time
point were also examined by analysis of covariance (adjusting for baseline score). Changes from baseline
score within groups were examined using paired t-tests.
A number of sensitivity analyses were performed on the primary outcome to test the robustness of the
results.77,78 Analyses were performed excluding data received subsequent to a crossover to the alternative
treatment group and also once study treatment was ceased altogether. Further sensitivity analyses included
assigning the best possible score (100) to those women who indicated that they were no longer experiencing
bleeding and did not complete the MMAS, and a carried forward (pre-intervention) score for those
undergoing hysterectomy or endometrial ablation. Further analyses included the exclusion of MMAS data from
late returned booklets (defined as more than 3 months past the due date) and an analysis assuming all missing
responses were the worst possible score (0). Missing MMAS responses were also simulated using a multiple
imputation approach with analysis performed on the resulting 20 simulated data sets.78
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Kaplan–Meier plots were constructed for time to first treatment change with women censored at date of
last follow-up or, if appropriate, date of death, withdrawal or loss to follow-up. A Cox proportional
hazards model was used to construct hazard ratios. Standard statistical methods were used to test the
statistical significance of other responses (chi-squared tests for dichotomous data, Cochrane–Armitage test
for trend and Wilcoxon signed-rank test for ordinal data). Effect sizes are presented with 95% CIs and
two-sided p-values for all. SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) was used for analyses.
Results
Patients and follow-up
Between February 2005 and July 2009, a total of 571 women with HMB from 63 UK centres (median centre
recruitment was three, interquartile range one to seven) were randomly assigned to either the LNG-IUS
(285 women) or usual medical treatment (286 women). Baseline characteristics were similar between the
two treatment groups (Table 2).
TABLE 2 Baseline characteristics of the patients
Characteristics Usual medical treatment (n= 286) LNG-IUS (n= 285)
Age (years)
≥ 35a 255 (89%) 257 (90%)
Mean (SD) 41.8 (5.5) 42.1 (5.0)
BMI (kg/m2)
≥ 25a 200 (70%) 200 (70%)
Mean (SD) 29.3 (6.7) 29.1 (6.1)
Ethnic groupb
White 246 (86%) 225 (79%)
Asian 23 (8%) 28 (10%)
Black 12 (4%) 18 (6%)
Mixed 4 (1%) 9 (3%)
Other 1 (< 1%) 4 (1%)
Duration of HMB ≥ 1 yeara 229 (80%) 231 (81%)
Presence of menstrual paina 211 (74%) 213 (75%)
Contraceptive requirementa 55 (19%) 55 (19%)
Copper or non-hormonal coil in place 10 (3%) 9 (3%)
a This characteristic was a minimisation variable and was assessed in the predefined subgroup analyses.
b Self-identified ethnic grouping. One ‘not given’ response in the LNG-IUS group.
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For 215 (75%) of the women assigned to usual medical treatment, the initial prescription, decided prior to
randomisation, was for mefenamic acid, tranexamic acid or a combination of the two drugs (Table 3);
55 (19%) of the women in the usual treatment group required contraception. Study questionnaire
booklets were returned by 478 (84%) of the patients at the 2-year time point (see Figure 1);38 of these
women, 45 (9%) could not complete the MMAS appropriately because their menstrual bleeding had
ceased, but they completed other parts of the booklet and this information was used to inform the
sensitivity analysis.
Of the 285 women randomly assigned to the LNG-IUS, 24 (8%) did not have the intrauterine system (IUS)
inserted: 10 chose usual medical treatment, six chose no treatment and, in eight, insertion of the system
was unsuccessful and, therefore, usual medical treatment was subsequently instituted (Figure 1).
Women in the LNG-IUS group were almost twice as likely as those in the usual treatment group to still be
receiving their assigned treatment at 2 years (64% vs. 38%; p< 0.001) (Figure 2). The most common
reasons cited for discontinuation of the LNG-IUS were lack of effectiveness (37%) and irregular or
prolonged bleeding (28%). Of the 163 women who discontinued usual medical treatment, 80 (49%)
switched to the LNG-IUS. The most common reason for discontinuation of usual medical therapy was lack
of effectiveness (53%). Reasons for discontinuing therapy are summarised in Appendices 1 and 2.
Primary outcome: Menorrhagia Multi-Attribute Scale
In both groups, total scores on the MMAS were significantly improved, compared with baseline scores,
at 6 months, and this improvement was maintained at 1 and 2 years (Figure 3 and Table 4) However,
improvements in scores were significantly greater among women assigned to the LNG-IUS than among
those assigned to usual treatment over the course of the 2 years (mean difference in scores 13.4 points,
95% CI 9.9 to 16.9 points; p< 0.001). This difference was apparent by 6 months and maintained thereafter.
TABLE 3 Intended prescriptions if allocated to the usual medical treatment group
Intended prescriptions Usual medical treatment (n= 286) LNG-IUS (n= 285)
Mefenamic acid and tranexamic acid 134 (47%) 123 (43%)
Tranexamic acid alone 50 (17%) 66 (23%)
Mefenamic acid alone 31 (11%) 23 (8%)
High-dose norethisterone alone 20 (7%) 23 (8%)
COC alone 16 (6%) 22 (8%)
Medroxyprogesterone acetate injection only 14 (5%) 1 (< 1%)
Mefenamic acid, tranexamic acid and COC 9 (3%) 14 (5%)
Other combinationa,b 12 (4%) 13 (5%)
a Usual medical treatment arm: mefenamic acid/tranexamic acid/desogestrel (n= 2); mefenamic acid/COC (n= 2);
tranexamic acid/COC (n= 2); tranexamic acid/norethisterone (n= 2); mefenamic acid/tranexamic acid/COC/
medroxyprogesterone acetate injection (n= 1); mefenamic acid/tranexamic acid/medroxyprogesterone acetate injection/
norethisterone (n= 1); mefenamic acid/tranexamic acid/COC/norethisterone (n= 1); and medroxyprogesterone acetate
injection/norethisterone (n= 1).
b LNG-IUS arm: mefenamic acid/tranexamic acid/desogestrel (n= 2); tranexamic acid/COC (n= 2); tranexamic acid/
norethisterone (n= 2); mefenamic acid/tranexamic acid/norethisterone (n= 2); mefenamic acid/COC (n= 1); mefenamic
acid/tranexamic acid/COC/medroxyprogesterone acetate injection (n= 1); mefenamic acid/tranexamic acid/
medroxyprogesterone acetate injection (n= 1); tranexamic acid/desogestrel (n= 1); and norethisterone/
desogestrel (n= 1).
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Women randomised 
(n = 571)
Allocated to LNG-IUS
(n = 285)
• Did not have insertion, 
   n = 24 
• Decided to have usual 
   medical treatment, n = 10
• Unsuccessful insertions, 
   given usual medical 
   treatment, n = 8
• Decided to take no 
   treatment, n = 6
Allocated to usual
medical treatment (n = 286)
• Did not take treatment,
   n = 6 
• Decided to take no 
   treatment, n = 5
• LNG-IUS insertion, n = 1
Exited trial (n = 33) 
• Lost to follow-up, 
   n = 6
• Contacted and did 
   not wish to complete 
   any more
   questionnaires, n = 27
Approached for consent 
after meeting eligibility criteria 
(n = 1132)
Not randomised (n = 561) 
• Preference for usual medical
   treatment, n = 190
• Preference for LNG-IUS, n = 130
• Declined to participate, n = 86
• Referral to secondary care, n = 25
• Did not want any treatment, n = 3
• Intended to become pregnant, n = 3
• No reason given, n = 124
Returned
questionnaire booklet at
6 months (n = 209)
• Discontinued treatment, 
   n = 57 
• LNG-IUS insertion, n = 35
• Decided to take no 
   treatment, n = 22Exited trial (n = 8) 
• Lost to follow-up, 
   n = 2
• Contacted and did 
   not wish to complete 
   any more 
   questionnaires, n = 6
Exited trial (n = 14) 
• Lost to follow-up, 
   n = 8
• Contacted and did 
   not wish to complete 
   any more
   questionnaires, n = 6
Exited trial (n = 22) 
• Lost to follow-up, 
   n = 6
• Contacted and did 
   not wish to complete 
   any more 
   questionnaires, n = 16
Exited trial (n = 8) 
• Lost to follow-up, 
   n = 3
• Contacted and did 
   not wish to complete 
   any more
   questionnaires, n = 5
Exited trial (n = 8) 
• Died, n = 1
• Lost to follow-up, 
   n = 4
• Contacted and did 
   not wish to complete 
   any more
   questionnaires, n = 3
• Discontinued treatment, 
   n = 42
• LNG-IUS insertion, n = 21
• Decided to take no 
  treatment, n = 21
• Discontinued treatment, 
   n = 64
• LNG-IUS insertion, n = 24
• Decided to take no 
   treatment, n = 40
• Discontinued treatment, 
   n = 32
• Changed to usual 
   medical treatment, n = 8
• Decided to take no 
   treatment, n = 24
• Discontinued treatment, 
   n = 21 
• Changed to usual 
   medical treatment, n = 9
• Decided to take no 
   treatment, n = 12
Returned
questionnaire booklet at
6 months (n = 218)
Returned
questionnaire booklet at
1 year (n = 220)
Returned
questionnaire booklet at
1 year (n = 219)
Returned
questionnaire booklet at
2 years (n = 231)
Returned
questionnaire booklet at
2 years (n = 247)
• Discontinued treatment,
   n = 26 
• Changed to usual 
   medical treatment, n = 12
• Decided to take no 
   treatment, n = 14
FIGURE 1 Enrolment, randomisation and follow-up to 2 years of the study patients. See Appendices 1 and 2 for
reasons for discontinuation of treatment.
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The effect in favour of the LNG-IUS was apparent in all six individual domains of the MMAS at every time
point through examination of the frequencies of responses (Table 5).
In a sensitivity analysis that excluded women who crossed over from the assigned treatment to the other
study treatments, improvement with the LNG-IUS, as compared with usual medical treatment, increased
(mean difference in scores over the course of 2 years, 17.8 points, 95% CI 14.1 to 21.5 points; p< 0.001).
Other sensitivity analyses yielded results that were not materially different from the results of the primary
analysis (p< 0.001 for all comparisons) (see Appendix 3).
In subgroup analyses, there was a significant interaction between treatment and BMI (p= 0.004). The
benefit of the LNG-IUS was greater in women with a BMI > 25 kg/m2 (16.7 MMAS points, 95% CI 12.6 to
20.9 MMAS points; p< 0.001) than in those with a BMI of ≥ 25 kg/m2 (5.4 MMAS points, 95% CI −1.0
to 11.8 MMAS points; p= 0.10). This finding appeared to be attributable to the superior outcome with
usual medical treatment in leaner women (see Appendix 4). Improvements with the LNG-IUS were similar
in both subgroups. None of the other tests for subgroup interaction was significant (p> 0.10).
Generic quality of life and sexual activity
The SF-36 domains were generally significantly improved from baseline in both groups at all time points,
although the scores for women in the LNG-IUS group were better than for those in the usual treatment
group in seven of the eight domains in the analyses over all time points (Table 6); mental health was the only
domain for which there were no significant between-group differences. The improvements appeared to be
greatest at 6 months, but had lessened by the 2-year follow-up assessment (see Appendix 5). No significant
differences were seen between treatments with respect to the EQ-5D instrument; scores were significantly
improved from baseline in both groups at 2 years, but not at earlier assessments (see Appendix 6). The
treatments did not differ significantly with respect to the scores for the pleasure, discomfort and frequency
domains of the SAQ (see Appendix 7).
Adverse events
There were no serious adverse reactions attributable to study treatments. There was no significant
difference between the two groups in the frequency of unrelated serious adverse events (58 in the usual
treatment group and 49 in the LNG-IUS group; p= 0.59). There was one death in the LNG-IUS group; the
cause of death was recorded by the coroner as inconclusive and the LNG-IUS was not in situ. Unrelated
serious adverse events are summarised in Appendix 8.
Surgical interventions
The frequency of surgical interventions for HMB within 2 years did not differ significantly between the
two groups. Hysterectomy was performed in 6% of the women in each group; endometrial ablations
were performed in 4% of women in the LNG-IUS group and in 6% of those in the usual treatment
group (p= 0.44).
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Discussion
The results of this trial show that, compared with usual medical therapies for HMB, the LNG-IUS leads to
greater improvement in women’s assessments of the effect of HMB on their daily routine, including work,
social and family life, and psychological and physical well-being.
At baseline, the women were substantially affected by HMB, as assessed with the use of condition-specific
(MMAS) and general (SF-36) health-related scales. The scores improved significantly over a period of
2 years in both the LNG-IUS group and the usual treatment group. However, improvements in average
MMAS scores were greater in the LNG-IUS group than in the usual medical treatment group over the
first 2 years, by an average of 13.4 points, in an intention-to-treat analysis. The greater improvement in
the LNG-IUS group than in the usual treatment group was both statistically significant and clinically
meaningful. The between-group difference was more than 0.5 SD, which is the minimum clinically
important difference identified in a systematic review of studies reporting such data for health-related QoL
measures.79 A 13.4-point difference represents a change in two or three MMAS domains: from being
substantially to minimally affected by HMB (e.g. from frequent to occasional disruptions of work and daily
routine) or from being minimally affected to being unaffected (e.g. from experiencing some strain in family
TABLE 6 Scores on the QoL questionnaires and the SAQ at baseline, and mean between-group difference over
2 years
Questionnaire
and domain
Baseline score (SD)
Difference between
groups over 2 years
(95% CI)a p-value
Usual medical
treatment LNG-IUS
SF-36b
Physical functioning 77.8 (24.7) 80.0 (20.4) 2.7 (0.0 to 5.4) 0.05
Physical role 68.9 (26.2) 72.1 (24.7) 5.9 (2.6 to 9.1) < 0.001
Emotional role 69.8 (26.8) 71.9 (25.1) 4.6 (1.3 to 8.0) 0.007
Social functioning 62.4 (25.9) 64.3 (24.5) 5.1 (2.0 to 8.1) 0.001
Mental health 59.0 (19.8) 60.3 (19.3) 1.5 (–1.0 to 3.9) 0.23
Energy/vitality 40.8 (21.7) 40.7 (20.9) 5.3 (2.5 to 8.2) < 0.001
Pain 49.5 (24.9) 54.2 (24.9) 7.8 (4.5 to 11.0)c < 0.001
General health perception 60.3 (21.9) 61.8 (21.4) 2.9 (0.3 to 5.4) 0.03
EQ-5D
EQ-5D descriptive systemd 0.714 (0.276) 0.756 (0.243) 0.013 (–0.016 to 0.042) 0.38
EQ-5D VASe 69.7 (19.8) 70.3 (19.1) 2.0 (–0.5 to 4.6)c 0.12
SAQf
Pleasure 10.9 (4.9) 10.8 (4.9) 0.4 (–0.3 to 1.1) 0.26
Discomfort 4.62 (1.69) 4.65 (1.48) –0.07 (–0.30 to 0.16) 0.55
a Estimated values > 0 favour LNG-IUS.
b The SF-36 has scores in each of the eight domains that range from 0 (severely affected) to 100 (not affected).
c Some evidence here of time by treatment effect (p≤ 0.05). Refer to Appendix 5 for full details of estimates at each
separate time point.
d The EQ-5D descriptive system has scores that range from −0.59 (state of health worse than death) to 1.00 (perfect state
of health).
e The EQ-5D VAS ranges from 0 (worst health state imaginable) to 100 (most perfect health state imaginable).
f The SAQ has scores for pleasure that range from 0 (lowest level) to 18 (highest level), and scores for discomfort that
range from 0 (greatest) to 6 (none).
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life to experiencing no strain in family life). The between-group difference reported here is also greater
than that reported in an observational study comparing women who did and those who did not undergo
surgery for HMB.65 The differences seen in favour of the LNG-IUS on the SF-36 domains were generally
highly statistically significant, but were on average small in magnitude (SD 0.2–0.3).79 It is therefore
debatable whether or not they are clinically important.
The strengths of our randomised trial include its size (larger than prior trials of treatments for HMB), the
multicentre design, the inclusion of patients ethnically representative of the UK population, the relatively
low rates of loss to follow-up, and the assessment of outcomes over a period of 2 years rather than 6 or
12 months, as in previous studies.28,45 In addition, previous trials have focused on the reduction of
menstrual blood loss, which does not reflect the full effect of HMB on women’s lives.28,45 In contrast, our
primary outcome measure was the patient-reported, psychometrically valid, condition-specific MMAS,
which better reflects women’s personal experience of the burden of HMB. Interference with the QoL,
rather than perceptions of HMB itself, appears to be the primary factor in women’s decision to
seek treatment.80
Some limitations of our study should be noted. The range of options available for medical treatment
complicates any efforts to compare the LNG-IUS with individual agents. However, the choice among the
various agents is representative of current clinical practice. In addition, substantial numbers of patients
switched treatments over the course of the study; however, these crossovers would be expected to
result in an underestimation of the benefits that might be achieved with perfect compliance. A range of
sensitivity analyses did not change the conclusions. Although the interventions studied in this trial
represent options available in primary care settings in the UK, insertion of intrauterine devices is not part
of primary care in all health-care settings, and in some circumstances it requires consultation with
a gynaecologist.
The 21.4-point improvement from baseline in the average MMAS score at 6 months in the usual treatment
group, which was sustained throughout the 2 years of follow-up, was not explained by a switch in
treatment, since similar improvements were noted when crossovers to the LNG-IUS were excluded from
the analyses. The higher rate of discontinuation in the usual treatment group than in the LNG-IUS
group could reflect greater symptom relief with the LNG-IUS, but another possible explanation is that
discontinuation of usual medical treatment does not require consultation. Nonetheless, at 2 years, 36% of
women in the LNG-IUS group had had the system removed, generally because of lack of effectiveness or
irregular or prolonged bleeding, which are well-recognised reasons for discontinuing the LNG-IUS.81,82
This proportion is consistent with the proportions of women who discontinued the LNG-IUS treatment
in smaller trials that compared it with hysterectomy50 (31% of 117 women at 12 months) or with
endometrial ablation (28% of 105 women at 2 years).30,49,81 In subgroup analyses, the LNG-IUS appeared
to be less beneficial in women with a BMI of 25 kg/m2 or less than in those with a BMI of more than
25 kg/m2, an observation that was explained by an apparently greater efficacy of usual medical treatments
in the leaner women. This analysis was one of several subgroup analyses and should be interpreted with
caution, since the findings may be explained by chance and require confirmation.
We expected fewer surgical interventions in the LNG-IUS group, but rates were similarly low in the
two groups. This finding may reflect the eligibility criteria for the trial, since women who had fibroids or
other disorders were excluded.
Finally, given the long natural history of HMB, study outcomes need to be assessed over a period that is
longer than 2 years; additional intention-to-treat analyses are reported for 5 years in Chapter 4 and
planned for 10 years.
In conclusion, our study showed that both the LNG-IUS and usual medical treatments reduced the adverse
effect of HMB on women’s lives over the course of 2 years, but the LNG-IUS was the more effective
first choice, as assessed by the impact of bleeding on the women’s QoL.
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Chapter 4 Methods and results of randomised
controlled trial at 5 years’ follow-up
Objectives
The objectives of the RCT presented in this chapter were to assess the clinical effectiveness of the LNG-IUS
compared with standard medical treatment for women seeking treatment for HMB in primary care in the
medium to long term (5 years’ follow-up).
Methods
Trial methods
For details on the population, randomisation and outcome measures the reader should refer to Chapter 3.
Statistical considerations
The sample size assumptions for MMAS scores were the same as previously detailed in Chapter 3,
Statistical consideration. Four hundred and seventy patients were required to have 90% power (p= 0.05)
to detect 0.3 SD in MMAS score. We ultimately received 424 responses at 5 years’ follow-up. A post-hoc
calculation suggests this many responses would provide 87% power (p= 0.05) to detect this same size of
difference. For progression to surgical intervention (hysterectomy or endometrial ablation), using an
assumed rate of 35% in the standard arm (a figure that was set out in the protocol), 424 women (the
number followed up to 5 years; see Figure 4 for details) would provide 80% power (p= 0.05) to detect an
absolute reduction of 12%, that is, 35% down to 23%.
The statistical methods used to analyse the data were similar to those set out in Chapter 3; however,
given the long length of time between this and the previous assessment point at 2 years, we felt a
repeated-measures analysis incorporating all accumulated responses to no longer be clinically meaningful
and therefore this has not been included.
Results
Patients and follow-up
See Chapter 2 for details on the demographics and prescribed treatments of those randomised and Figure 4
for losses to follow-up. Study questionnaire booklets were returned by 424 (74%) of the participants.
One hundred and fifteen of the women (27%) declined to complete the MMAS, but indicated on the form
that they were no longer bleeding; their score was assumed to be the maximum achievable (100, ‘no
problems’). These women completed other parts of the questionnaire booklet and a sensitivity analysis of
MMAS responses without any assumption was also performed.
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The 5-year allocated treatment retention rate was estimated to be 47% (95% CI 40% to 52%) in the
LNG-IUS group and 15% (95% CI 11% to 20%) in the usual treatment group (Figure 5). Reported reasons
for discontinuation of treatment are summarised in Appendices 9 and 10. Lack of efficacy was cited 41%
(94/228) of the time in the usual treatment group and 24% (36/148) of the time in the LNG-IUS group.
Of the 228 recorded instances of treatment change in women allocated usual medical treatment, 97
(43%) were to the LNG-IUS. In the LNG-IUS group, 39% (57/148) of treatment switches were to usual
treatment. There was no significant difference between the groups in the total number of serious adverse
events up to 5 years (see Appendix 11).
Menorrhagia Multi-Attribute Scale
After 5 years, scores on the MMAS were significantly improved compared with baseline in both groups
(Table 7). This improvement was greater, on average, among women assigned to the LNG-IUS, but the
difference was not statistically significant (3.9 points, 95% CI –0.6 to 8.3 points; p= 0.09). The same analysis
without any assumption about MMAS scores where a blank form was returned and the woman indicated she
was no longer bleeding returned a similar result (5.2 points difference in favour of the LNG-IUS, 95% CI –0.4
to 10.8 points; p= 0.07). Per-protocol analysis (excluding women who switched or stopped taking treatment) –
limited to 28 responses in the usual treatment group and 88 in the LNG-IUS group – returned a 15.8-point
difference in favour of the LNG-IUS (95% CI 7.4 to 24.2 points; p= 0.0003).
Women randomised 
(n = 571)
Allocated to LNG-IUS
(n = 285)
• Did not have insertion, 
   n = 24
• Decided to have usual 
   medical treatment, n = 10
• Unsuccessful insertions, 
   given usual medical 
   treatment, n = 8
• Decided to take no 
   treatment, n = 6
Allocated to usual
medical treatment (n = 286)
• Did not take treatment, 
   n = 6
• LNG-IUS insertion, n = 1
• Decided to take no 
   treatment, n = 5
Exited trial (n = 78) 
• Lost to follow-up, 
   n = 37
• Contacted and did 
   not wish to 
   complete any more
   questionnaires, 
   n = 41
Approached for consent 
after meeting eligibility criteria 
(n = 1132)
Not randomised (n = 561) 
• Preference for usual medical 
   treatment, n = 190
• Preference for LNG-IUS, n = 130
• Declined to participate, n = 86
• Wanted referral to secondary 
   care, n = 25
• Did not want any treatment, n = 3
• Intended to become pregnant, n = 3
• No reason given, n = 124
Returned
questionnaire booklet at
5 years (n = 208)
• Recorded instances 
   of discontinued 
   treatment,a,b n = 222
• LNG-IUS insertion, n = 96
• Decided to take no 
   treatment, n = 126
Exited trial (n = 69) 
• Died, n = 1
• Lost to follow-up, 
   n = 39
• Contacted and did 
   not wish to 
   complete any more
   questionnaires, 
   n = 29
Returned
questionnaire booklet at
5 years (n = 216)
• Recorded instances 
   of discontinued 
   treatment,a,b n = 124 
• Changed to usual 
   medical treatment, n = 39
• Decided to take no 
   treatment, n = 85
FIGURE 4 Enrolment, randomisation and follow-up up to 5 years of the study patients. a, See Figure 5 for time to first
treatment change survival estimates; b, see Appendices 9 and 10 for reason reported for discontinuing treatment.
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Surgical interventions
There were 53 surgical events (endometrial ablation or hysterectomy) in the LNG-IUS group, compared
with 56 in the usual treatment group, that were included in the surgery-free survival analysis (109 events
in total). This difference was not statistically significant (hazard ratio 0.90, 95% CI 0.62 to 1.31; p= 0.6)
(Figure 6). Analysis excluding participants who crossed over from one group to another returned a similar
result (HR 0.96, 95% CI 0.60 to 1.52; p= 0.9). Five-year surgery-free survival rates were estimated to be
80% (95% CI 74% to 84%) in the LNG-IUS group compared with 77% (95% CI 71% to 82%) in the
usual treatment group. In total, there were 24 ablations in the LNG-IUS group compared with 31 in
the usual treatment group as well as 30 hysterectomies in both groups (115 operations in total; the extra
six events coming from patients who had both types of surgery).
Generic quality of life and sexual activity
Responses to the EQ-5D and SF-36 instruments were generally significantly improved from baseline in both
groups (Table 8); the only statistically significant difference between groups was seen in the general
health perception domain of the SF-36 and favoured the LNG-IUS (4.7 points, 95% CI 0.6 to 8.8 points;
p= 0.02). The treatment groups did not differ significantly with respect to any of the domains of the SAQ.
Discussion
In Chapter 3, analysis of trial data showed significant benefit over 2 years after women sought and were
treated for HMB in primary care, from both usual medical treatments (tranexamic acid, mefenamic acid,
COCs, high-dose progestogens and medroxyprogesterone acetate or a combination of these methods) and
the LNG-IUS. However, the superiority of the LNG-IUS in improving women’s general QoL and reducing
the effect of their HMB on their work, social and family lives was highlighted. This research remains the
world’s largest long-term multicentre RCT of non-surgical treatments for HMB. A high follow-up rate of
84% at 2 years has been sustained at 5 years at 74% (424/571 randomised patients) by using systematic
methods of ongoing communication and feedback with participants.
Our results are encouraging in showing that the significant improvement in both HMB-specific and generic
QoL was sustained 5 years after commencing either usual medical treatments or the LNG-IUS. However,
the greater clinical efficacy of the LNG-IUS compared with usual medical treatment seen at 2 years has
now diminished. Although MMAS scores and the majority of QoL domains at 5 years still favoured the
LNG-IUS, these were no longer statistically significant, and contrast with the relatively large differences we
noted at the 2-year follow-up. Even if we consider our finding for MMAS to be of borderline statistical
significance (the p-value was 0.09), the difference between group means was estimated to be 3.9 points
on average, which is less than 0.2 SD and unlikely to be clinically meaningful. This lack of persistence of
TABLE 7 Menorrhagia Multi-Attribute Scale summary scores at baseline and 5 years’ follow-up
Treatment group and comparisons Baseline score 5-year score
Usual medical treatment (SD, n) 39.2 (21.3, 269) 83.1 (24.4, 208)
Change within group (95% CI) – 43.4 (39.1 to 47.7; p< 0.0001)
LNG-IUS (SD, n) 42.5 (20.5, 280) 87.1 (22.1, 216)
Change within group (95% CI) – 44.9 (4.10 to 48.8; p< 0.0001)
Difference between groups (95% CI) – 3.9 (–0.6 to 8.3; p = 0.09)
METHODS AND RESULTS OF RANDOMISED CONTROLLED TRIAL AT 5 YEARS’ FOLLOW-UP
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
0
0
12
24
36
48
60
72
2550
Proportion surgery-free (%)
7510
0
Ti
m
e 
(m
o
n
th
s)
LN
G
-I
U
S
U
su
al
 t
re
at
m
en
t
LN
G
-I
U
S:
U
su
al
 t
re
at
m
en
t:
28
5
28
6
25
3
24
3
22
7
20
9
20
4
19
4
19
6
18
0
13
2
12
5
11 11
Pa
ti
en
ts
FI
G
U
R
E
6
Su
rg
er
y-
fr
ee
(h
ys
te
re
ct
o
m
y/
en
d
o
m
et
ri
al
ab
la
ti
o
n
)
su
rv
iv
al
an
al
ys
is
o
ve
r
5
ye
ar
s’
fo
llo
w
-u
p
.
DOI: 10.3310/hta19880 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 88
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Gupta et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31
TA
B
LE
8
Sc
o
re
s
o
n
th
e
Q
o
L
q
u
es
ti
o
n
n
ai
re
an
d
SA
Q
at
b
as
el
in
e
an
d
5
ye
ar
s’
fo
llo
w
-u
p
Q
u
es
ti
o
n
n
ai
re
an
d
d
o
m
ai
n
B
as
el
in
e
sc
o
re
(S
D
,n
)
5-
ye
ar
sc
o
re
(S
D
,
n
)
D
if
fe
re
n
ce
b
et
w
ee
n
g
ro
u
p
s
o
ve
r
5
ye
ar
s
(9
5%
C
I,
p
-v
al
u
e)
a
C
h
an
g
e
w
it
h
in
g
ro
u
p
(9
5%
C
I,
p
-v
al
u
e)
U
su
al
m
ed
ic
al
tr
ea
tm
en
t
LN
G
-I
U
S
U
su
al
m
ed
ic
al
tr
ea
tm
en
t
LN
G
-I
U
S
U
su
al
m
ed
ic
al
tr
ea
tm
en
t
LN
G
-I
U
S
SF
-3
6b
Ph
ys
ic
al
fu
nc
tio
ni
ng
77
.8
(2
4.
7,
26
4)
80
.0
(2
0.
4,
27
2)
83
.0
(2
6.
3,
20
8)
85
.4
(2
3.
5,
21
6)
1.
6
(–
2.
7
to
5.
9;
p
=
0.
5)
5.
6
(1
.8
to
9.
5;
p
=
0.
00
4)
5.
9
(2
.8
to
9.
1;
p
=
0.
00
03
)
Ph
ys
ic
al
ro
le
68
.9
(2
6.
2,
26
4)
72
.1
(2
4.
7,
27
6)
80
.6
(2
7.
2,
20
8)
83
.9
(2
5.
5,
21
7)
2.
7
(–
2.
1
to
7.
5;
p
=
0.
3)
12
.6
(7
.9
to
17
.2
;
p
<
0.
00
01
)
13
.3
(9
.5
to
17
.1
;
p
<
0.
00
01
)
Em
ot
io
na
lr
ol
e
69
.8
(2
6.
8,
26
4)
71
.9
(2
5.
1,
27
6)
83
.3
(2
5.
3,
20
8)
81
.4
(2
6.
9,
21
7)
–
2.
0
(–
6.
8
to
2.
9;
p
=
0.
4)
13
.1
(8
.7
to
17
.6
;
p
<
0.
00
01
)
10
.9
(6
.7
to
15
.1
;
p
<
0.
00
01
)
So
ci
al
fu
nc
tio
ni
ng
62
.4
(2
5.
9,
26
8)
64
.3
(2
4.
5,
27
7)
76
.9
(2
5.
5,
20
7)
79
.5
(2
5.
1,
21
4)
2.
2
(–
2.
5
to
6.
9;
p
=
0.
4)
14
.0
(9
.4
to
18
.5
;
p
<
0.
00
01
)
15
.6
(1
1.
6
to
19
.6
;
p
<
0.
00
01
)
M
en
ta
lh
ea
lth
59
.0
(1
9.
8,
26
7)
60
.3
(1
9.
3,
27
7)
72
.6
(1
9.
4,
20
6)
71
.4
(2
0.
5,
21
4)
–
1.
6
(–
5.
2
to
2.
0;
p
=
0.
4)
13
.6
(1
0.
5
to
16
.7
;
p
<
0.
00
01
)
11
.4
(8
.5
to
14
.3
;
p
<
0.
00
01
)
En
er
gy
/v
ita
lit
y
40
.8
(2
1.
7,
26
8)
40
.7
(2
0.
9,
27
7)
56
.6
(2
3.
1,
20
6)
59
.2
(2
1.
0,
21
3)
2.
8
(–
1.
2
to
6.
9;
p
=
0.
2)
15
.7
(1
1.
9,
19
.4
;
p
<
0.
00
01
)
18
.6
(1
5.
2
to
22
.0
;
p
<
0.
00
01
)
Pa
in
49
.5
(2
4.
9,
26
8)
54
.2
(2
4.
9,
27
8)
71
.3
(2
8.
6,
20
7)
76
.1
(2
4.
8,
21
4)
3.
7
(–
1.
3
to
8.
7;
p
=
0.
1)
21
.4
(1
6.
9
to
25
.8
;
p
<
0.
00
01
)
22
.7
(1
8.
6
to
26
.9
;
p
<
0.
00
01
)
G
en
er
al
he
al
th
pe
rc
ep
tio
n
60
.3
(2
1.
9,
26
4)
61
.8
(2
1.
4,
27
4)
61
.9
(2
3.
8,
20
7)
67
.8
(2
2.
1,
21
4)
4.
7
(0
.6
to
8.
8;
p
=
0.
02
)
2.
0
(–
1.
5
to
5.
6;
p
=
0.
26
)
5.
1
(2
.0
to
8.
3;
p
=
0.
00
2)
EQ
-5
D
EQ
-5
D
de
sc
rip
tiv
e
sy
st
em
c
0.
71
(0
.2
8,
26
9)
0.
76
(0
.2
4,
27
7)
0.
82
(0
.2
5,
20
7)
0.
81
(0
.2
5,
21
4)
–
0.
02
(–
0.
06
to
0.
02
;
p
=
0.
4)
0.
10
(0
.0
6,
0.
14
;
p
<
0.
00
01
)
0.
06
(0
.0
2,
0.
09
;
p
=
0.
00
3)
EQ
-5
D
V
A
Sd
69
.7
(1
9.
8,
24
6)
70
.3
(1
9.
1,
25
0)
76
.1
(1
8.
8,
19
8)
77
.3
(1
9.
9,
20
7)
0.
6
(–
3.
2
to
4.
5;
p
=
0.
8)
6.
3
(2
.9
to
9.
8;
p
=
0.
00
04
)
6.
5
(3
.0
to
9.
9;
p
=
0.
00
03
)
SA
Q
e
Pl
ea
su
re
10
.9
(4
.9
,
19
9)
10
.8
(4
.9
,
21
0)
11
.8
(4
.6
,
10
0)
11
.2
(4
.5
,
11
1)
–
0.
4
(–
1.
7
to
0.
9;
p
=
0.
6)
0.
6
(–
0.
6
to
1.
7;
p
=
0.
4)
0.
1
(–
1.
0
to
1.
2;
p
=
0.
9)
D
is
co
m
fo
rt
4.
6
(1
.7
,
20
1)
4.
7
(1
.5
,
20
9)
4.
8
(1
.6
,
10
1)
4.
8
(1
.6
,
11
1)
0.
0
(–
0.
4
to
0.
4;
p
=
0.
9)
0.
1
(–
0.
2
to
0.
4;
p
=
0.
7)
0.
1
(–
0.
3
to
0.
4;
p
=
0.
7)
a
Es
tim
at
ed
va
lu
es
>
0
fa
vo
ur
th
e
LN
G
-IU
S.
b
Th
e
SF
-3
6
ha
s
sc
or
es
in
ea
ch
of
th
e
ei
gh
t
do
m
ai
ns
th
at
ra
ng
e
fr
om
0
(s
ev
er
el
y
af
fe
ct
ed
)
to
10
0
(n
ot
af
fe
ct
ed
).
c
Th
e
EQ
-5
D
de
sc
rip
tiv
e
sy
st
em
ha
s
sc
or
es
th
at
ra
ng
e
fr
om
−
0.
59
(s
ta
te
of
he
al
th
w
or
se
th
an
de
at
h)
to
1.
00
(p
er
fe
ct
st
at
e
of
he
al
th
).
d
Th
e
EQ
-5
D
V
A
S
ra
ng
es
fr
om
0
(w
or
st
he
al
th
st
at
e
im
ag
in
ab
le
)
to
10
0
(m
os
t
pe
rf
ec
t
he
al
th
st
at
e
im
ag
in
ab
le
).
e
Th
e
SA
Q
ha
s
sc
or
es
fo
r
pl
ea
su
re
th
at
ra
ng
e
fr
om
0
(lo
w
es
t
le
ve
l)
to
18
(h
ig
he
st
le
ve
l),
an
d
sc
or
es
fo
r
di
sc
om
fo
rt
th
at
ra
ng
e
fr
om
0
(g
re
at
es
t)
to
6
(n
on
e)
.
Re
su
lts
at
ea
ch
tim
e
po
in
t
ad
ju
st
ed
fo
r
ba
se
lin
e
sc
or
e.
C
ha
ng
e
w
ith
in
gr
ou
p
co
m
pa
re
d
w
ith
ba
se
lin
e.
METHODS AND RESULTS OF RANDOMISED CONTROLLED TRIAL AT 5 YEARS’ FOLLOW-UP
NIHR Journals Library www.journalslibrary.nihr.ac.uk
32
difference between trial treatment groups may be unsurprising given the high proportions of women who,
by this 5-year stage, had changed to a treatment that worked for them or had ceased bleeding – either
naturally or through surgical intervention (retention rates were 15% with usual medical therapy and
47% in the LNG-IUS group).
Similar reasons may explain why our 5-year data provided no evidence of any reduction in surgical
interventions with the LNG-IUS, compared with usual medical therapy (even when we discounted the
significant number of treatment crossovers), despite the large differences observed in symptom-related QoL
at 2 years post randomisation. We recognise this could also possibly be because of a lack of power to
detect a difference, although we had sufficient power to detect a relative reduction of approximately 34%.
At 2 years post randomisation we reported that surgical interventions were similarly low at about 10% in
both medical treatment groups and this has increased to approximately 20% in both treatment groups at
5 years. However, this rate remains considerably lower than the high surgical intervention rate identified in
a previous Cochrane review of trials of women comparing oral medical therapy to surgical interventions.
This showed 58% of women with medical treatment subsequently undergoing endometrial ablation or
hysterectomy by 2 years.51 Our low surgical intervention rates may possibly be explained by the exclusion
of women with known uterine disease such as fibroids and enlarged uteri and who were deemed suitable
for treatment in a community setting.
We are aware of few trials in this field reporting outcomes at 5 years.38,58 The current data have allowed
an accurate estimate of the 5-year retention rate of the LNG-IUS – at around half of those initially allocated
to this treatment at randomisation. In addition, they offer a good estimate of the proportions of women
progressing to surgical intervention after 5 years from initial presentation with HMB to their GP. Our results
at 5 years provide unique and valuable practical information for women and clinicians considering what
to expect from these medical treatments for HMB over the medium term. Moreover, the low surgical
intervention rates observed may underline the importance and feasibility of emphasising initial medical
management of women with HMB in primary care and avoiding referral to secondary care.
Our results suggests that women who are found to have a relatively normal-sized uterus with HMB and
no other risk factors (i.e. intermenstrual bleeding, post-coital bleeding, irregularity of the menstrual cycle
that has been assessed by an endometrial biopsy) can be successfully treated in the primary care setting
with significant benefit from medical treatment in reducing the impact of HMB on their QoL that is
sustained over 5 years. We intend to follow up patients to 10 years. This will be important as we expect
that over half of our cohort will have reached menopause at that stage (mean age at randomisation was
42 years). With most women’s menopause occurring at approximately 51–52 years, we thus expect to
determine the final rates of surgical intervention in the majority of participants.
DOI: 10.3310/hta19880 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 88
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Gupta et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
33

Chapter 5 Women’s experiences of medical
treatments for heavy menstrual bleeding:
a longitudinal qualitative study
Introduction
Heavy menstrual bleeding and other changes in menstrual experience may affect many aspects of women’s
health, well-being and social functioning.83 Although there is existing evidence comparing the effectiveness of
various treatments in reducing menstrual blood loss, we know less about women’s experiences or expectations
of medical treatments. The ECLIPSE trial, therefore, provided an opportunity to generate qualitative insights in
this context by exploring the perspectives of trial participants or women with HMB who declined to be
randomised, but who nevertheless commenced medical treatment in primary care. A longitudinal qualitative
study was undertaken to enable the ECLIPSE trial outcomes to be further contextualised in ways that may
enhance the utility of the quantitative results and their application in clinical practice.
Women have discussed the management of menstruation including its concealment in order to conform
to societal norms,84 their reluctance to request treatment85,86 and their experience of a change in
menstruation requiring further explanation. Women with psychological distress appear more likely to
report heavy periods13,87 and the effect of menstrual bleeding on mood may influence a woman’s ability
to continue life as normal.88 Similarly, other menstrual symptoms such as pain, mood changes and irregular
bleeding may influence perceptions of the severity of HMB.2,89
Women who seek treatment for HMB can have predetermined expectations and preferences for a
treatment influenced by diverse factors, such as employment status as well as severity of symptoms.90,91
They may also reflect contraceptive preferences, attitudes to hormonal treatments, ‘the pill’ or ‘coil’ and
the presence of other symptoms such as painful periods.
Clinical guidelines for HMB from NICE, issued towards the end of the current ECLIPSE trial recruitment,1
introduced the option of the LNG-IUS on the basis of limited evidence to date, with other usual, and
mainly oral, medical treatments as further choices. Women’s expectations about treatments have obvious
implications in discussing these options and concordance with treatment. There was also a need to better
understand the impact of medical treatments on HMB-related QoL from a qualitative perspective,1,92
alongside the trial’s quantitative measures of the QoL. This study sought to explore women’s experiences
and expectations of medical treatments used in the ECLIPSE trial for HMB.
Methods
Sampling
A purposeful sample was selected from women approached for inclusion in the ECLIPSE trial of the
effectiveness of medical treatments for HMB in primary care.93 They had consulted their GP about HMB
(lasting three or more consecutive cycles). Women participating in the trial had either agreed to be
randomised to the LNG-IUS or to other standard treatment (including oral tranexamic acid, mefenamic
acid, norethisterone, contraceptive pill or medroxyprogesterone acetate injection) or had declined to enter
the trial because they had a strong preference for a particular medical treatment, which they had then
commenced. We selected women from eight general practices across five counties of the UK of varying
demographics (age, social and educational background, ethnicity) and parity, who experienced different
medical treatments for HMB of differing treatment duration.
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Recruitment and consent
Practitioners identified potential participants at the time that interest in participation in the ECLIPSE trial
was discussed, and trial participation accepted or declined. Permission was sought to pass contact details
to the research team, who sent study information and a request for written consent, translated where
appropriate, to participants.
Data generation and analysis
Semistructured face-to-face interviews were conducted by a female researcher (G Prileszky), with a
midwifery background, at respondents’ convenience and in their own homes. The support of an interpreter
was offered where appropriate (four cases), but all interviewees opted to be interviewed in English. Initial
interviews were conducted within 1–3 months of commencing medical treatments. A second interview was
conducted, if participants were willing, between 12 and 14 months following commencement of treatment
to explore any changes in experience or treatment, or in views occurring over time.
Interviews were digitally audio-taped and transcribed verbatim, and contemporaneous field notes kept of
the interview context. Verbatim quotations are annotated with participant number and suffixed with ‘A’
for the initial interview and ‘B’ for the follow-up interview. They followed broad topic areas including
menstrual history and experience, social factors influencing experience, relationships and family life, and
emotional well-being as well as treatment preference and experience of treatments. The topic prompts
were modified and refined following early interviews, with participants encouraged to discuss their
perceptions and experiences freely. A sample of participants was also asked to participate in further
respondent validation.
Data were analysed using constant comparison94 by the field researcher, with two researchers of different
disciplinary backgrounds (academic midwifery and clinical primary care) contributing to development of
the analysis. Coding was aided by application of NVivo software (QSR International, Warrington, UK) in
identifying emerging themes from the data. Data generation and analysis were iterative, each informing
the other, with further theoretical sampling and data collection to extend and challenge earlier data and
interpretation, both within and between first and second interview data sets. This tested the integrity
and credibility of the analysis until no new themes emerged, which suggested saturation.
Validation
Interim findings were also fed back and reviewed with a sample of six interviewees who were willing to be
involved a third time. This was by audio-taped telephone interview following prior distribution of written
summaries. Respondents were asked to consider and comment on the findings, enabling the research
team to confirm and further refine data interpretation and analysis where appropriate.
Findings
Consent to contact forms were received from 52 women over an 18-month period of recruitment, of
whom 27 were purposefully selected and interviewed within 3 months of commencing treatment for HMB.
Of these women, 24 were interviewed again more than 12 months after commencing treatment. The
51 interviews lasted between 30 and 85 minutes. Characteristics of women are summarised in Table 9.
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TABLE 9 Characteristics of women interviewed in the qualitative study
Characteristics Number of women (n= 27)
Age range (years)
20–29 2
30–39 9
40–49 15
> 50 1
Ethnicity
White/British 23
Asian/Indian 2
White/mixed 1
Black/Caribbean 1
Parity
No children 4
One child 5
Two or more children 18
Highest formal educational attainment
No qualification 6
GCSE or equivalent 9
NVQ3/A-level or equivalent 7
Degree or higher 5
Experience of HMB
≤ 1 year 9
1–5 years 6
> 5 years 12
Initial medical treatment for HMB
Trial participants 17
LNG-IUS 8
Tranexamic acid 5
Medroxyprogesterone 2
Oral contraceptive pill 1
Norethisterone 1
Declined trial participation 10
LNG-IUS 6
Tranexamic acid 4
Changed treatment for HMB during study period
No change 15
Changed once 10
Changed twice 2
A-level; advanced level; GCSE, General Certificate of Secondary Education; NVQ, National Vocational Qualification.
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Concealment of menstruation
Framing women’s experiences of treatments, women felt a strong societal pressure to remain silent about
menstruation, which remained taboo and was amplified by experiencing HMB.
I think in society it’s quite a taboo subject. I work in an all-female environment with one man who is
obviously married, who has got children but if we were actually talking about periods we would stop
if he came into the room.
11B
It makes me feel not so much like a normal woman really when I have a heavy period because you
feel like you’re the only one that’s having a heavy period. Obviously there are hundreds of women out
there that are having them but it’s not common knowledge that a lot of women are having heavy
periods like I did, I kept it quiet.
15A
The taboo existed within families and among friends. It was strongest in the workplace and could persist
within consultation with a health professional.
A lot of women don’t like to go [to the GP] because it’s this taboo subject, so it has to start
somewhere other than a GP. It’s got to start somewhere that you know that it is acceptable to have a
problem, there isn’t a right and a wrong.
27B
Women could maintain the societal norm by denying their problems, lying to employers and withholding
information from their doctors in order to stay silent about HMB. Not speaking about HMB (and
menstruation in general) had a negative impact on most women’s QoL.
I had gone to the doctors a few times and somebody had asked me and I wished somebody had
asked me earlier and perhaps if you talk about it then somebody perhaps at work might actually well I
am doing this, this and this and then you are more confident then to seek help.
26B
Women also expressed a strong sense that women should ‘put up’ with HMB and not complain about it
by maintaining a stoic silence. The decision to seek treatment and therefore break the silence was seen as
a weakness or failure and was often associated with reduced self-esteem.
And you just feel a bit, not worthless because worthless is the wrong word – but you think some
people must think you are one of these women. That you have just got a heavy period – get on and
sort of deal with it – but you can’t physically get on unless you have actually been through a phase of
having heavy periods – you can’t. And I am the same because I didn’t understand when people said
they had really heavy periods because I never had them before.
26B
Expectations of treatments
Many women interviewed had high expectations of a prompt positive outcome from their treatments, both
those prescribed standard treatments and those prescribed the LNG-IUS. Women recounted only positive
information tended to be shared by friends about treatment for HMB, using upbeat language. The
reported benefits of a particular treatment in the lay press or online underline this, in particular,
expectations for the effectiveness for the LNG-IUS. Some women expected a very significant impact, not
only on a range of menstrual issues, but also on other areas of life, such as life at home, relationship issues
and career. This highlighted how HMB could dominate their lives.
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I would never have to worry again, it might be the miracle cure that I am after.
18A
Most women had other concerns in relation to HMB. These included pain (cramping period pain), fatigue,
anaemia, irritability, low mood, joint pain, lack of energy and headaches. These were highly individual and
often combined. Many women did not think of their menstrual bleeding in terms of blood volume, but
were far more concerned about rate of blood flow, the presence of blood clots and controlling this flow in
order to maintain concealment of their menstrual state. In addition, related pain, cramps and backache
were the most significant issues they wanted to address. Many of these women felt this pain to be severe
and debilitating and were completely unable to continue with their normal daily activities during
menstruation, resulting in taking time off work.
It’s a strange sensation because it’s coming away from you and you have no control over it . . . I have
blood clots sometimes the size of a fist and it’s awful.
15A
But it wasn’t the actual bleeding part, it was more the pain … doubled over with the pain.
5A
Then the last year they have got worse with pain and having to have time off work for a couple of
days … It always felt like my insides were dropping out the pain on the first 2–3 days.
5A
Women described complex behaviours and coping mechanisms to enable them to both manage their
menstrual bleeding and to conceal their condition not only from work colleagues and friends, but also
from family members. Preparatory coping behaviours included carrying extra sanitary protection at
all times, frequent changes and checking of blood loss, and having a spare change of clothes
(sometimes two).
It was every handbag had some sanitary wear in it just in case . . . I always knew it was best to stock
up at that time ready for next time.
29B
Avoidance behaviours included rescheduling activities at home and at work, cancelling meetings both
social and professional, taking time off sick from work and remaining at home during menstruation. Other
mechanisms included having someone else take care of children, or take their place or shift at work. These
coping mechanisms for HMB allowed the woman to rest and ensured that their menstrual difficulties
remained concealed. If these failed, women reported feeling embarrassment, guilt and shame, particularly
if other people needed to help them. They often became distressed and upset, affecting self-esteem
and mood.
It was on our staff party [date] it was and it was mid-afternoon and . . . I just thought I need to go to
the ladies but . . . when I got to the ladies toilets . . . I had wet my, soiled my trousers, my underwear
was saturated through and the pain and the contractions were really bad and it was just pouring out
of me . . . I was too embarrassed to come out . . .
39B
Heavy menstrual bleeding could have a negative and wide-ranging impact on women’s QoL, which was
most often related to their ability to function effectively in their daily roles, to be able to cope well with
their responsibilities at home, at work and within their relationship with their partner during menstruation.
The negative impact of HMB on their roles and responsibilities was influential in women’s decisions to
seek treatment.
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I would say it’s not trivial. You know to them it may be something that you know if they are a
gynaecologist and they are dealing with it may be the least of someone’s problems but to that woman
it is the butt of her problems you know and it has an impact on her whole being her whole holistic
being revolves around that one thing.
27B
Beyond peers and family, few women had sought information about treatment from other sources such as
the Internet and all had a treatment preference prior to their medical consultation. The most requested
treatment was the LNG-IUS. Women who expressed a preference for other standard treatments did not
want the LNG-IUS because of its effect on fertility and also the invasive nature of the coil. Women who
rejected the LNG-IUS because of its contraceptive effect were all in their forties and most strongly wanted
to conceive a child.
Initial experiences of the levonorgestrel-releasing intrauterine system
Many women who were treated with the LNG-IUS found the coil fitting to be more distressing than
anticipated and some felt unprepared psychologically for the procedure. While many doctors did not
recommend the LNG-IUS for nulliparous women, multiparous women still had problems. They recounted
feeling pain and discomfort in excess of other medical procedures within their previous experience and
used emotive language.
I suppose I was a bit naïve, I suppose a picture might have helped. I was thinking of like a smear test
but they actually have to open you up a bit more and obviously that’s not very pleasant.
29B
I had it done [LNG-IUS fitting] and it really hurt. I think you would really have to make that clear to
somebody. Even if they have not even had a baby or something. It hurts for a short time I suppose.
But you wouldn’t like, if you were doing that to somebody’s neck it would be classed as torture or
something you know it really is nasty. You know a bit sort of medieval.
29B
Some women had been told to take oral analgesia before the procedure, but many did not. Most women
did not specifically mention or recall local anaesthesia in discussing their experience of the LNG-IUS
insertion but those that did were dissatisfied with it.
I don’t think she put any [expletive] numbing lotion there to be fair, there is no way on earth that she
put anything to numb me because there was no numbness.
Women felt that health professionals taking consent for the procedure had downplayed the possible
intensity of the pain and also the complexity of the procedure itself. Women had a strong sense that while
this was a simple procedure for the health professional, it was not simple for them experiencing it.
She said it’s going to be feeling like this, this, and this, you are going to feel a little bit of pain and it
should be over and done within like 2 minutes, OK, right, not a problem. Oh how very wrong she
was. The little [nationality] nurse I was holding her hand and I had to let go of her hand because I
would have broke her fingers because in the end it was literally gripping on to the sides of the bed,
tears coming down my eyes, excruciating pain . . . I felt sick, I felt giddy I just wanted to be sick and
then she done it and the pain was just excruciating, she said you are going to have to wait like half an
hour in here. I couldn’t walk when I got off.
23A
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Women then found the LNG-IUS troublesome within the first 3 months of treatment because irregular
bleeding interfered with women’s long-established behavioural coping mechanisms.
I was quite anxious because I kept thinking that at some point they could come back or they could
start or I could spot and that did actually happen. Initially I was having spotting or a mild period pain
and things like that but they just got less and less.
Some considered removal of the LNG-IUS during this time but did not seek to do this partly because they
were advised or anticipated it would improve over time, or they thought removal would be difficult, or
they might lack an alternative treatment. Some women did not ask for the LNG-IUS to be removed
because they did not want to go through the process of revisiting their GP and having a vaginal
examination within such a short time.
The other day it [intermittent bleeding following treatment with LNG-IUS] drove me so mad somebody
actually offered me pliers and I nearly took them [pause] you know.
27B
Tell you the truth I did actually think about going back to the doctor because I thought . . . perhaps
there was something wrong, perhaps the coil perhaps wasn’t working properly or perhaps something
had happened and it was sort of making it go a bit weird but then I never sort of got round to making
an appointment and then the next month would come and it would be a bit better and then by the
third or fourth month it seemed to have settled down anyway.
Most women attending for their routine check, around 6 weeks after IUS fitting, were asked by health
professionals about whether or not their menstrual blood loss had reduced. However, women found that
explaining blood loss in terms of volume was challenging and, moreover, felt that questioning changes in
menstrual blood flow did not reflect a more desired holistic change for them.
I think sometimes [doctors] are dealing with the problem as opposed to the woman and that is the
mistake; that is the mistake.
27B
Women expected a period of transition following the initial fitting of the LNG-IUS, perhaps reflecting
information given by most health professionals about the initial side effects at the time the LNG-IUS was
fitted. However, women were surprised at the amount of disruption to their cycle or amount of irregular
bleeding as this was greater than either their peers or health professionals had indicated, and indeed some
had thought their menstrual bleeding would cease completely within 1 or 2 months
It took a while, it didn’t do much at the beginning, it took a while for it to do anything. I didn’t think
it was going to do anything at first but yeah, it took a while and I noticed it slowing down. That was
the big thing for me. It didn’t matter if it didn’t stop or anything, just slowing it down. It has done it in
the same year, it has done it bit by bit, it slowed down and slowed down and now for the last 2 or
3 months I have not had anything, not a thing.
15B
Women who had a positive experience of treatment were more inclined to talk about it, while women
who had had a negative experience of treatment were more likely to remain silent. Women did not
anticipate major changes in their menstrual cycle, such as irregular bleeding and spotting, or that this
might last much longer than expected before they saw an improvement in their condition.
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Experiences of the levonorgestrel-releasing intrauterine system after
12 months of treatment
Most women persevered with the LNG-IUS and at 12 months were satisfied with this treatment,
experiencing a positive and often major impact on their QoL. The treatment took effect gradually over the
first 3–6 months.
It started off really, really excellent then we tended to have a bit of a dip where it was a bit hit and
miss some months but now it seems to have settled back down again so I don’t know whether that
was just a fluke or perhaps whether I was a bit more stressed at work at the time and you know busy
in my life that made an impact on that but now on the whole is the best decision I could have made.
26B
Most women had, as expected, experienced amenorrhoea (cessation of periods) with this treatment after
12 months, but even those still having menstrual periods felt significantly better.
I was concerned because obviously they advised that if this [LNG-IUS] didn’t control it, it would be a
hysterectomy, which was obviously not what I would like. I was only 40, 39 or 40, at the time and so
I had that fitted now for a while and everything is now wonderful so I have had no more problems
any more.
42B
It is such a relief, it really is, after the pain that I used to have before and the tiredness and the
flooding and the whole, it was almost like your whole life revolved around periods and being
comfortable or uncomfortable and you know it was, it was awful and I was feeling constantly tired
and thinking this is just, you know, that just awful and now that has all gone and it is just such a
relief, it really is.
16B
It just sort of gave us I suppose my bit of life back, my bit of independence back that I could do, you
know carry on without thinking you know have I leaked.
26B
Most women with a LNG-IUS were happy to continue with this treatment long term. Several women who
had considered hysterectomy prior to commencing their treatment with the LNG-IUS now no longer
considered surgery as necessary or appropriate use of health-service resource.
What I have now is not worth going through an operation for . . . If it hadn’t worked and I was still
having heavy periods then I would think about it but no, not with the coil, no it’s not worth having
that done, taking up space in the hospital just to have that.
5B
Experiences of standard treatments
Women who were prescribed standard treatments (most commonly oral tranexamic acid, but also
norethisterone, medroxyprogesterone acetate injection and the oral contraceptive pill) had widely varying
perceptions and experiences. They were regularly less satisfied with their treatment, with most having
ceased prescribed medication at 12 months.
Women were generally dissatisfied with tranexamic acid, but did acknowledge some reduction in menstrual
blood flow. Some were concerned about the physical size of tablets and the number that they had to take
each day (two tablets, three times per day is commonly recommended). Most did not perceive significant
improvements in the short term and so stopped taking their medication after 2 months.
WOMEN’S EXPERIENCES OF MEDICAL TREATMENTS FOR HEAVY MENSTRUAL BLEEDING
NIHR Journals Library www.journalslibrary.nihr.ac.uk
42
If I take them it does keep the bleed, you know, under control. If I leave it a little bit too long before
I take the next lot I am just like flooding again so it’s, I am not really one to take tablets though,
it’s very hard.
32B
It’s like remembering to take X, Y, Z and the amount of tablets all the time, that can be a
problem . . . remembering to take tablets and making sure there’s the right spaces in the day between
these tablet taking that can be a problem in itself ‘cos you might not be where your tablets are or you
might be, you know, hung on at work doing extra hours and that and it’s all that and it’s all that
added stress that you don’t really need.
7B
I was taking, I had got good at remembering to take them, take them just before and take the
maximum dose and I thought they are not making much difference at all, I still can’t get out of bed
without hopping to the bathroom cross-legged.
29B
The experience of the few women prescribed oral and injectable contraception for HMB was also generally
not satisfactory.
I hardly have any periods, I think I have 2 days of bleeding, don’t get any pain but 2 weeks before my
period is due I get terrible depression where I am always crying. I just feel dead depressed and I just let
small things become big things and it’s just when I am coming up to my period.
43B (oral contraceptive)
So I had the injection in [month] I haven’t stopped bleeding since, now it’s not working and I am
getting chronic migraines all the time. And I have ballooned in weight in the last 3 months so
suddenly it is not working, not suiting me. I am changing my treatment as of next week.
18B (Depo-Provera)
Oral contraception was continued for other reasons such as familiarity, reversible contraceptive effect and
lack of interference with other medical treatments.
I have been taking the iron tablets, which help with the dizzy spells and things like that. I did try the
other medication [tranexamic acid] but I tried it and I felt, no, I didn’t feel anything changes much and
therefore I thought is there any point taking another medicine if it doesn’t make any difference? I still
have the pain and I still felt the same and the blood flow seems to be no better so I haven’t taken
it again.
28B
Women perceived standard treatments to be a short-term measure. Many who discontinued treatment
elected not to try any other treatment, preferring to manage their condition themselves by changing
coping behaviours and strategies. This was particularly true of the women who had a long history of HMB
and those who anticipated the onset of menopause within the next few years.
Some women were concerned about the physical amount of tablets that they would have to take over the
course of their remaining years of menstruation. Most disliked the thought of taking medication, with
concerns about the long-term effects of the medications prescribed. For some, this was related to potential
unknown side effects.
They [tranexamic acid] did work but I didn’t like the quantity of tablets that I was taking.
18A
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I will probably go back to the doctor and get some more tablets . . . unless there was something else
that they could try instead rather than stay on them long term. But in the short term, yes . . . I know
they research them but they never know until years later the effects. It might not have an effect now
but in years to come and I’d rather not take the risk of causing anything long term. If I had a choice
I would rather not take the tablets.
30B
Women who were initially treated with standard treatments commonly changed their treatment over time,
with six women in this sample eventually opting not to use any treatment at all and manage without:
two resuming standard treatment after intervals of using no treatment and four women switching to the
LNG-IUS. One woman had a hysterectomy.
Discussion
This study has found women’s expectations, and experiences of use and effectiveness, of medical
treatments for HMB to vary considerably and change over time. These findings highlight a range of
implications for clinical practice, which are discussed in Implications for Practice below, and may be used to
enhance more informed shared decision-making and improve care for HMB when women seek help.
Strengths and limitations
The work provides qualitative insights in to how women experience current medical treatments for HMB,
with the advantage of a longitudinal design, over a timeframe of around 1 year. Methods were used
to enhance rigour, including purposeful sampling, involving researchers from differing disciplines in analysis
and respondent validation. The sample is described in some detail, which may aid assessment of relevance
of findings beyond the study and trial context. However, it is recognised that this was inevitably a selected
sample of women willing to articulate their experiences. Although participants were engaged in the
context of clinical trial recruitment, we actively included those unwilling to be randomised and those with
preferences for a particular treatment for HMB.
Comparison with existing work
Previous work has found that health professionals may be preoccupied with volume of blood loss, within a
biomedical model, rather than addressing the impact on women’s health.95,96 Although highlighted in
more recent research,89 assessing reduction in blood volume for treatment efficacy,97 or what reduction
in menstrual blood loss is meaningful to women,98 remains a focus of research. Higher volume of daily
menstrual blood loss has been correlated with limitations in functioning and social activities.99 Women in
this study were as concerned with menstrual pain and psychological distress affecting their health and QoL
as with HMB itself. This finding is consistent with other work.95,96 Going beyond reduction in volume of
blood loss alone, measures of QoL are now becoming more widely used to determine treatment efficacy.69,93
More than 1 year following initial treatment with the LNG-IUS most women were satisfied with their
treatment and had experienced an improvement in their perceived QoL. This finding concurs with the
quantitative results of the ECLIPSE trial in Chapters 3 and 4.93 Narrative accounts were overwhelmingly
positive and a number of women used emotive language to describe the improvement in their health and
well-being. Most women had experienced amenorrhoea, but even women who still experienced regular
menstrual bleeding felt better. The change in perceptions of health and well-being was always associated
with being able to fulfil roles and responsibilities. Some women described an improvement in physical
well-being, but the emphasis for all was on the psychological benefits of being able to maintain the societal
norms of concealment of menstruation. The later acceptability of the LNG-IUS reported here concurs with
Lete et al.,100 who found that 87.9% of pre-menopausal women in their study would use a second
LNG-IUS device.
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Women who were prescribed tranexamic acid initially took the medication as prescribed and experienced
some benefit, but most did not feel better quickly enough to continue with their treatment. However,
others have found long-term use of tranexamic acid to be well tolerated over a 15-month timeframe,
although emergent adverse effects such as headaches, menstrual and back pain were commonly reported.86
Implications for practice
These qualitative findings suggest that discussion with women about medical treatments for HMB should
not be confined to orthodox clinical considerations, such as volume of heavy bleeding or a woman’s wish
to avoid having an IUS or contraception. Rather, health professionals could also helpfully consider the
wider impacts of HMB on women’s lives and respond to these appropriately in sharing decision-making
with women about choosing and using treatments. Women’s high expectations of a prompt effect from
treatments may be understood in terms of their prolonged toleration of the impacts of HMB and its
concealment, which had typically preceded seeking medical help. Potentially high expectations of
treatment (and the potential influence of peers) should be appreciated and explored appropriately when
discussing treatment.
In assessing treatments with women, practitioners should consider that issues such as effect on rate of
blood flow, pain and well-being, as well as wider functioning socially or at work, may be as or more
important to individuals than amount of menstrual blood loss. Women’s accounts also underline other
points for helping women make more informed decisions. These include avoiding ‘underplaying’ initial
problems that may be unanticipated by those considering the LNG-IUS, by ensuring that women are
appropriately prepared (physically and psychologically) for fitting the LNG-IUS in practice, and in particular
for troublesome changes in pattern of bleeding that may commonly occur and can be prolonged.
Unpredictable irregular bleeding with the LNG-IUS was more problematic than the volume of blood loss
for women in this study owing to its impact on their established behavioural coping mechanisms for HMB.
Irregular bleeding is recognised as a common reason for discontinuing the LNG-IUS.48,81 Nevertheless, the
current qualitative findings, in line with the strong pragmatic clinical trial evidence reported in Chapters 3
and 4, underline that women can be advised that, if they persevere with leaving their IUS in place, they are
likely to experience significant improvement in menstrual symptoms and related QoL.
Women’s perceptions of other treatment options, as a more short-term measure they could control
themselves (stopping and starting as they wished), may provide helpful information to offer women
considering what may suit their individual circumstances. Information provided may highlight that
improvements in the impact of HMB may be expected, but may be variable and may not be as substantial
as for the LNG-IUS, in line with the trial evidence. Women may also be given advice regarding practical
considerations, such as the inconvenience of taking several large tablets in the case of the most commonly
prescribed oral medication, tranexamic acid.
The findings also highlight an important wider context for discussing HMB treatments in relation to effect
on fertility and desire to conceive among women in their forties presenting to services with change in
menstrual experience, often at a time of other life transitions.
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Chapter 6 Economic evaluation alongside the
ECLIPSE trial
Introduction
In this section, the economic evaluation that was carried out alongside the ECLIPSE RCT is reported. The
objective of the ECLIPSE trial was to compare the clinical effectiveness and cost-effectiveness of the LNG-IUS
and usual medical treatment. Following the recommendations of NICE, that surgical intervention should
be the last course of treatment for patients with HMB, the clinical effectiveness and cost-effectiveness of
non-surgical interventions has become the primary focus of clinicians and decision-makers alike.
In 2007, NICE introduced guidelines1 for the LNG-IUS to be used for first-line treatment of HMB, but this
was based on limited evidence of cost-effectiveness from one trial.50 An updated review identified seven
further randomised trials38–44 which compared the LNG-IUS with non-hormonal treatments, but none was
considered cost-effective.
The aim of the analysis reported here is to conduct an economic evaluation alongside the ECLIPSE trial to
provide robust evidence on the cost-effectiveness of the LNG-IUS compared with usual medical treatment.
Furthermore, as impact on QoL is the primary outcome measure in HMB, the outcome was measured using
a number of different instruments, including the EQ-5D, Short Form questionnaire-6 Dimensions (SF-6D)
and MMAS. Although MMAS is disease specific, the EQ-5D and SF-6D are both general health-related
instruments that represent the extra-welfarist approach to measure outcomes. However, at the inception of
this trial in 2002, the use of SF-6D was in its infancy and still being developed.101 It was included in the
current study as a methodological component. In the intervening years much has been written on the
different results produced by the EQ-5D and SF-6D instruments, especially regarding floor and ceiling
effects. Further exploration of the methodological differences is beyond the scope of this study. Therefore,
for clarity, the base case will report results based on the EQ-5D, although results using the other instrument
will also be reported. The influence on the cost-effectiveness results of using these different extra-welfarist
measures is explored briefly. As the ECLIPSE trial has been described in Chapters 3 and 4 of this report, only
a brief overview of the trial is provided here as part of the methods. The remaining section of the methods
describes the model, the derivation of transition probabilities and utility values using the trial data and
resource use.
Methods
A model-based economic evaluation in the form of a cost–utility analysis (CUA) based on an outcome
of cost per QALY was carried out alongside the ECLIPSE trial.93 The analysis took a UK NHS perspective
in a primary care setting and provides an assessment of the difference in costs and QALYs. The QALY
encapsulates quantity of life and QoL into a single metric. Two analyses based on two different time
horizons are considered. The first is analysis based on the outcome at 2 years and the second is based on
the outcome at 5 years. As the economic evaluation was carried out alongside a trial, an intention-to-treat
analysis was adopted. A societal perspective to include private costs to women was considered, but
deemed not to be feasible given the resource constraints for data collection.
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Participants and trial design
The key information required to understand the economic evaluation is summarised again here. Briefly,
571 women with HMB from 63 UK centres were randomised between February 2005 and July 2009.
Women between 25 and 50 years of age presenting to their GP with HMB, occurring over at least three
consecutive cycles, provided written informed consent to participate. Women were randomised to having a
LNG-IUS fitted, or usual medical treatment, chosen by the GP and the woman, based on contraceptive
needs or desire to avoid hormonal treatment.
Usual medical treatment options included mefenamic acid, tranexamic acid, norethisterone, a
combined oestrogen–progestogen or progestogen-only oral contraceptive pill (any formulation), or
medroxyprogesterone acetate injection.1,18 The particular medical treatment was specified prior to
randomisation. Treatment reviews by GPs were carried out at 6 weeks and 3 months. Subsequently,
treatments could be changed or discontinued owing to perceived lack of benefit, side effects, change in
contraception requirements, referral for endometrial ablation or hysterectomy as per usual practice.1,18
Treatment changes reported by patients were confirmed with the GP.
Model
A model-based analysis was used as a vehicle for the within-trial economic analysis to comprehensively
account for the changes in QoL that occurred while the women were taking these treatments, but all the
QoL data used in the model are based on primary data collected in the trial.
As outlined in Quality-of-life measures, data on utilities (or QoL) were collected at baseline and at 6 months,
1, 2 and 5 years. The trial data showed that, because of its non-curative nature, women were changing
their treatment more frequently within this time to identify the best method for managing HMB, and this
process had an influence on their QoL. The analysis does not lend itself to a regression framework because
patients change between different health states on a monthly basis and QoL was not measured at that
frequency. It would therefore be inappropriate to infer QALYs in a typical trial-based analysis from the QoL
scores at the time point they happen to be taken in the trial. The most suitable method to capture changes
in QoL occurring throughout the trial and provide a robust CUA is to represent these experiences as health
states in a decision model, which follows the process of management of HMB used in the ECLIPSE trial.
Therefore, QoL values were attached to the health states. A measure of change in utility from baseline to
the end point of the trial, as in a typical trial-based analysis that does not use a decision model, would not
accurately capture the health states that women had experienced throughout the time span of the trial.
Furthermore, a trial-based analysis, without a decision model, would not comprehensively capture the time
spent in health states or the associated repetitive costs and resource use. The decision model, based on trial
data, provides a more realistic explanation of the utility pathway, providing information that can be
synthesised with other data and projected forward.
A state transition102 model was developed using Microsoft Excel® (Microsoft Corporation, Redmond, WA,
USA). A Markov model appropriately combines data for each of the pathways and takes account of the
cyclical and repetitive nature of events and facilitates a simulation approach. All parameters used in
the model were based on the trial data.
Model structure
The model structure was informed by clinical input and the pathways followed by women in the trial.
Several iterations of the structure were made as the model was continuously modified to ensure that it
most closely reflected the trial data. Although the structure was not informed by literature, the health
states for the model were developed using trial data and by adapting those used previously.1,103 The
inclusion of menopause as a health state was considered but the 2-year time horizon of the analysis and
the age of the patients, between 25 and 50 years, meant very few women, if any, would be reaching
ECONOMIC EVALUATION ALONGSIDE THE ECLIPSE TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
menopause within 2 years. At the 5-year time point the inclusion of menopause was considered but
deemed inappropriate as this specific information was not captured (see Additional model assumptions for
the analysis based on the outcome at 5 years). For similar reasons, death was not included as a health
state: the interventions do not cause death and the age of the women meant that the likelihood of death
from natural causes was minimal. As models are a simplification of reality, it is necessary to include only
transitions between health states that commonly occur for the majority of patients, and this was not the
case for death and menopause.
Figure 7 presents the clinical pathways and the progress of the two cohorts of women in the ECLIPSE trial
who were randomised to either the LNG-IUS or usual medical treatment. The pathway for each treatment
can be represented in the same structure.
Definition of health states for levonorgestrel-releasing intrauterine
system pathway
l HMB: every woman in the ECLIPSE trial cohort suffers from HMB.
l LNG-IUS: all women have the LNG-IUS inserted.
l Well with the LNG-IUS: following the insertion of the LNG-IUS women are satisfied with treatment and
remain in this health state.
l Symptomatic with the LNG-IUS: following the insertion of the LNG-IUS, adverse effects may arise and
women may feel unsettled with their current treatment. From this state women may remain in the
state or change to an alternative treatment, (i.e. usual treatment, surgery or no treatment).
l Surgery: women may choose to have surgery, which includes endometrial ablation or hysterectomy,
determined from the data. Women can move to surgery from ‘symptomatic with the LNG-IUS’, ‘change
to usual medical treatment’ or ‘no treatment’.
Allocated
treatment
No
treatment
Menorrhagia
Well with other
treatment
Symptomatic
with allocated
Well with
allocated
Post surgery
Change to other
treatment
Surgery
FIGURE 7 Clinical pathway for the LNG-IUS and usual medical treatment.
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l Post surgery: following ‘surgery’, women will then remain in the ‘post-surgery’ state.
l Change to usual medical treatment: if women have chosen ‘no treatment’ or are ‘symptomatic with
the LNG-IUS’ they may choose to begin usual medical treatment. Women may immediately become
‘well with usual medical treatment’ or may experience adverse effects and feel unsettled with usual
medical treatment and then eventually become ‘well with usual medical treatment’. Alternatively,
women may choose to have ‘surgery’ or ‘no treatment’. If women are in this state at 3 months, the
cost of a GP review will be incurred. Women can change to usual medical treatment from the LNG-IUS
in the first cycle. (see Model assumptions for further details).
l Well with usual medical treatment: following ‘change to usual medical treatment’ women are satisfied
with this treatment and remain in this health state.
l No treatment: following the LNG-IUS, ‘symptomatic with the LNG-IUS’ and ‘change to usual medical
treatment’, women may choose to discontinue treatment altogether. Following this, women may
decide to ‘change to usual medical treatment’ or have ‘surgery’.
Definition of health states for usual medical treatment pathway
l HMB: every woman in the ECLIPSE trial cohort suffers from HMB.
l Usual medical treatment: all women have usual medical treatment.
l Well with usual medical treatment: following ‘usual medical treatment’ women are satisfied and
remain in this health state.
l Symptomatic: following usual medical treatment, adverse effects may arise and women may feel
unsettled. From this state, women may have an alternative treatment (i.e. ‘change to the LNG-IUS’,
’surgery’ or ‘no treatment’).
l Surgery: women may choose to have surgery, which includes endometrial ablation or hysterectomy,
determined from the data. Women can move to surgery from ‘symptomatic with usual medical
treatment’, ‘change to the LNG-IUS’ or ‘no treatment’.
l Post surgery: following ‘surgery’, women will then remain in the ‘post-surgery’ state.
l Change to the LNG-IUS: if women have chosen ‘no treatment’ or are ‘symptomatic with usual medical
treatment’ they may choose to begin treatment with the LNG-IUS. Women may immediately become
‘well with the LNG-IUS’ or may experience adverse effects and feel unsettled with the LNG-IUS and
then eventually become ‘well with the LNG-IUS’. Alternatively, women may choose to have ‘surgery’ or
‘no treatment’. Women can change to the LNG-IUS from usual medical treatment in the first cycle.
(see Model assumptions for further details).
l Well with the LNG-IUS: following ‘change to the LNG-IUS’ women are satisfied with treatment and
remain in that health state.
l No treatment: following ‘usual medical treatment’, ‘symptomatic with usual medical treatment’ and
‘change to the LNG-IUS’ women may choose to discontinue treatment altogether. Following this,
women may decide to ‘change to the LNG-IUS’ or have ‘surgery’.
Time cycle
A monthly time cycle was used in the analysis as this represents the clinically meaningful changes observed
in treatment and resource use. The ECLIPSE trial data showed that, in many cases, treatments had been
altered and women had visited their GP within a month of treatment administration. A monthly time cycle
was therefore required to reflect the data and incorporate the associated costs and treatment changes
into the CUA. A half-cycle correction is not applicable in this model because the monthly time cycles used
in the model are genuine discrete time events and this transition did not occur in the middle of a cycle. On
this basis, a correction would not have made a substantial difference to the costs and outcomes.104
The following assumptions were made and developed based on clinical expertise from practising primary
care and gynaecology clinicians, in addition to standard treatment protocol. The first set of analyses to be
carried out was based on the outcome at 2 years post intervention. Some additional assumptions were
required to extend the analysis to include a 5-year time horizon and these are reported separately. For
both sets of analyses, the assumptions were agreed prior to conducting the analysis. Unless otherwise
stated, the assumptions used for the analysis at 2 years were maintained for the 5-year analysis.
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Model assumptions
Model assumptions for the analysis based on the outcome at 2 years
l A woman is ‘well’ with the allocated treatment if she does not change or stop treatment. Some of
these women may not be ‘well’, but are coping with treatment, and the utility values for the ‘well’ with
allocated treatment state reflect this.
l A woman who is ‘well with the LNG-IUS’ and ‘well with usual medical treatment’ may report different
QoL scores. This is because the LNG-IUS tends to stop bleeding, whereas oral medication helps to
manage the bleeding.
l A woman who is ‘well with the LNG-IUS’ or ‘well with usual medical treatment’ cannot spontaneously
become ‘symptomatic’.
l Based on the data, if in the first cycle women move from the allocated treatment to an alternative state
other than ‘well’, it is assumed that they move to either the ‘change to alternative treatment’ or ‘no
treatment’ state. It is assumed that they do not move to the ‘symptomatic’ state in the first cycle
because insufficient time has elapsed for this to be established and so it is assumed they changed for
other reasons.
l From the second cycle onwards, if women change from their allocated treatment they do not go to
‘well’ but to the ‘symptomatic’ state and move on from there.
l For the transition to ‘surgery’, data were collected on whether or not a woman had ablation or
hysterectomy, but not the precise technique (e.g. thermal balloon endometrial ablation or microwave
endometrial ablation). Data on the weighted likelihood of surgery undertaken were taken from a
previous study.103 It is assumed that if a woman in the trial has endometrial ablation then it will be for
her first ablation and we apply the cost for first-line endometrial ablation techniques.
l Once a woman has changed from the allocated treatment, it is not possible for the woman to move
back to the allocated treatment.
l It is assumed that if a woman ‘changes to the other treatment’, she must spend at least one cycle in
‘change to other treatment’ before she can move to ‘well with other treatment’. This is assumed as it
will take at least one menstrual cycle for any effect to become apparent.
l Adjustment for baseline differences in QoL were not been incorporated because of the risk of imposing
a difference at every point in time over the time period of analysis.
Additional model assumptions for the analysis based on the outcome at 5 years
l Only data up to 5 years will be considered in the analysis.
l The utilities and transition probabilities for the 2-year analysis have now been updated to reflect the
changes in 5-year data. For example, where a woman did not change treatment during the first 2 years
she would have been classed as ‘well’. However, if the same was later observed to change treatment at
4 years, at this time point in the 5-year analysis she would be moved to ‘symptomatic’ and so the new
utility values and transition probabilities reflect the updated data.
l Explicit data were not available on whether or not women were experiencing menopause.
l In total across both arms of the trial, in eight cases (five in usual treatment and three in the LNG-IUS),
women who were in the ‘well’ state at the 2-year analysis stated that they have stopped treatment
because it was no longer needed. Where a woman stops treatment and the notes state that treatment
is ‘no longer needed’ the woman will remain in the ‘well’ state.
l As few women have stopped treatment in the ‘well’ state because treatment is no longer needed, the
cost of stopping treatment is negligible and there is little value in adding complexity to the analysis for
this group of women.
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l Where a woman stops treatment and provides no reason or states ‘lack of efficacy’, these women will
move to ‘symptomatic’ first and then reach the ‘stop treatment’ health state. The utility value for the
‘stop treatment’ health state therefore reflects both those who may be experiencing menopause and
those who no longer want to try any other treatment for the condition.
l A paper reporting the results for the 2-year cost-effectiveness analysis for the ECLIPSE trial has been
published,69 so to maintain consistency with the previous analysis, costs reported here are not inflated
to 2013 and all are reported in 2011 prices.
Calculating transition probabilities
To use the trial data in the model, it was necessary to identify the distribution of women in the states at
any time and the transition probabilities between health states.
For every patient, the time in months from randomisation to every event (i.e. ‘stop treatment’) was
calculated. For each arm of the trial, the movements of all patients between states for every time cycle
were identified to determine the transitions made in each cycle. Then from each state (e.g. the LNG-IUS)
the total number of transitions from this state were summed to calculate the transition probabilities to
each health state, the number of people moving to each state (e.g. well) was divided by the total number
of movements from the LNG-IUS. This process was repeated for every other transition from the state and
then repeated for all remaining states.
In cases where women made moves that were not possible in the model, for example returning to
allocated treatment after changing to another state, these women were censored at the last point a move
was possible. This change only occurred in four cases and is advised against clinically. Therefore, this
transition was not considered to be a typical pathway and does not represent the population. As the point
in the cycle when the women moved back to ‘usual medical treatment’ is unknown, the women were
censored at one cycle prior to the return to randomised treatment.
To be consistent and prevent biasing any data, the two patients who changed to the other treatment arm
within the first month of treatment allocation were moved directly to this state without spending any
time in symptomatic, as reflected in the data. The treatment was never taken and so considering these
patients as symptomatic would not be accurate.
Where the woman ‘changes to the other treatment arm’ to ‘well with the other treatment arm’, one of
the model assumptions set out above should again be highlighted. That is, women must spend at least
one cycle in ‘change to other treatment’ to then enter the ‘well with other treatment’ state as it will take
this long for the treatment effects to be seen.
As women cannot stay in surgery, it is constructed as a transition state and therefore all of the women in
‘surgery’ move to ‘post surgery’ after one cycle. ‘Post surgery’ and ‘well’ are both absorbing states.
Therefore, as women cannot leave the state once they have entered, the probability of remaining in these
states is fixed to one.
The calculation of the utility values assigned to each health state will be described in Quality-of-life
measures following a description of the outcome measures collected in the trial.
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Quality-of-life measures
Outcome measures were collected using both the EQ-5D and the SF-36 at baseline prior to randomisation,
then by post at 6 months, and 1 and 2 years post randomisation. The booklet questionnaire given to
women in the trial contained the generic EQ-5D 3-level questionnaire, which measures the impact of
treatment on broader aspects of health-related QoL.105 The SF-36 was converted into SF-6D using the
algorithm.106 Utility values for each state in the model were calculated by averaging the EQ-5D or SF-6D
values for each woman in the given state at any given time.
Utility values for the individual states were calculated by averaging the EQ-5D and SF-6D values obtained by
each woman in the given state at any given time. For example, if a woman is randomised to the LNG-IUS
and then does not change treatment she is considered to be in the ‘well’ state for the remainder of the
analysis, as outlined in the model assumptions previously. Therefore, all of the woman’s utility values
collected at 6 months and 1, 2 and 5 years will be assigned to the ‘well’ health state in the model. Similarly,
if a woman is initially ‘symptomatic with the LNG-IUS’ and then moves to ‘no treatment’ at 2 or 5 years,
the utility values for the intermediate months will be assigned to ‘symptomatic’ and the utilities for 2 and
5 years assigned to the ‘no treatment’ health state. This method was used to derive the utility values
because the utility for the state is important, not the values associated with the individual woman’s journey,
as decision models are a reflection of the typical population.
Costs and resource use
Costs were collected from a UK NHS perspective. Data on health-care resource use, including GP or
gynaecologist consultations, were collected from women alongside other outcome measures. Similar to
the utility values, data on costs and resource use from the trial were collated and analysed according to the
randomised treatment arm. The general health-care costs for both groups included health-care staff costs
and the cost of the interventions. LNG-IUS fitting is estimated to take 20 minutes (informed by clinical
experts within trial team), requires both a GP and nurse to be present and also requires disposable
consumables. Treatment review by the GP was assumed to last 10 minutes (informed by clinical experts
within trial team). Staff costs were calculated using nationally recognised reference costs.107 The costs of
standard medical treatment and the LNG-IUS were estimated from the British National Formulary.23
Cost data on surgical interventions were taken from a previously published study and inflated to 2011
prices.103,107 As recommended by NICE, a discount rate of 3.5% was applied to both costs and utilities as the
model time horizon is beyond 1 year.108 All costs are reported in 2011 prices in UK sterling (£) using the UK
hospital and community health services index.96,107 Tables 10–12 present the data used in the analysis.
In cases where women were prescribed a combination of usual medical treatments, a weighted average of
the cost was taken. Similarly, repeat prescription costs were calculated based on the average weighted
cost of repeat prescriptions in the ‘change to usual medical treatment’ state of the LNG-IUS arm. As the
most commonly prescribed usual medical treatments involved GP review for effectiveness at 3 months, it
was assumed that GP review occurs at 3 months.
Where one-off costs were incurred, such as the cost of LNG-IUS removal, these costs were assigned to the
transition arrow.
Analysis
An incremental CUA provides information on the difference in costs and QALYs between the LNG-IUS and
usual medical treatment and is reported in terms of incremental cost-effectiveness ratios (ICERs), as cost
per QALY gained. If a treatment is less costly and generates a greater number of QALYs, dominance is
said to occur. Analysis was by intention to treat to provide a pragmatic estimate of ICERs. The base-case
analysis and three deterministic sensitivity analyses were carried out using the EQ-5D. An additional
sensitivity analysis, repeating the base case and its three deterministic sensitivity analyses, was carried out
using the SF-6D.
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TABLE 10 Cost data used in the analysis at 2 and 5 years
Cost component Unit cost (£) Source
LNG-IUS
Consultation (GP, 10 minutes) 26.67 PSSRU 2011107/expert opinion
Insertion
GP (20 minutes) 53.33 PSSRU 2011107/expert opinion
Practice nurse (20 minutes) 17.00 PSSRU 2011107/expert opinion
Device cost 88.00 BNF 6223
Sterile pack (insertion) 21.63 NICE (inflated to 2011)
Discontinuation
GP (10 minutes) 26.67 PSSRU 2011107/expert opinion
Practice nurse (10 minutes) 8.50 PSSRU 2011107/expert opinion
Sterile pack (removal) 3.77 NICE (Inflated to 2011)
Follow-up
6-week review (GP, 10 minutes) 26.67 PSSRU 2011107/expert opinion
3-month review (GP, 10 minutes) 26.67 PSSRU 2011107/expert opinion
Usual medical treatment
Progestogen (Cerazette®, Merck Sharp & Dohme Ltd) 8.68 BNF 6223
Tranexamic acid (Cyclokapron®, Meda) 14.30 BNF 6223
Mefenamic acid (Ponstan®, Chemidex) 15.72 BNF 6223
Norethisterone 2.18 BNF 6223
COC (Microgynon®, Bayer) 2.82 BNF 6223
Medroxyprogesterone acetate injections 6.01 BNF 6223
Consultation (GP, 10 minutes) 26.67 PSSRU 2011107/expert opinion
3- or 6-month review (GP, 10 minutes) 26.67 PSSRU 2011107/expert opinion
Discontinuation (GP, 10 minutes) 26.67 PSSRU 2011107/expert opinion
Surgery
Cost of surgery 1720.18 Weighted cost from trial
BNF, British National Formulary.
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TABLE 12 Probability parameters used in the analysis
Probability parameters
Monthly
probability
(2-year analysis)
PSA
distribution
Monthly
probability
(5-year analysis)
PSA
distribution
LNG-IUS
LNG-IUS to well with the LNG-IUS 0.639 (182, 103)a 0.502 (143, 142)a
LNG-IUS to symptomatic with the LNG-IUS 0.253 (72, 213)a 0.389 (111, 174)a
LNG-IUS to change to usual medical treatment 0.067 (19, 266)a 0.067 (19, 266)a
LNG-IUS to no treatment 0.042 (12, 73)a 0.042 (12, 273)a
Remain well with the LNG-IUS 1 Fixed 1 Fixed
Symptomatic with the LNG-IUS to well with the
LNG-IUS
0 Fixed 0 Fixed
Remain symptomatic with the LNG-IUS 0.907 (700, 72)a 0.953 (2236, 111)a
Symptomatic with the LNG-IUS to change to
usual medical treatment
0.035 (27, 745)a 0.015 (36, 2311)a
Symptomatic with the LNG-IUS to no treatment 0.041 (32, 740)a 0.022 (52, 2295)a
Symptomatic with the LNG-IUS to surgery 0.017 (13, 759)a 0.010 (23, 2324)a
Remain change to usual medical treatment 0.708 (109, 45)a 0.864 (311, 49)a
Change to usual medical treatment to well with
usual medical treatment
0.208 (32, 122)a 0.092 (33, 327)a
Change to usual medical treatment to
no treatment
0.045 (7, 147)a 0.028 (10, 350)a
Change to usual medical treatment to surgery 0.039 (6, 148)a 0.017 (6, 354)a
Remain well with usual medical treatment 1 Fixed 1 Fixed
No treatment to change to usual
medical treatment
0 (1, 547)a 0 (1, 2393)a
Remain no treatment 0.984 (540, 8)a 0.995 (2383, 11)a
No treatment to surgery 0.016 (10, 538)a 0.004 (10, 2384)a
Surgery to post surgery 1 Fixed 1 Fixed
Remain post surgery 1 Fixed 1 Fixed
Usual medical treatment
Usual medical treatment to well with usual
medical treatment
0.402 (115, 171)a 0.225 (64, 221)a
Usual medical treatment to symptomatic with
usual medical treatment
0.566 (162, 124)a 0.744 (212, 73)a
Usual medical treatment to change to the
LNG-IUS
0.007 (2, 284)a 0.007 (2, 283)a
Usual medical treatment to no treatment 0.024 (7, 279)a 0.025 (7, 278)a
Remain well with usual medical treatment 1 Fixed 1 Fixed
Symptomatic with usual medical treatment to
well with usual medical treatment
0 Fixed 0 Fixed
Remain symptomatic with usual
medical treatment
0.901 (1474, 162)a 0.943 (3450, 210)a
Symptomatic with usual medical treatment to
change to the LNG-IUS
0.049 (80, 1556)a 0.025 (92, 3568)a
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Uncertainty in the model was explored by conducting both deterministic and probabilistic sensitivity
analysis (PSA). Population heterogeneity was not considered by assessing the cost-effectiveness according
to population subgroups because there was no a priori reason for expecting different treatment effects in
different subgroups.
Deterministic sensitivity analysis at 2 years:
1. Mean utility values for each state used in the base case were replaced by the median utility value.
Previously, some published studies109,110 used the median and not the mean value, which greatly
impacts the cost-effectiveness results and is argued to be inappropriate.103 The current analysis assesses
the impact of using such values when primary data are collected.
2. The assumptions used in the UK national guidelines costing template replaced the expert opinion and
trial data that were used in the base case. This change applied to the clinical staff member present for
the initial consultation, which used a practice nurse and was assumed to be 10 minutes for the initial
consultation and insertion (GP in the base case for the initial consultation and 20 minutes for the
insertion with both GP and practice nurse), treatment review by a nurse at 6 weeks (GP was used in
the base case) only for those with a LNG-IUS fitted and annual follow-up for both treatment groups
thereafter (no annual follow-up in the base case).1
3. In the base case, it was assumed that when an EQ-5D completion date and notification of change of
treatment coincide, the EQ-5D value will belong to the subsequent state. In sensitivity analysis 3, we
assigned the EQ-5D value to the state prior to the change.
4. The base-case analyses and the three deterministic analyses (described in 1 to 3 above) were repeated
using the SF-6D instead of the EQ-5D to generate QALYs.
The base-case analysis was also carried out for the 5-year time horizon, but it was not deemed necessary
to carry out a complete set of deterministic sensitivity analyses if the base-case results at 5 years were
unchanged from the results at 2 years. However, the analysis at the 5-year end point was carried based
on QALYs generated by both the EQ-5D and SF-6D. The PSA simultaneously changes all the utilities and
probability parameters as presented in Tables 11 and 12. However, some parameters are fixed, for
TABLE 12 Probability parameters used in the analysis (continued )
Probability parameters
Monthly
probability
(2-year analysis)
PSA
distribution
Monthly
probability
(5-year analysis)
PSA
distribution
Symptomatic to no treatment 0.040 (65, 1571)a 0.026 (95, 3565)a
Symptomatic to surgery 0.010 (17, 1619)a 0.006 (23, 3637)a
Remain change to the LNG-IUS 0.603 (120, 79)a 0.845 (496, 91)a
Change to the LNG-IUS to well with the LNG-IUS 0.312 (62, 137)a 0.107 (63, 524)a
Change to the LNG-IUS to no treatment 0.045 (9, 190)a 0.027 (16, 571)a
Change to the LNG-IUS to surgery 0.040 (8, 191)a 0.020 (12, 575)a
Remain well with the LNG-IUS 1 Fixed 1 Fixed
No treatment to change to the LNG-IUS 0.001 (1, 852)a 0 (2, 4207)a
Remain no treatment 0.992 (846, 7)a 0.998 (4200, 9)a
No treatment to surgery 0.007 (6, 847)a 0.002 (7, 4202)a
Surgery to post surgery 1 Fixed 1 Fixed
Remain post surgery 1 Fixed 1 Fixed
PSA, probabilistic sensitivity analysis.
a Dirichlet distribution.
α and β values for the PSA distribution are rounded to the nearest whole number.
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example surgery to post surgery, as that is an essential feature of the model. For each parameter, a
distribution is assigned and a value for each parameter is randomly drawn from the assigned distribution.
This is repeated 1000 times and the range of incremental cost and QALY results for the LNG-IUS and usual
medical treatment are presented on the cost-effectiveness plane.111 These 1000 values were used to
construct a cost-effectiveness acceptability curve (CEAC) to illustrate the probability of the LNG-IUS being
more cost-effective than usual medical treatment across a range of monetary values that decision-makers
may be willing to pay for an additional QALY. This was carried out using both the EQ-5D and SF-6D.
Distributions for the probabilistic sensitivity analysis
A Dirichlet distribution was used for the transition probabilities because this distribution allows for a possible
movement to more than two states. Where a transition between states is possible, but did not occur in the trial
data, a value of 1 is added to all such transitions to enable the Dirichlet distribution to be assigned and to
compensate for not observing the transition in the data.112 In Table 12 it can be seen that some distributions are
fixed at the given value. This is because these transitions are not dependent on the data and logically it would
not be appropriate for the transition to be made probabilistic. Utility parameters are assigned a beta distribution.
Costs are not assigned distributions because they are primarily unit costs, which are variable, but not
uncertain. Where costs are uncertain, the PSA on utilities and transitions will be sufficient to account for
this uncertainty. Furthermore, as distributions for these costs and transitions would be particularly complex,
the small number of uncertain costs and very small cost values are unlikely to affect the results in a manner
sufficient to warrant using a separate distribution.
Results
The results of the base-case analysis and sensitivity analyses are presented in two parts. Part 1 depicts the
results using the EQ-5D for the outcome at 2 years and 5 years. Part 2 shows the results using the SF-6D
for 2 years and 5 years. The results of the model are presented here as aggregate outcomes. The
intermediate outcomes of the model are presented in Appendix 12 for the usual medical treatment group
and Appendix 13 for the LNG-IUS group.
Part 1a: European Quality of Life-5 Dimensions at 2 years
Table 13 presents a summary of the base-case and the deterministic sensitivity analysis results using the EQ-5D.
The base-case results show that the LNG-IUS costs £100 more than usual medical treatment, as the
LNG-IUS costs £430 and usual medical treatment costs £330. However, the LNG-IUS also generated 0.067
more QALYs than usual medical treatment, as the LNG-IUS generated 1.580 QALYs and usual medical
treatment 1.513 QALYs. The ICER for the base-case analysis shows that the LNG-IUS generates £1600 per
additional QALY when compared with usual medical treatment.
In all three of the deterministic sensitivity analyses, the findings supported the base-case results. However,
the ICER in each analysis did differ. Sensitivity analyses 1 and 2 had a slightly less favourable effect,
increasing the ICER to £2030 and £1640 per QALY gained respectively, while sensitivity analysis 3 resulted
in a more favourable effect on the ICER, with a reduction to £1560 per additional QALY.
The results of the PSA in Figure 8 illustrate the distribution of the incremental costs and effects from 1000
Monte Carlo simulations. It is shown that the majority of the incremental costs and effects lie in the upper
right-hand quadrant of the cost-effectiveness plane. This indicates that the LNG-IUS is both more costly
and more effective than usual medical treatment. The uncertainty is then summarised in relation to the
changes in the decision-makers’ threshold for considering an intervention cost-effective in Figure 9. This
figure depicts the CEAC, which shows that, from £2000 per QALY, the LNG-IUS has a greater probability
of being the more cost-effective intervention. This probability increases to over 90% at approximately
£4000 per QALY and this figure is maintained at the subsequent thresholds.
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TABLE 13 Base-case and deterministic sensitivity analysis results using the EQ-5D at 2 years
Analysis
Total mean costs
per intervention (£)
Total mean QALYs
per intervention
ICER (£) (vs. usual
medical treatment)
Summary of base-case deterministic results
Usual medical treatment 330 1.513 1600
LNG-IUS 430 1.580 –
Mean difference 100 0.067 –
Deterministic sensitivity analysis 1a
Usual medical treatment 330 1.590 2030
LNG-IUS 430 1.643 –
Mean difference 100 0.053 –
Deterministic sensitivity analysis 2b
Usual medical treatment 340 1.513 1640
LNG-IUS 450 1.580 –
Mean difference 110 0.067 –
Deterministic sensitivity analysis 3c
Usual medical treatment 330 1.514 1560
LNG-IUS 430 1.582 –
Mean difference 100 0.068 –
a Deterministic sensitivity analysis 1 used median utility values.
b Deterministic sensitivity analysis 2 used NICE assumptions.
c Deterministic sensitivity analysis 3 assigning the EQ-5D completion date utility for change treatment if change treatment
date is the same as the EQ-5D completion date.
Costs are rounded to nearest £10. QALYs are rounded to three decimal places.
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FIGURE 8 Results of the PSA (EQ-5D) at 2 years. The sloping line indicates the £20,000/QALY threshold.
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Part 1b: European Quality of Life-5 Dimensions at 5 years
The base-case results at 5 years for the EQ-5D (summarised in Table 14) show that the LNG-IUS costs £10
more than usual medical treatment (the LNG-IUS costs £517; usual treatment costs £507). The LNG-IUS
also generates 0.090 more QALYs than usual treatment (the LNG-IUS generated 3.698 QALYs and usual
medical treatment 3.608 QALYs). Therefore, the additional costs of the LNG-IUS compared with usual
medical treatment was £114 per additional QALY gained.
The results of the PSA at 5 years are presented in Figures 10 and 11 in the CEAC. The CEAC shows that
the LNG-IUS has a greater probability of being the more cost-effective intervention from approximately
£500 per QALY onwards.
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FIGURE 9 Cost-effectiveness acceptability curves for usual medical treatment and the LNG-IUS using the EQ-5D at
2 years. Note that the CEACs have stabilised well before the £20,000 per QALY value. Extending these curves could
mean loss of clarity in the early part.
TABLE 14 Base-case analysis results using the EQ-5D at 5 years
Analysis
Total costs per
intervention (£)
Total QALYs
per intervention
ICER (£) (vs. usual
medical treatment)
Summary of base-case deterministic results
Usual medical treatment 507 3.608 114
LNG-IUS 517 3.698 –
Mean difference 10 0.090 –
Costs are rounded to nearest £10. QALYs are rounded to three decimal places.
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Part 2a: Short Form questionnaire-6 Dimensions at 2 years
Table 15 presents the base-case and deterministic sensitivity analysis results for the SF-6D.
The base-case results show that the LNG-IUS costs £100 more than usual medical treatment as the LNG-IUS
costs £430 and usual medical treatment costs £330. However, when the SF-6D is used, usual medical
treatment is shown to generate 0.002 more QALYs than the LNG-IUS, as usual medical treatment generated
1.200 QALYs and the LNG-IUS 1.198 QALYs. Therefore, it is shown that usual medical treatment dominates
the LNG-IUS.
In two of the three deterministic sensitivity analyses, the findings supported the base-case results. In
sensitivity analyses 1 and 2, usual medical treatment dominated the LNG-IUS, whereas in sensitivity
analysis 3 usual medical treatment does not dominate the LNG-IUS. The LNG-IUS was shown to be more
effective than usual medical treatment and more expensive, generating an ICER of approximately £110,000.
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FIGURE 10 Results of the PSA (EQ-5D) at 5 years. The sloping line indicates the £20,000/QALY threshold.
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FIGURE 11 Cost-effectiveness acceptability curves for usual medical treatment and the LNG-IUS using the EQ-5D at
5 years. Note that the CEACs have stabilised well before the £20,000 per QALY value. Extending these curves
could mean loss of clarity in the early part.
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The results of the PSA in Figure 12 are presented on the cost-effectiveness plane and show the distribution
of the incremental costs and effects from the 1000 Monte Carlo simulations. In this case, when the SF-6D
is used to generate the effectiveness outcome, it can be seen that the incremental costs and effects are
spread between the upper right-hand and upper left-hand quadrant of the cost-effectiveness plane,
indicating that the LNG-IUS is either more costly and more effective or more costly and less effective.
This is then summarised in the CEAC in Figure 13 to show that, for any threshold willingness to pay per
QALY, usual medical treatment has the greater probability of being the more cost-effective intervention.
This probability is 100% at £0 per QALY and decreases to 90% at approximately £20,000 per QALY.
Part 2b: Short Form questionnaire-6 Dimensions at 5 years
Table 16 presents the results based on using the SF-6D at 5 years. When the EQ-5D values used to
generate QALYs were replaced with the SF-6D values, usual medical treatment generates 0.002 more
QALYs than the LNG-IUS (usual treatment generated 2.797 QALYs and the LNG-IUS generated 2.795).
The costs were unchanged from the previous analysis. Therefore, usual medical treatment is shown to be
less costly, but generates more QALYs than the LNG-IUS and, thus, usual medical treatment is said to
dominate the LNG-IUS.
The results of the PSA presented in Figure 14 and the CEAC (Figure 15) show that, for any threshold
willingness-to-pay per QALY, usual medical treatment has the greater probability of being the more
cost-effective intervention.
TABLE 15 Base-case and deterministic sensitivity analysis results using the SF-6D at 2 years
Analysis
Total mean costs
per intervention (£)
Total mean QALYs
per intervention
ICER (vs. usual
medical treatment)
Summary of base-case deterministic results
Usual medical treatment 330 1.200 Dominates
LNG-IUS 430 1.198 –
Mean difference 100 –0.002 –
Deterministic sensitivity analysis 1a
Usual medical treatment 330 1.215 Dominates
LNG-IUS 430 1.215 –
Mean difference 100 0 –
Deterministic sensitivity analysis 2b
Usual medical treatment 340 1.200 Dominates
LNG-IUS 450 1.198 –
Mean difference 110 –0.002 –
Deterministic sensitivity analysis 3c
Usual medical treatment 330 1.198 £112,340
LNG-IUS 430 1.199 –
Mean difference 100 0.001 –
a Deterministic sensitivity analysis 1 used median utility values.
b Deterministic sensitivity analysis 2 used NICE assumptions.
c Deterministic sensitivity analysis 3 assigning the SF-6D completion date utility for change treatment if change treatment
date is the same as the SF-6D completion date.
Costs are rounded to nearest £10. QALYs are rounded to three decimal places.
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FIGURE 12 Results of the PSA (SF-6D) at 2 years. The sloping line indicates the £20,000/QALY threshold.
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FIGURE 13 Cost-effectiveness acceptability curves for usual medical treatment and the LNG-IUS using the SF-6D at
2 years.
TABLE 16 Base-case analysis results using the SF-6D at 5 years
Analysis
Total costs per
intervention (£)
Total QALYs
per intervention
ICER (vs. usual
medical treatment)
Summary of base-case deterministic results
Usual medical treatment 507 2.797 Dominates
LNG-IUS 517 2.795 –
Mean difference 10 –0.002 –
Costs are rounded to nearest £10. QALYs are rounded to three decimal places.
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Discussion
Main findings at 2 years
In the primary care setting, treating HMB using the LNG-IUS costs more, but is also more effective than
usual medical treatment. The relative cost-effectiveness of the LNG-IUS compared with usual medical
treatment is £1600 per QALY. This means every additional QALY costs an extra £1600. The deterministic
sensitivity analyses showed the uncertainty in this ICER to be in the range of £1560 to £2030 for an
additional QALY gained. As the NICE guidelines recommend new interventions into practice if the ICER is
below £20,000 per QALY, the LNG-IUS would be considered cost-effective and recommended as the
primary choice for women who require treatment, have no preference against contraception or
intrauterine device insertion and no contraindication to LNG-IUS insertion.
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FIGURE 15 Cost-effectiveness acceptability curves for usual medical treatment and the LNG-IUS using the SF-6D at
5 years.
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FIGURE 14 Results of the PSA (SF-6D) at 5 years. The sloping line indicates the £20,000/QALY threshold.
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However, the importance of selecting the most appropriate QoL instrument is highlighted when the
measure used to assess QoL is changed in sensitivity analysis 4 from the EQ-5D to the SF-6D. In sensitivity
analysis 4, where utility values from the SF-6D are used rather than the EQ-5D, the cost-effectiveness
results differ. In contrast to the findings using the EQ-5D, usual medical treatment is the more
cost-effective intervention. Usual medical treatment was found to dominate the LNG-IUS in the base-case
and the two deterministic sensitivity analyses. In the third deterministic analysis, the ICER for the LNG-IUS
was over £100,000 per QALY, which is much higher than the £20,000/QALY threshold currently set by
NICE; therefore, usual medical treatment would be recommended for implementation in clinical practice.
The difference in the cost-effectiveness results derived by using the alternative measures to value QoL has
a considerable impact on the cost-effectiveness decision. The different measures resulted in a change, not
just in the strength of cost-effectiveness of the same treatment, but also in what was the most
cost-effective treatment. Therefore, the recommendation to decision-makers would differ depending on
the QoL instrument used.
Main findings at 5 years
The overall findings based on the 5-year time horizon support the findings of the 2-year analysis for both
the EQ-5D and the SF-6D. Using the EQ-5D, the LNG-IUS is more costly and more effective than usual
medical treatment. The relative cost-effectiveness of the LNG-IUS compared with usual medical treatment
is now £114 per QALY. The mean difference in QALYs generated using the EQ-5D between the 2-year
and 5-year analysis has increased by 0.023. The costs have reduced from a difference of £100 between
the two treatments at 2 years to a difference of £17 at 5 years. The ICER reduced from £1600 per QALY in
the 2-year analysis to £114 per QALY in the 5-year analysis. These findings show that at 5 years the
LNG-IUS becomes more cost-effective using the EQ-5D, relative to the 2-year analysis. Using the NICE
£20,000 per QALY threshold, the LNG-IUS is cost-effective and should be recommended as first-line
treatment for HMB.
However, in contrast to the findings, when the EQ-5D is used to estimate the QALY, the results based on
the SF-6D show that usual medical treatment is again less costly and more effective. At 5 years, using the
SF-6D, usual medical treatment again dominates. While the mean difference in QALYs generated between
the treatments is the same for the SF-6D in the 2-year and 5-year analysis (–0.002), the reduction in cost
difference between the treatments from 2 years and 5 years (£100 difference between treatments at
2 years and £17 difference at 5 years) has meant that the extent of the dominance has ‘increased’. These
findings show that at 5 years, using the SF-6D, usual medical treatment would be recommended as
first-line treatment for HMB.
The reasons for the costs converging at the 5-year analysis could relate to the LNG-IUS having an initial
one-off ‘upfront’ cost only and usual treatment a small, but continuous cost over time. Alternatively, owing
to the non-curative nature of these treatments and the impact on QoL, it could be caused by the numbers
of women who changed treatments and treatment arms in both arms of the trial, in addition to the
number of women who had surgery, a cure, in both arms.
Strengths and limitations
The strength of this CUA is that it is based on data from the largest multicentre randomised trial
undertaken for HMB. As the treatment is aimed at managing the condition, the changes in both QoL
and costs throughout the woman’s treatment journey are critical to the analyses and these are most
appropriately captured by using the trial data to populate a model. The model structure was developed
based on the women’s pathway, data from the trial and supported by the advice of expert clinicians. All
assumptions were agreed by the team in the model development stage prior to analysis. A further strength
is that all data on resource use and outcomes were collected prospectively alongside the trial and the
economic evaluation was an integral component of the trial design from the outset.
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Some limitations exist as a result of some of the assumptions required for the model; for example, it was
assumed that women are ‘well’ if they do not change treatment. Nonetheless, this assumption is mitigated
by the fact that, if women enter the ‘well’ state, but are not well, this will be reflected in the overall utility
value for ‘well’. Furthermore, utility data were collected at 6 months and at 1, 2 and 5 years and were
averaged, so there were insufficient data available to test the time dependency of health states. A further
potential limitation is that baseline differences in QoL data at the outset of the trial were not adjusted to
be the same. If we did adjust fully for the difference in baseline we would find the LNG-IUS to be less
effective than usual medical treatment, but, in so doing, the assumption would be imposed that the
difference would be maintained over the time horizon. This would not be an appropriate assumption since
the probability of regression to the mean over time would be ignored. It is therefore acknowledged that
the base-case results might be slightly overoptimistic, but it is not clear how much of an adjustment, if any,
would be appropriate. The initial EQ-5D score in the LNG-IUS group was 0.042 higher at the outset of the
trial than in usual medical treatment and this difference is significant (p< 0.05). These data are based on
individuals who have been randomised, so it is assumed that this difference occurred by chance and it
does not follow that this initial difference between groups would be sustained over the 2-year or 5-year
time horizon in the absence of treatment. Adjustment for baseline, therefore, risks imposing a difference
at every point in time over the time period of analysis.
Comparison with other studies
To our knowledge, this is the first study to conduct a CUA using prospectively collected primary data from
a trial to directly compare the LNG-IUS with usual medical treatment for women with HMB. Other
economic evaluations of the LNG-IUS have been carried out; however, none has drawn a comparison of
the LNG-IUS directly against usual treatment using primary data. Another primary study has shown the
LNG-IUS to be cost-effective, but the comparator was hysterectomy and the study is considered to have
methodological flaws.58,103 Other studies have compared alternative treatments using model-based analyses
and secondary data from reviews,1,113,114 although the studies typically compared the LNG-IUS, various oral
treatments and various surgical techniques against one another. Two of these showed the LNG-IUS to be
the most cost-effective intervention.1,113 The remaining study suggested that hysterectomy was the optimal
intervention, but the authors acknowledged that insufficient published data on the effectiveness of the
LNG-IUS were available at the time.114 Although the LNG-IUS is shown to be cost-effective against surgical
interventions in these studies, it does not provide evidence for the LNG-IUS being cost-effective against
other pharmaceutical treatments.
Implications and further research
The results, based on the decision-maker-recommended EQ-5D, provide clear evidence in support of the
NICE guidelines that recommend that the LNG-IUS be considered the primary treatment for HMB. The
main objective of this study was to provide evidence to decision-makers on the cost-effectiveness of two
treatments for HMB; therefore, the primary results are based on the EQ-5D. However, as SF-6D data were
also collected, the use of this measure was deemed worthy of exploration in the sensitivity analysis.
When the SF-6D is used to generate QALYs, the main base-case results are reversed and usual medical
treatment is shown to be the more cost-effective intervention, and this is the case in analyses at both the
2-year and 5-year end points, hence the recommendation to decision-makers differs depending on the
outcome measure used. The conflicting findings suggest that these measures may be capturing different
aspects of QoL, which clearly has an impact on the results. Reasons why these instruments produce
different results have been further explored by other authors,115,116 but that research is methodological and
so far inconclusive, and at the current time does not help to guide which instrument is more appropriate
within the context of HMB, particularly when the results are so sensitive to that choice. It may well be that
neither instrument is appropriate, with their focus exclusively on health-related QoL and, as evidenced in a
recent review of measures for HMB,69 consideration needs to be given to alternative measures, such as
willingness to pay, which provides a broader assessment of well-being.
Additional work is ongoing by the authors of this report to explore the impact on the results of the use of WTP
in a cost–benefit analysis. This is in contrast to the more commonly used measures, the EQ-5D and SF-6D,
which may be limited by the recall periods used in these measures and their focus on health-related QoL.
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Chapter 7 Discussion
Introduction
We completed the following distinct studies as part of this health technology assessment project:
l assessed the clinical effectiveness of the LNG-IUS compared with usual medical treatment for women
seeking treatment for HMB in primary care in the short term (2 years following randomisation) through
the ECLIPSE pragmatic, multicentre RCT
l assessed the clinical effectiveness in the medium term by follow-up of the ECLIPSE trial cohort of
women for 5 years following randomisation
l determined the cost-effectiveness of the LNG-IUS compared with usual medical treatment in the short
and medium term through a parallel economic evaluation
l explored the perspectives of trial participants, and women with HMB who declined to be randomised,
in a longitudinal qualitative study
l demonstrated the reliability and validity properties of the MMAS.
Each of these studies has been described in detail, with the main findings reported and the conclusions
derived in the light of any limitations identified at the end of each Chapters 2–6. This chapter attempts
to focus on the key findings and limitations emerging from the ECLIPSE trial and associated studies. It is
not a comprehensive summary of all of the issues raised, for which the reader is encouraged to consult
Chapters 2–6.
Principal findings
Evidence for clinical effectiveness
Between February 2005 and July 2009, a total of 571 women with HMB from 63 UK centres were
randomly assigned to either the LNG-IUS (285 women) or usual medical treatment (286 women). In the
usual medical treatment group, 75% were initially treated with mefenamic acid or tranexamic acid or a
combination of these two drugs.
At baseline, the women were substantially affected by HMB, as assessed with the condition-specific MMAS
and general (SF-36) health-related scales. There were significant improvements over a period of 2 years in
both the LNG-IUS and usual medical treatment groups, which were maintained to 5 years. However,
improvements in average MMAS scores were greater within the LNG-IUS group than in the usual medical
treatment group over the first 2 years, by an average of 13.4 points in an intention-to-treat analysis.
Although MMAS scores and the majority of the SF-36 QoL domains at 5 years still favoured the LNG-IUS,
these were no longer statistically significant, and contrast with the relatively large differences we noted at
2 years of follow-up.
The greater improvement with the LNG-IUS over the first 2 years was seen despite 36% of women having
had the system removed, generally owing to the lack of effectiveness or to irregular prolonged bleeding,
which are well-recognised reasons for discontinuing the LNG-IUS.61,66 There were higher rates of
discontinuation in those allocated usual medical treatments (64% at 2 years’ follow-up). The diminution of
a difference between trial treatment groups may be unsurprising given the high proportions of women
who, by 5 years, had changed to a treatment that worked for them or had ceased bleeding, with only
15% still taking usual medical therapy and 47% having a LNG-IUS in place.
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We expected fewer surgical interventions in the LNG-IUS group, but the rates were similarly low in the both
groups, with approximate 10% at 2 years and 20% at 5 years. Compared with previous trials,38,49,51,56,81 this
low rate may reflect the eligibility criteria for the trial, since women who had fibroids or other disorders
were excluded. However, this finding also suggests that women who present in primary care with an
uncomplicated presentation of HMB can be both successfully treated at the initial point of contact, with
persisting improvement in impact on QoL and avoid referral to secondary care.
Evidence for cost-effectiveness
Alongside the ECLIPSE trial, an economic evaluation provided robust evidence on the cost-effectiveness of
the LNG-IUS compared with usual medical treatment. The general health-related instruments, the EQ-5D
and SF-6D, represent the extra-welfarist approach to measure cost-effectiveness. A model-based CUA,
based on an outcome of cost per QALY, was carried out.
Using the EQ-5D, at 2 years the relative cost-effectiveness of the LNG-IUS compared with usual medical
treatment was £1600 per QALY, which by 5 years was reduced to £114 per QALY. This increase in
cost-effectiveness is caused both by the mean difference in QALYs generated increasing by 0.023 and by
the costs reducing from a difference of £100 between the two treatments at 2 years, to a difference of
£17 at 5 years. However, using the SF-6D to produce utility values, usual medical treatment was assessed
as less costly and more effective at both 2 and 5 years.
It can be seen that the difference in the cost-effectiveness results derived by using the alternative measures
to value QoL will have a considerable impact on cost-effectiveness decisions. The different measures did
not just change the strength of cost-effectiveness of the same treatment, but the most cost-effective
treatment itself changed. Therefore, any recommendation to decision-makers will differ depending on the
QoL instrument used.
Qualitative insights
There was a need to better understand women’s experiences of medical treatments for HMB from a
qualitative perspective, alongside quantitative measures. The qualitative longitudinal design of our study
over a time frame of around 1 year involved a purposeful sample of women willing to articulate their
experiences. This included women participating in the trial and, in addition, those not willing to be
randomised because they had a specific preference for a particular treatment for HMB.
The results show that women’s experiences and expectations of medical treatments for HMB vary considerably
and change over time. In addition to a range of practical considerations for treatments, they emphasise that
practitioners should consider that rate of menstrual blood flow, pain and well-being, alongside wider
functioning socially or at work, may be as or more important to women as menstrual blood loss experienced.
Women had high expectations of a prompt effect from treatments. Unpredictable irregular bleeding with
the LNG-IUS was more problematic than the volume of blood loss for women in this study, owing to its
impact on their established behavioural coping mechanisms for HMB.
Measurement properties of Menorrhagia Multi-Attribute Scale
We investigated further the psychometric properties of the MMAS. We demonstrated that, in addition to
having high face validity, the MMAS has good convergent and discriminant validity and test–retest
reliability. This supported our decision to use the MMAS to measure the impact of HMB and its treatment
on women in the ECLIPSE trial.
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Strengths and limitations
The strengths of this health technology assessment project is that it is based around a large, well-designed
randomised trial. The ECLIPSE study is the world’s largest trial comparing medical treatments for HMB over
the short to medium term, rather than 6 or 12 months, as in previous studies.24,33 It had a multicentre
design and included patients ethnically representative of the UK population, with relatively low rates of loss
to follow-up and the assessment of outcomes over 2 and 5 years (84% and 74% of outcomes collected,
respectively). Treatment options in the usual medical treatment group accommodated women’s preference
for hormonal or non-hormonal treatments and requirements for contraception. Our study also had a
primary outcome measure, a patient-reported psychometrically valid condition-specific instrument, MMAS,
that better reflects women’s personal experience of the burden of HMB. The qualitative findings that
describe patient experience were afforded rigour by purposeful sampling, respondent validation and
longitudinal design, and support our decision to use the MMAS.
The data provide valuable information for women and clinicians considering what to expect from the
medical treatments for HMB over the medium term in a real-world situation. Changes in both QoL and
cost throughout women’s treatment journey are critical to the economic analysis and these were
appropriately captured prospectively in the ECLIPSE trial, with the economic evaluation designed as an
integral component of the trial from the outset. The model structure was developed based on the
women’s pathway data from the trial and supported by the advice of expert clinicians, with all
assumptions agreed prior to analysis.
Some limitations of our study should be noted. The range of options available for medical treatment
complicates any efforts to compare the LNG-IUS with individual agents. However, the choice among the
various treatments is representative of current clinical practice. Although the interventions studied in this
trial represent options available in primary care settings in the UK, insertion of intrauterine devices is not
part of primary care in all health-care settings, and in some circumstances, it requires consultation with
a gynaecologist.
In addition, substantial numbers of patients switched treatments over the course of the study; however,
these crossovers would be expected to result in an underestimation of the benefits that might be achieved
with perfect compliance. A range of sensitivity analyses did not change the clinical effectiveness conclusions.
Implications for practice
The results provide unique and valuable practical information for women and primary care practitioners when
considering choice of, and what to expect from, medical treatments for HMB. Our clinical results support the
NICE guidelines,1 which recommend that medical treatment options should be considered when women
initially present with HMB in primary care and that the LNG-IUS should be considered first. Women with HMB,
a relatively normal-sized uterus on examination and no other risk factors (i.e. intermenstrual bleeding,
post-coital bleeding or irregularity of the menstrual cycle which has been assessed by an endometrial biopsy)
can be successfully treated and expect a significant reduction in the range of negative impacts of HMB on
QoL. Although the LNG-IUS is more effective in this regard than other usual medical options within the first
2 years of treatment, both the LNG-IUS and usual medical treatments are shown to be helpful initial choices
5 years later. The low overall rates of surgery underline the importance and feasibility of initial medical
management of women with HMB in primary care and the avoidance of referral to secondary care.
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Using the EQ-5D, there is clear cost-effectiveness evidence to support NICE guidelines that recommend
the LNG-IUS should be considered the first-line medical treatment for HMB. However, when the SF-6D is
used to generate QALYs, the main base-case results are reversed and usual medical treatment is shown
to be more cost-effective at both the 2- and 5-year time-points. Therefore, the recommendation to
decision-makers differs depending on the outcome measure used.
Qualitative data indicate that clinicians in primary care should also focus on the wider context for those
presenting with HMB rather than solely on the amount of blood loss experienced by women. A general
acknowledgement of their HMB, which results in a medical treatment option, should be instigated at the
point of contact. Wider public awareness is needed among women so that, should they choose to seek
help for HMB, they can benefit from such treatment. This will result in significant impact on the QoL of
many thousands of women.
Recommendations for research
It will be important to continue assessment of the ECLIPSE trial participants to 10 years, as we expect that
over half of our cohort will have reached menopause at that stage, as our initial recruitment age was a
median of 42 years. This would examine the clinical and health service trajectories that women initially
treated for HMB in primary care may follow in the longer term. Relevant data are lacking in these contexts.
Such further research may helpfully identify the nature of continuing use of treatments, particularly the
LNG-IUS, and any differential impact on frequency of surgical interventions.
The difference in the results of the economic outcomes arising from the different instruments used to derive
utilities may be explained by the limited recall periods used in these measures and their focus only on
health-related QoL. These conflicting findings suggest that these measures may be capturing different aspects
of QoL, which clearly has an impact on the results. Further consideration of alternative measures to assess
cost-effectiveness, such as WTP, which provides a broader assessment of well-being,70 is also needed.
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Appendix 1 Reported reasons for discontinuing
treatment up to 2 years’ follow-up: usual medical
treatment group
Reason for discontinuing Frequency
0–6 months
Cannot swallow tablets 1
Depression, weight gain 1
Diarrhoea 1
Did not like tablets 1
Disliked taking tablets 2
Disliked treatment 1
Family history of blood clots 1
Hair loss 1
Irregular bleeding, eczema 1
Irregular bleeding, prolonged bleeding, depression 1
Irregular, prolonged bleeding, required operation 1
Lack of effectiveness, irregular bleeding, depression 1
Lack of efficacy 26
No longer needed 2
None given 8
PCOS 1
Pelvic pain 1
Pelvic pain, prolonged bleeding 1
Pregnant 1
Prolonged bleeding, skin allergy 1
Sister had pulmonary embolism 1
Skin allergy 1
Trying for baby 1
Total 57
6–12 months
Disliked taking tablets 2
Disliked treatment 2
Irregular bleeding 1
Irregular bleeding, prolonged bleeding, pelvic pain, depression, skin allergy 1
Lack of effectiveness, pelvic pain, depression, weight gain 1
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Reason for discontinuing Frequency
Lack of efficacy 14
Lack of efficacy, irregular bleeding 2
Lack of efficacy, required operation 1
No longer needed 1
None given 11
Pelvic pain, dislikes taking tablets 1
Pregnant 3
Vomiting, irregular bleeding, prolonged bleeding, pelvic pain, depression 1
Weight gain 1
Total 42
12–24 months
Chest pain 1
Concerned about long-term effects 1
Disliked taking tablets 1
Disliked treatment 2
Fibroids for operation 1
High blood pressure 1
Irregular bleeding 1
Irregular bleeding, prolonged bleeding 1
Irregular bleeding, prolonged bleeding, pelvic pain 1
Lack of effectiveness, irregular bleeding, prolonged bleeding 1
Lack of effectiveness, irregular bleeding, prolonged bleeding, pelvic pain 1
Lack of efficacy 24
Lack of efficacy, irregular bleeding 1
Lack of efficacy, pelvic pain 2
Lack of efficacy, upset tummy 1
Lack of efficacy, vomiting, diarrhoea 1
Lack of efficacy, required operation 1
Menopausal 1
No longer needed 2
None given 13
Pelvic pain 1
Pelvic pain, weight gain, headaches, leg cramps 1
Prolonged bleeding, depression 2
Sickness, dizziness 1
Wanted to see if periods had returned to normal without medication 1
Total 64
PCOS, polycystic ovary syndrome.
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
82
Appendix 2 Reported reasons for discontinuing
treatment up to 2 years’ follow-up: the
levonorgestrel-releasing intrauterine system group
Reason for discontinuing Frequency
0–6 months
Abdominal pain 1
Coil expelled 3
Heavy bleeding 1
Irregular bleeding, depression, pelvic pain 1
Irregular, prolonged bleeding 1
Lack of effectiveness, irregular bleeding, pelvic pain, coil expelled 1
Lack of efficacy 1
Leg pains, depressed 1
None given 2
Pain 2
Pain in legs 1
Pelvic pain 2
Pelvic pain, infection 1
Prolonged bleeding 7
Prolonged bleeding, required operation 1
Total 26
6–12 months
Coil expelled 1
Depression, weight gain, bloating 1
Disliked treatment 3
For operation 1
Irregular bleeding, acne 1
Lack of effectiveness, irregular bleeding, prolonged bleeding 1
Lack of effectiveness, pelvic pain, depression 1
Lack of effectiveness, thread problems, loss of libido 1
Lack of effectiveness, vomiting, prolonged bleeding, pelvic pain, depression, clotting, anaemia 1
Lack of efficacy 3
Lack of efficacy, prolonged bleeding 1
Mood swings 1
None given 1
Not happy with treatment 1
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Reason for discontinuing Frequency
Prolonged bleeding 1
Uterine prolapse 1
Vomiting, diarrhoea, depression, mood swings 1
Total 21
12–24 months
Coil expelled 1
Coil moved, pelvic pain 1
Depression, weight gain 1
Disliked treatment 1
For operation 2
Irregular bleeding, prolonged bleeding, weight gain 1
Lack of effectiveness, irregular bleeding, prolonged bleeding, pelvic pain, weight gain 1
Lack of effectiveness, prolonged bleeding, pelvic pain, depression 1
Lack of efficacy 7
Lack of efficacy, prolonged bleeding 1
Lack of efficacy, for operation 3
None given 3
Pelvic pain 1
Pelvic pain, depression, weight gain, tender breasts 1
Prolonged bleeding 1
Prolonged bleeding, pelvic pain 1
Swelling hands, body 1
Thread problems 1
Weight gain 2
Weight gain, metallic taste 1
Total 32
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Appendix 3 Results of primary outcome:
Menorrhagia Multi-Attribute Scale sensitivity analysis
(overall difference between groups over 2 years)
Assumption
Difference between groupsa
(95% CI)
Excluding women who switched treatment or ceased taking treatment altogether 18.7 (14.8 to 22.6; p< 0.001)
Women who indicated they were no longer bleeding and did not complete
MMAS given best possible score of 100
12.8 (9.3 to 16.3; p< 0.001)
As above, but also carrying forward a pre-surgery score for those undergoing
hysterectomy/ablation
12.2 (8.6 to 15.8; p< 0.001)
Excluding MMAS from late returned booklets (> 3 months past due date) 14.5 (10.9 to 18.1; p< 0.001)
Missing responses given worst possible score (0) 11.9 (7.2 to 16.7; p< 0.001)
Using multiple imputation for missing responses 12.3 (9.2 to 15.4; p< 0.001)
a Based on a repeated measures model. See Chapter 3, Statistical analysis for details.
Point estimates (95% CI, p-value) shown for differences between groups. Estimates > 0 from differences between groups
favour LNG-IUS treatment.
0=worst affected; 100= not affected.
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Appendix 4 Menorrhagia Multi-Attribute Scale
overall score stratified by body mass index and
treatment group up to 2 years’ follow-up
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Appendix 5 Comprehensive results of Short
Form-questionnaire-36 items up to 2 years’ follow-up
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Appendix 7 Comprehensive assessment of the
Sexual Activity Questionnaire up to 2 years’ follow-up
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Appendix 8 Serious adverse events reported
within the ECLIPSE trial between February 2005 and
August 2011
System (event or reason
for hospitalisation) Usual medical treatment, n (%) (N= 286) LNG-IUS, n (%) (N= 285)
Total number of SAEsa 58 (20.3) 49 (17.2)
Number of women with SAEsb 51 (17.8) 46 (16.1)
Cancer – 1 (0.4)
Colectomy – 1 (0.4)
Cardiac 1 (0.4) 1 (0.4)
Chest pains/shortness of breath 1 (0.4) 1 (0.4)
Ear and labyrinth – 1 (0.4)
Stapendectomy – 1 (0.4)
Gastrointestinal 9 (3.1) 2 (0.7)
Cholecystectomy 4 (1.4) –
Cholelithotomy 1 (0.4) –
Recurrent abdominal pains 2 (0.7) 2 (0.7)
Hernia repair 1 (0.4) –
Appendectomy 1 (0.4) –
Immune system 2 (0.7) 2 (0.7)
Crohn’s disease 1 (0.4) –
Lupus – 1 (0.4)
Allergic reaction to MRI contrast – 1 (0.4)
Pulmonary sarcoidosis 1 (0.4) –
Infections and infestations 2 (0.7) 1 (0.4)
Cellulitis 1 (0.4) –
Food poisoning – 1 (0.4)
Suspected viral meningitis 1 (0.4) –
Metabolism and nutrition – 1 (0.4)
Diabetes – 1 (0.4)
Nervous system 2 (0.7) 2 (0.7)
Cluster headaches/migraine 1 (0.4) –
Stroke – 2 (0.7)
Non-specific headache 1 (0.4) –
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System (event or reason
for hospitalisation) Usual medical treatment, n (%) (N= 286) LNG-IUS, n (%) (N= 285)
Pregnancy, puerperium and
perinatal situations
7 (2.4) 1 (0.4)
Childbirth – post-partum
recoveryc
7 (2.4) 1 (0.4)
Psychiatric 3 (1.0) –
Overdose 3 (1.0) –
Renal and urinary 2 (0.7) 1 (0.4)
Incontinence surgery 2 (0.7) –
Partial cystectomy – 1 (0.4)
Reproductive system and breast 21 (7.3) 24 (8.4)
Endometrial ablation 2 (0.7) 1 (0.4)
Hysterectomy 17 (5.9) 19 (6.7)
Ovarian cyst removal – 1 (0.4)
Uterine prolapse repair – 1 (0.4)
Bartholin’s cyst drainage – 1 (0.4)
Dilatation and cutterage 1 (0.4) –
Laparoscopy for pelvic pain 1 (0.4) 1 (0.4)
Other surgical and medical
procedures
9 (3.1) 11 (3.9)
Blood transfusion 1 (0.4) –
Breast reduction 1 (0.4) 2 (0.7)
Hip replacement – 1 (0.4)
Tonsillectomy – 1 (0.4)
Gastric band surgery 2 (0.7) 1 (0.4)
Cosmetic surgery 1 (0.4) 1 (0.4)
CT/MRI scan 2 (0.7) –
Fracture repair 1 (0.4) 2 (0.7)
Back operation (not specified) 1 (0.4) –
Abscess drainage following
procedure
– 3 (1.0)
Death – 1 (0.4)
CT, computerised tomography; MRI, magnetic resonance imaging; SAE, serious adverse event.
a All listed were classified as SAEs as they resulted in hospitalisation (apart from the recorded death). p= 0.34.
b p= 0.59 (seven women had two SAEs each in the usual medical treatment group; one woman had three SAEs in the
LNG-IUS group, while another had two SAEs).
c All women had ceased treatment prior to becoming pregnant.
Eight women experienced two SAEs. Chest pains/shortness of breath and suspected viral meningitis (n= 1);
cholecystectomy and cholelithotomy (n= 1); recurrent abdominal pains and non-specific headache (n= 1); childbirth –
post-partum recovery and overdose (n= 1); incontinence and hysterectomy (n= 1); hysterectomy and laparoscopy for
pelvic pain (n= 1); and hysterectomy and a blood transfusion (n= 1). One woman experienced three events: two strokes
and a hip replacement.
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Appendix 9 Reported reasons for discontinuing
treatment over the whole period of follow-up:
usual medical treatment group
Reason for discontinuing Frequency
Cannot swallow tablets 1
Chest pain 1
Could not find the time to get tablets from chemist 1
Crohn’s disease 1
Depression, weight gain 1
Diarrhoea 1
Did not like tablets 1
Did not start treatment, pregnant 1
Did not want to take medication 1
Did not want to take tablets 1
Did not want treatment 1
Disliked taking tablets 5
Disliked treatment 6
Doctor advised owing to age 1
Owing to cancer treatment 1
Family history of blood clots 1
Fibroids, required operation 1
Flooding 1
For operation 4
GP would not prescribe because of health 1
Hair loss 1
IVF treatment 1
Irregular bleeding 2
Irregular bleeding, eczema 1
Irregular bleeding, prolonged bleeding 1
Irregular bleeding, prolonged bleeding, depression 1
Irregular bleeding, prolonged bleeding, pelvic pain 1
Irregular bleeding, prolonged bleeding, pelvic pain, depression, skin allergy 1
Irregular, prolonged bleeding, required operation 1
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Reason for discontinuing Frequency
Lack of effectiveness, irregular bleeding, depression 1
Lack of effectiveness, irregular bleeding, pelvic pain, weight gain 1
Lack of effectiveness, irregular bleeding, prolonged bleeding 1
Lack of effectiveness, irregular bleeding, prolonged bleeding, pelvic pain 1
Lack of effectiveness, pelvic pain, depression, weight gain 1
Lack of effectiveness, prolonged bleeding, depression, weight gain 1
Lack of efficacy 72
Lack of efficacy, anaemia 1
Lack of efficacy, for operation 1
Lack of efficacy, irregular bleeding 4
Lack of efficacy, irregular bleeding, pelvic pain 1
Lack of efficacy, irregular bleeding 1
Lack of efficacy, operation 2
Lack of efficacy, pelvic pain 2
Lack of efficacy, upset tummy 1
Lack of efficacy, vomiting, diarrhoea 1
Lack of efficacy, required operation 2
Menopausal 1
Never took tablet 1
No longer needed 5
No periods 1
No reason given 1
None given 54
PCOS 1
Pelvic pain 2
Pelvic pain, dislikes taking tablets 1
Pelvic pain, prolonged bleeding 1
Pelvic pain, weight gain, headaches, leg cramps 1
Periods better 1
Periods stopped 3
Pregnant 4
Prolonged bleeding 1
Prolonged bleeding, depression 2
Prolonged bleeding, skin allergy 1
Sickness, dizziness 1
Sister had pulmonary embolism 1
Skin allergy 2
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Reason for discontinuing Frequency
Trying for baby 1
Vomiting, diarrhoea, depression 1
Vomiting, irregular bleeding, prolonged bleeding, pelvic pain, depression 1
Wanted a break from treatment 1
Wanted to see if periods had returned to normal without medication 1
Weight gain 2
Total 228
IVF, in vitro fertilisation; PCOS, polycystic ovary syndrome.
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Appendix 10 Reported reasons for discontinuing
treatment over the whole period of follow-up:
levonorgestrel-releasing intrauterine system group
Reason for discontinuing Frequency
Abdominal pain 1
Bacterial vaginosis 1
Coil expelled 7
Coil migrated, surgery required 1
Coil moved, pelvic pain 1
Constant bleeding 2
Depression 1
Depression, weight gain 1
Depression, weight gain, bloating 1
Did not have coil replaced 1
Did not want coil fitted 2
Did not want it fitted 7
Disliked treatment 5
Failed to fit coil 3
For operation 8
Heavy bleeding 1
Infection 1
Irregular bleeding, acne 1
Irregular bleeding, depression 1
Irregular bleeding, depression, pelvic pain 1
Irregular bleeding, pelvic pain 1
Irregular bleeding, prolonged bleeding, weight gain 1
Irregular, prolonged bleeding 1
Lack of effectiveness, irregular bleeding, pelvic pain, coil expelled 1
Lack of effectiveness, irregular bleeding, prolonged bleeding 1
Lack of effectiveness, irregular bleeding, prolonged bleeding, pelvic pain, weight gain 1
Lack of effectiveness, pelvic pain, depression 1
Lack of effectiveness, prolonged bleeding, pelvic pain, depression 1
Lack of effectiveness, thread problems, loss of libido 1
Lack of effectiveness, vomiting, prolonged bleeding, pelvic pain, depression, clotting, anaemia 1
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Reason for discontinuing Frequency
Lack of efficacy 19
Lack of efficacy, coil expelled 1
Lack of efficacy, operation 1
Lack of efficacy, prolonged bleeding 3
Lack of efficacy, for operation 5
Leg pains, depressed 1
Mood swings 1
Mood swings, depression 1
No longer needed 1
No reason given 1
None given 19
Not happy with treatment 1
Nulliparous, obese, uterine length 4.5 cm 1
Pain 2
Pain in legs 1
Pelvic pain 3
Pelvic pain, anaemia, for operation 1
Pelvic pain, depression, weight gain, tender breasts 1
Pelvic pain, infection 1
Periods improved 1
Pregnant 1
Prolonged bleeding 9
Prolonged bleeding, pelvic pain 1
Prolonged bleeding, for operation 1
Swab showed infection 1
Swelling hands, body 1
Technical difficulties 2
Thread problems 1
Thread problems, spotting, irritated cervix 1
Too painful 1
Uncomfortable 1
Uterine prolapse 1
Vomiting, diarrhoea, depression, mood swings 1
Weight gain 3
Weight gain, metallic taste 1
Total 148
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Appendix 11 Serious adverse events reported
within the ECLIPSE trial between February 2005 and
September 2014
System (event or reason
for hospitalisation) Usual medical treatment, n (%) (N= 286) LNG-IUS, n (%) (N= 285)
Total number of SAEsa,b 68 (23.7) 58 (20.3)
Number of women with SAEsc 61 (21.3) 54 (18.9)
Cancer – 1 (0.4)
Colectomy – 1 (0.4)
Cardiac 1 (0.4) 1 (0.4)
Chest pains/shortness of breath 1 (0.4) 1 (0.4)
Heart attack – 2 (0.7)
Ear and labyrinth – 1 (0.4)
Stapendectomy – 1 (0.4)
Gastrointestinal 9 (3.1) 2 (0.7)
Cholecystectomy 4 (1.4) –
Cholelithotomy 1 (0.4) –
Recurrent abdominal pains 2 (0.7) 2 (0.7)
Hernia repair 1 (0.4) –
Appendectomy 1 (0.4) –
Immune system 2 (0.7) 2 (0.7)
Crohn’s disease 1 (0.4) –
Lupus – 1 (0.4)
Allergic reaction to
MRI contrast
– 1 (0.4)
Pulmonary sarcoidosis 1 (0.4) –
Infections and infestations 2 (0.7) 1 (0.4)
Cellulitis 1 (0.4) –
Food poisoning – 1 (0.4)
Suspected viral meningitis 1 (0.4) –
Metabolism and nutrition – 1 (0.4)
Diabetes – 1 (0.4)
Nervous system 2 (0.7) 2 (0.7)
Cluster headaches/migraine 1 (0.4) –
Stroke – 2 (0.7)
Non-specific headache 1 (0.4) –
Pregnancy, puerperium and
perinatal situations
7 (2.4) 1 (0.4)
Childbirth – post-partum
recoveryd
8 (2.8) 2 (0.7)
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System (event or reason
for hospitalisation) Usual medical treatment, n (%) (N= 286) LNG-IUS, n (%) (N= 285)
Psychiatric 3 (1.0) –
Overdose 3 (1.0) –
Renal and urinary 2 (0.7) 1 (0.4)
Incontinence surgery 2 (0.7) –
Partial cystectomy – 1 (0.4)
Reproductive system and breast 21 (7.3) 24 (8.4)
Endometrial ablation 2 (0.7) 1 (0.4)
Hysterectomy 23 (8.0) 22 (7.7)
Ovarian cyst removal – 1 (0.4)
Uterine prolapse repair – 2 (0.7)
Bartholin’s cyst drainage – 1 (0.4)
Dilatation and cutterage 1 (0.4) –
Laparoscopy for pelvic pain 1 (0.4) 1 (0.4)
Spontaneous miscarriage – 1 (0.4)
Egg harvesting 1 (0.4)
Other surgical and medical
procedures
9 (3.1) 11 (3.9)
Blood transfusion 1 (0.4) 1 (0.4)
Breast reduction 1 (0.4) 2 (0.7)
Hip replacement – 1 (0.4)
Tonsillectomy – 1 (0.4)
Gastric band surgery 2 (0.7) 1 (0.4)
Cosmetic surgery 1 (0.4) 1 (0.4)
CT/MRI scan 2 (0.7) –
Fracture repair 1 (0.4) 2 (0.7)
Back operation (not specified) 1 (0.4) –
Abscess drainage following
procedure
– 3 (1.0)
Tension of lower bowel 1 (0.4)
Polyp removal 1 (0.4)
Death – 1 (0.4)
CT, computerised tomography; MRI, magnetic resonance imaging; SAE, serious adverse event.
a All listed were classified as SAEs as they resulted in hospitalisation (apart from the recorded death).
b p= 0.32.
c p= 0.48 (seven women had two SAEs each in the usual medical treatment group; one woman had three SAEs in the
LNG-IUS group, while another had two SAEs).
d All women had ceased treatment prior to becoming pregnant.
Nine women experienced two SAEs. Chest pains/shortness of breath and suspected viral meningitis (n= 1); two heart
attacks (n= 1); cholecystectomy and cholelithotomy (n= 1); recurrent abdominal pains and non-specific headache (n= 1);
childbirth – post-partum recovery and overdose (n= 1); incontinence surgery and hysterectomy (n= 1); hysterectomy and
laparoscopy for pelvic pain (n= 1); and hysterectomy and a blood transfusion (n= 1). One woman experienced three events:
two strokes and a hip replacement.
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Appendix 12 Intermediate outcomes for the
usual medical treatment group
Month
Usual
treatment, n
Well with
usual, n
Symptomatic
with usual
treatment, n
Change to
LNG-IUS, n
Well with
LNG-IUS, n
No
treatment, n
Surgery,
n
Post
surgery, n
Month 1 285 0 0 0 0 0 0 0
Month 2 0 64 211 2 0 7 0 0
Month 3 0 64 200 7 2 11 0 0
Month 4 0 64 190 10 6 13 1 0
Month 5 0 64 179 11 13 16 0 1
Month 6 0 64 174 8 17 17 1 1
Month 7 0 64 158 15 19 23 1 2
Month 8 0 64 147 14 23 30 1 3
Month 9 0 64 137 15 26 36 0 4
Month 10 0 64 128 17 28 40 1 4
Month 11 0 64 125 16 30 41 1 5
Month 12 0 64 121 14 31 44 2 6
Month 13 0 64 114 14 32 49 0 8
Month 14 0 64 107 9 35 55 3 8
Month 15 0 64 102 11 35 56 1 11
Month 16 0 63 93 14 36 59 2 12
Month 17 0 63 88 13 39 59 3 14
Month 18 0 63 84 12 41 62 0 17
Month 19 0 63 78 11 41 64 4 17
Month 20 0 63 70 14 41 65 4 21
Month 21 0 63 66 13 42 68 1 25
Month 22 0 63 62 16 42 68 1 26
Month 23 0 63 57 14 45 71 1 27
Month 24 0 63 54 16 46 71 0 28
Month 25 0 63 48 16 47 73 3 28
Month 26 0 63 45 15 49 75 0 31
Month 27 0 63 43 14 50 77 0 31
Month 28 0 63 42 15 50 77 0 31
Month 29 0 63 42 15 51 77 0 31
Month 30 0 63 40 15 52 78 0 31
Month 31 0 63 39 13 53 79 1 31
Month 32 0 63 37 13 53 81 0 32
Month 33 0 63 36 13 53 81 1 32
Month 34 0 63 36 12 53 81 1 33
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Month
Usual
treatment, n
Well with
usual, n
Symptomatic
with usual
treatment, n
Change to
LNG-IUS, n
Well with
LNG-IUS, n
No
treatment, n
Surgery,
n
Post
surgery, n
Month 35 0 63 36 11 53 82 0 34
Month 36 0 63 36 11 53 81 0 34
Month 37 0 63 36 11 53 80 0 34
Month 38 0 63 36 10 53 81 0 34
Month 39 0 63 36 9 53 82 0 34
Month 40 0 63 34 10 53 83 0 34
Month 41 0 63 33 10 53 84 0 34
Month 42 0 63 31 9 53 85 2 34
Month 43 0 63 29 7 53 87 0 36
Month 44 0 63 26 10 53 86 0 36
Month 45 0 63 22 7 56 90 0 36
Month 46 0 63 21 6 57 91 0 36
Month 47 0 63 18 6 57 93 1 36
Month 48 0 63 17 6 57 94 0 37
Month 49 0 63 15 5 57 97 0 37
Month 50 0 63 13 5 57 99 0 37
Month 51 0 63 12 6 57 99 0 36
Month 52 0 63 10 5 58 100 1 36
Month 53 0 63 9 5 58 100 1 37
Month 54 0 63 8 5 58 101 0 38
Month 55 0 63 6 3 59 102 2 38
Month 56 0 63 5 2 59 103 1 40
Month 57 0 63 5 2 59 103 0 41
Month 58 0 63 5 1 59 103 0 41
Month 59 0 63 4 1 59 102 0 41
Month 60 0 63 1 2 60 103 0 41
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Appendix 13 Intermediate outcomes for the
levonorgestrel-releasing intrauterine system group
Month LNG-IUS, n
Well with the
LNG-IUS, n
Symptomatic
with the
LNG-IUS, n
Change to
usual, n
Well with
usual, n
No
treatment, n
Surgery,
n
Post
surgery, n
Month 1 285 0 0 0 0 0 0 0
Month 2 0 143 111 19 0 12 0 0
Month 3 0 143 104 10 13 14 1 0
Month 4 0 143 100 11 15 14 1 1
Month 5 0 143 98 9 18 15 0 2
Month 6 0 143 95 10 18 17 0 2
Month 7 0 143 92 10 19 18 1 2
Month 8 0 143 88 10 19 20 2 3
Month 9 0 143 83 10 19 24 1 5
Month 10 0 143 80 11 20 24 1 6
Month 11 0 143 78 11 21 24 0 7
Month 12 0 143 77 9 22 25 1 7
Month 13 0 143 70 10 22 27 3 8
Month 14 0 143 66 11 23 28 1 11
Month 15 0 143 62 9 24 32 1 12
Month 16 0 143 60 8 24 33 2 13
Month 17 0 143 60 7 24 32 2 15
Month 18 0 143 55 9 24 33 2 17
Month 19 0 143 54 8 25 32 2 19
Month 20 0 143 49 7 25 34 4 21
Month 21 0 143 47 9 25 34 0 25
Month 22 0 143 43 9 26 36 1 25
Month 23 0 143 41 8 27 37 1 26
Month 24 0 143 38 7 27 39 2 27
Month 25 0 143 38 6 27 40 0 29
Month 26 0 143 36 7 27 41 0 29
Month 27 0 143 35 7 27 42 0 29
Month 28 0 143 35 7 27 42 0 29
Month 29 0 143 35 6 27 42 1 29
Month 30 0 143 34 6 27 42 1 30
Month 31 0 143 34 6 27 42 0 31
Month 32 0 143 30 8 27 43 1 31
Month 33 0 143 30 7 28 43 0 32
Month 34 0 143 29 7 28 44 0 32
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Month LNG-IUS, n
Well with the
LNG-IUS, n
Symptomatic
with the
LNG-IUS, n
Change to
usual, n
Well with
usual, n
No
treatment, n
Surgery,
n
Post
surgery, n
Month 35 0 143 28 8 28 44 0 32
Month 36 0 143 28 7 29 44 0 32
Month 37 0 143 28 7 29 43 0 32
Month 38 0 143 27 8 29 43 0 32
Month 39 0 143 27 6 30 44 0 32
Month 40 0 143 25 6 30 46 0 32
Month 41 0 143 23 6 30 48 0 32
Month 42 0 143 21 5 30 49 1 32
Month 43 0 143 17 4 30 53 0 33
Month 44 0 143 15 3 31 55 0 33
Month 45 0 143 15 3 31 55 0 33
Month 46 0 143 15 3 31 54 0 33
Month 47 0 143 12 4 31 55 1 33
Month 48 0 143 12 3 32 54 0 34
Month 49 0 143 11 2 32 54 1 34
Month 50 0 143 10 1 32 56 0 35
Month 51 0 143 9 0 32 56 1 35
Month 52 0 143 8 1 32 56 0 36
Month 53 0 143 8 0 33 56 0 36
Month 54 0 143 6 0 33 56 2 36
Month 55 0 143 5 0 33 56 1 38
Month 56 0 143 3 0 33 58 0 39
Month 57 0 143 2 0 33 59 0 39
Month 58 0 143 2 0 33 59 0 39
Month 59 0 143 2 0 33 59 0 39
Month 60 0 143 1 0 33 60 0 39
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Appendix 14 The ECLIPSE trial collaborators
Names in bold indicate the principal investigator for that centre.
Aberdeen Street Medical Centre, Birmingham
RP Kulshrestha and S Kulshrestha.
Albany House Medical Centre, Wellingborough
K O’Brien, W Coulson, J Craig, L Descals, A Kownacki and E Montague.
Ash Lodge Medical Centre, Chesterfield
B McKenzie and CA Spooner.
Ashby Health Centre, Ashby-de-la-Zouch
N Sanganee.
Ashfield Surgery, Sutton Coldfield
IP Collier, SJ Cope, A Goodwin and LJ Sheldrake.
Bellevue Medical Centre, Birmingham
C Hanly and R Rajesh.
Birmingham Heartlands Hospital, Birmingham
S Hutchon.
Birmingham Women’s Hospital, Birmingham
T Bingham, JK Gupta, J Ingram, L Ingram and H Soneja.
Bluebell Medical Centre, Sheffield
R Pettinger.
DOI: 10.3310/hta19880 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 88
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Gupta et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
111
Brailsford Medical Centre, Brailsford
C Sadler.
Bridge Street Surgery, Brigg
M Brown, J Chaffey and V Cowan.
Bulwell Health Centre, Nottingham
L Brain and HS Pabla.
Castle Donington Surgery, Derby
H Godridge, MEA Horner, PD Horton, MF McGhee, M McGrath, KR Sumner, GJ Ward-Campbell and
S Williams.
Cavendish Surgery, Birmingham
P Madhavan.
Chapel Street Medical Centre, Derby
L Brewin, A Glenchcliffea and DJ Young.
Church Lane Surgery, Birmingham
K Heslington, D Hunt and N Saikia-Varman.
Church Road Surgery, Birmingham
M Jones, L Kavi and L Kidd.
Derby Lane Medical Centre, Derby
J Kai.
Dovecote Surgery, Warley
K Ladha and M Morris.
Dudley Park Medical Centre, Birmingham
K O’Neill, JN Patel and JE Waddell.
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Eden Court Medical Practice, Birmingham
PG Beighton, FH Cole and RM Edwards.
Enki Medical Practice, Birmingham
A Thompson.
Fernley Medical Centre, Birmingham
J Ayres, J Davies, TL Poltock, M Smith and H Talbot.
Four Oaks Medical Centre, Birmingham
AJ Cuthbert and S Horwell.
Frankley Health Centre, Birmingham
C Jenkins, G Sinha and K Weaver.
Grange Hill Surgery, Birmingham
B Goodwin and RP Patel.
Granton Surgery, Birmingham
SE Debenham.
Hall Green Health, Birmingham
AD Cartmill, S Parker, E Pennington, SJ Pennington and GB Young.
Handsworth Wood Medical Centre, Birmingham
S Butler, PA Hamilton and L Warhad.
Hannage Brook Medical Centre, Wirksworth
J Elliott, E Lawrence and J North.
Harborne Medical Practice, Birmingham
CI Elliott.
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Hawkesley Health Centre, Birmingham
S Jerome and PA Shipman.
High Street Surgery, Birmingham
R Bagchi and N Sheerin.
Hollybrook Medical Centre, Derby
C Blackwall, V Divers and J Siddall.
Jiggins Lane Medical Centre, Birmingham
HJ Parle and S Read.
Keynell Covert Surgery, Birmingham
SK Patodi.
Kings Mill Hospital, Nottingham
S Amis and S Moloney.
Lea Road Medical Practice, Wolverhampton
HH Leung, HU Obi and M Sidhu.
Leach Heath Medical Centre, Birmingham
N Ahmed, S R Carter, W Davies, H Harvey, K Khanna, PF Rice, L Shapiro and J Stone.
Limes Medical Centre, Alfreton
T Parkin.
Lister House, Derby
JM Craig, PJ Moss and V Steele.
The Goldenbrook Practice, Nottingham
JE Cartwright.
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Lordswood House, Birmingham
MG Edward and C Harrison.
Meadowfields Practice, Derby
R Francis and P Hassall.
Northgate Practice, Aldridge
CE Lloyd.
Parkfield Medical Centre, Birmingham
J Haynes, S Budh-Raja and VP Budh-Raja.
Prestwood House Surgery, Derby
SP Patel and JH Redferne.
Queens Medical Centre, Nottingham
S Deb, A Lancaster, MC Powell and J Wragg.
Richmond Medical Practice, Solihull
DC O’Brien.
Ripley Medical Centre, Ripley
S Milner and DW Taylor.
Riverlyn Medical Centre, Nottingham
D Davies, AK Tangri and C Tangri.
Royal Derby Hospital, Derby
S Amer, G Prileszky, C Warlow and P Whatmough.
Saffron Group Practice, Leicester
CH Duncan.
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Solihull Hospital, Solihull
W Bower and S Irani.
Springfield Medical Practice, Birmingham
S Rajput and VK Rajput.
St Mary’s Surgery, Ely
K Young.
Staffa Health, Alfreton
RE Cooper.
Staffordshire General Hospital, Stafford
K Chin, D Scott and J Stacey.
The Castle Practice, Birmingham
C Dadd and KG Joshi.
The Colston Health Centre, Birmingham
K Sundar.
The Hawthorns Surgery, Sutton Coldfield
RM Broomhead, MP Clarke, E Sangha and J Wood.
The Karis Medical Centre, Birmingham
B Fitzgerald-Jones and GR Harley-Mason.
The Kings Norton Surgery, Birmingham
AD Coward, CM Coward and J Pash.
The New Sheepmarket Surgery, Birmingham
HM Little, AG Macdonald and JP Williams.
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The Old Priory Surgery, Birmingham
J Marshall, H McBride and KA Watson.
The Poplars Surgery, Birmingham
SN Clay and SA Walker.
The Southgate Surgery, Birmingham
J Billington, H Griffiths and R Mehta.
The Spring Health Centre, Chesterfield
CJ Emslie.
Tower Hill Medical Centre, Birmingham
SS Bath, W Chiam, KR Gordon, M Latthe and DK Nandi.
University Medical Practice, Birmingham
VA Lilford and G Smith.
Victoria Health Centre, Nottingham
E Godfrey, S Griffiths and C Porter.
Wake Green Surgery, Birmingham
MS Baird, C Crombie, D O’Donnell and V Horton.
Wellside Medical Centre, Derby
RE Kelsey.
Wilson Street Surgery, Derby
JD Fletcher, F Hall and C Lenton.
Woodlands Road Surgery, Birmingham
MP Allen.
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Wychall Lane Surgery, Birmingham
J Heanue and JH McDonnell.
Yardley Medical Centre, Birmingham
J Hancock and BL Pattni.
Yardley Wood Health Centre, Birmingham
ST Banerjee and S Pate.
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